OA18697A - Heteroaryl derivatives as PARP inhibitors - Google Patents
Heteroaryl derivatives as PARP inhibitors Download PDFInfo
- Publication number
- OA18697A OA18697A OA1201800055 OA18697A OA 18697 A OA18697 A OA 18697A OA 1201800055 OA1201800055 OA 1201800055 OA 18697 A OA18697 A OA 18697A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- oxo
- piperazin
- substituted
- alkyl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 29
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 17
- 239000003112 inhibitor Substances 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 822
- 201000011510 cancer Diseases 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 238
- -1 -OH Chemical group 0.000 claims description 107
- 239000001257 hydrogen Substances 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 59
- 229910052799 carbon Inorganic materials 0.000 claims description 53
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 51
- 150000002431 hydrogen Chemical group 0.000 claims description 48
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 102100014579 PARP1 Human genes 0.000 claims description 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
- 101700053624 PARP2 Proteins 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 101700007241 APOC4 Proteins 0.000 claims description 34
- 101710038729 F2R Proteins 0.000 claims description 34
- 101700036247 PARP1 Proteins 0.000 claims description 34
- 101700027237 PROA Proteins 0.000 claims description 34
- 101700004528 arp Proteins 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000004043 oxo group Chemical group O=* 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 20
- 201000009030 carcinoma Diseases 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 17
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 229910021386 carbon form Inorganic materials 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- HESPPRHPBBEMRI-NRFANRHFSA-N CC1=C(NC(=O)C2=CC=CN=C12)C1=C[C@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N Chemical compound CC1=C(NC(=O)C2=CC=CN=C12)C1=C[C@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N HESPPRHPBBEMRI-NRFANRHFSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- HESPPRHPBBEMRI-OAQYLSRUSA-N CC1=C(NC(=O)C2=CC=CN=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N Chemical compound CC1=C(NC(=O)C2=CC=CN=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N HESPPRHPBBEMRI-OAQYLSRUSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 125000005842 heteroatoms Chemical group 0.000 claims description 9
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 8
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 8
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 8
- AWAYHRFOTVWUEK-HXUWFJFHSA-N O=C1NC(=CC2=CC=CN12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N Chemical compound O=C1NC(=CC2=CC=CN12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N AWAYHRFOTVWUEK-HXUWFJFHSA-N 0.000 claims description 8
- GCPSAEQUOPIBKC-OAQYLSRUSA-N O=C1NC(=CC2=CN=CC=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound O=C1NC(=CC2=CN=CC=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 GCPSAEQUOPIBKC-OAQYLSRUSA-N 0.000 claims description 8
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 8
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims description 7
- 206010025650 Malignant melanoma Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 230000003389 potentiating Effects 0.000 claims description 7
- 230000003211 malignant Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 6
- DUPNPBCUJHMSFZ-UHFFFAOYSA-N 5H-thieno[3,2-c]pyridin-4-one Chemical compound O=C1NC=CC2=C1C=CS2 DUPNPBCUJHMSFZ-UHFFFAOYSA-N 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 5
- 125000005418 aryl aryl group Chemical group 0.000 claims description 5
- 230000000973 chemotherapeutic Effects 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 5
- 229960004964 temozolomide Drugs 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 4
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical group CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- YZQRAQOSAPWELU-UHFFFAOYSA-O 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol Chemical compound C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 YZQRAQOSAPWELU-UHFFFAOYSA-O 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- MLFKVJCWGUZWNV-REOHCLBHSA-N ALANOSINE Chemical compound OC(=O)[C@@H](N)CN(O)N=O MLFKVJCWGUZWNV-REOHCLBHSA-N 0.000 claims description 4
- 229950005033 ALANOSINE Drugs 0.000 claims description 4
- 229960004176 Aclarubicin Drugs 0.000 claims description 4
- 229960002756 Azacitidine Drugs 0.000 claims description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001561 Bleomycin Drugs 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 229940112129 Campath Drugs 0.000 claims description 4
- 229960004562 Carboplatin Drugs 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 Chlorambucil Drugs 0.000 claims description 4
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229960004679 Doxorubicin Drugs 0.000 claims description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- 229960001904 EPIRUBICIN Drugs 0.000 claims description 4
- 229960001433 Erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960005420 Etoposide Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960002949 Fluorouracil Drugs 0.000 claims description 4
- 229960002258 Fulvestrant Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 Ifosfamide Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960003539 Mitoguazone Drugs 0.000 claims description 4
- 229960004857 Mitomycin Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001156 Mitoxantrone Drugs 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 229960002700 Octreotide Drugs 0.000 claims description 4
- 108010016076 Octreotide Proteins 0.000 claims description 4
- 229960001592 Paclitaxel Drugs 0.000 claims description 4
- OGSBUKJUDHAQEA-WMCAAGNKSA-N Pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 229960001603 Tamoxifen Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 4
- 229960003048 Vinblastine Drugs 0.000 claims description 4
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- 229960004528 Vincristine Drugs 0.000 claims description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000237 Vorinostat Drugs 0.000 claims description 4
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 4
- 229960001573 cabazitaxel Drugs 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001338 colchicine Drugs 0.000 claims description 4
- 229960002448 dasatinib Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229950007539 elliptinium Drugs 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 4
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 4
- 229940027318 hydroxyurea Drugs 0.000 claims description 4
- 229960004942 lenalidomide Drugs 0.000 claims description 4
- 229960003881 letrozole Drugs 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims description 4
- 229960000801 nelarabine Drugs 0.000 claims description 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000639 pazopanib Drugs 0.000 claims description 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 4
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims description 4
- 229960005079 pemetrexed Drugs 0.000 claims description 4
- 229960000214 pralatrexate Drugs 0.000 claims description 4
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 4
- 229960003452 romidepsin Drugs 0.000 claims description 4
- 108010091666 romidepsin Proteins 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 229960001796 sunitinib Drugs 0.000 claims description 4
- 229930003347 taxol Natural products 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims description 4
- 229960002066 vinorelbine Drugs 0.000 claims description 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 3
- IBBZXRLLZKUNIM-HXUWFJFHSA-N O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 IBBZXRLLZKUNIM-HXUWFJFHSA-N 0.000 claims description 3
- GDTWZFDBIKWFBV-LJQANCHMSA-N O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C(=O)N)C=C1 Chemical compound O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C(=O)N)C=C1 GDTWZFDBIKWFBV-LJQANCHMSA-N 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 239000005864 Sulphur Chemical group 0.000 claims description 3
- 229960003433 Thalidomide Drugs 0.000 claims description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- 229960005454 Thioguanine Drugs 0.000 claims description 3
- 229960001727 Tretinoin Drugs 0.000 claims description 3
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims description 3
- GCPXMJHSNVMWNM-UHFFFAOYSA-N Trihydroxyarsenite(Iii) Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 claims description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002594 arsenic trioxide Drugs 0.000 claims description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 3
- 229960002707 bendamustine Drugs 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960002014 ixabepilone Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- 229960001346 nilotinib Drugs 0.000 claims description 3
- 150000002829 nitrogen Chemical group 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 231100000202 sensitizing Toxicity 0.000 claims description 3
- 230000001235 sensitizing Effects 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004276 zoledronic acid Drugs 0.000 claims description 3
- 108010007562 Adalimumab Proteins 0.000 claims description 2
- 210000004404 Adrenal Cortex Anatomy 0.000 claims description 2
- 108010005144 Bevacizumab Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 210000004556 Brain Anatomy 0.000 claims description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000002047 Essential Thrombocythemia Diseases 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 206010020583 Hypercalcaemia Diseases 0.000 claims description 2
- 206010020718 Hyperplasia Diseases 0.000 claims description 2
- 206010022498 Insulinoma Diseases 0.000 claims description 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 229960002450 Ofatumumab Drugs 0.000 claims description 2
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims description 2
- 108010061219 Panitumumab Proteins 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000008696 Polycythemia Vera Diseases 0.000 claims description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 2
- 108010010691 Trastuzumab Proteins 0.000 claims description 2
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims description 2
- 208000008383 Wilms Tumor Diseases 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 2
- 201000003963 colon carcinoma Diseases 0.000 claims description 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 201000009251 multiple myeloma Diseases 0.000 claims description 2
- 201000005962 mycosis fungoide Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 108010052070 ofatumumab Proteins 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005161 thyroid carcinoma Diseases 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- HZHCYJBRGJBALY-OAQYLSRUSA-N CC1=CC=C2C(=O)NC(=CC2=N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N Chemical compound CC1=CC=C2C(=O)NC(=CC2=N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N HZHCYJBRGJBALY-OAQYLSRUSA-N 0.000 claims 2
- MLDGCCXVLCPKFU-HXUWFJFHSA-N CNC(=O)C1=CC=C(C=C1)N1CCN(CC1)[C@@H]1CCC(=C1)C1=CC2=NC=CC=C2C(=O)N1 Chemical compound CNC(=O)C1=CC=C(C=C1)N1CCN(CC1)[C@@H]1CCC(=C1)C1=CC2=NC=CC=C2C(=O)N1 MLDGCCXVLCPKFU-HXUWFJFHSA-N 0.000 claims 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 2
- HKVAMNSJSFKALM-XJFKSLPYSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-XJFKSLPYSA-N 0.000 claims 2
- IBBZXRLLZKUNIM-FQEVSTJZSA-N O=C1NC(=CC2=NC=CC=C12)C1=C[C@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N Chemical compound O=C1NC(=CC2=NC=CC=C12)C1=C[C@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N IBBZXRLLZKUNIM-FQEVSTJZSA-N 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- 230000001154 acute Effects 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 229910004755 ORb Inorganic materials 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 abstract description 17
- 150000003839 salts Chemical class 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 229910052727 yttrium Inorganic materials 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 330
- 239000011541 reaction mixture Substances 0.000 description 234
- 239000000243 solution Substances 0.000 description 183
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 157
- 238000006243 chemical reaction Methods 0.000 description 156
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 155
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 127
- 229940093499 ethyl acetate Drugs 0.000 description 110
- 235000019439 ethyl acetate Nutrition 0.000 description 110
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 106
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 97
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 84
- 230000002829 reduced Effects 0.000 description 78
- 239000012043 crude product Substances 0.000 description 77
- 239000012044 organic layer Substances 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 75
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 70
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 69
- 239000000203 mixture Substances 0.000 description 69
- 239000008079 hexane Substances 0.000 description 61
- 239000003480 eluent Substances 0.000 description 50
- 229910052938 sodium sulfate Inorganic materials 0.000 description 50
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 48
- 238000000034 method Methods 0.000 description 47
- 239000000047 product Substances 0.000 description 47
- 239000000741 silica gel Substances 0.000 description 47
- 229910002027 silica gel Inorganic materials 0.000 description 47
- 235000011152 sodium sulphate Nutrition 0.000 description 47
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 45
- 239000002904 solvent Substances 0.000 description 45
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 43
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 39
- 229960004132 diethyl ether Drugs 0.000 description 39
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 36
- 238000003818 flash chromatography Methods 0.000 description 36
- 239000002585 base Substances 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- 230000002194 synthesizing Effects 0.000 description 25
- 238000007792 addition Methods 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- 239000001184 potassium carbonate Substances 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 21
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 17
- ONDSBJMLAHVLMI-UHFFFAOYSA-N Trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 16
- VKYABZXPNHHDSD-UHFFFAOYSA-N bis(2-methylpropyl)alumanylium;hydride Chemical compound [H-].CC(C)C[Al+]CC(C)C VKYABZXPNHHDSD-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 229940086542 triethylamine Drugs 0.000 description 14
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 101700046984 CDK20 Proteins 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 10
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 10
- 230000001808 coupling Effects 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000376 reactant Substances 0.000 description 9
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- VKJAUWMYHCXNIX-CQSZACIVSA-N C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C VKJAUWMYHCXNIX-CQSZACIVSA-N 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 7
- 229960001701 Chloroform Drugs 0.000 description 7
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- IYOLIXRFRLZZCC-LURJTMIESA-N (3S)-3-hydroxycyclopentene-1-carbonitrile Chemical compound O[C@H]1CCC(C#N)=C1 IYOLIXRFRLZZCC-LURJTMIESA-N 0.000 description 6
- MMWNKXIFVYQOTK-UHFFFAOYSA-N 2-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Br MMWNKXIFVYQOTK-UHFFFAOYSA-N 0.000 description 6
- NKBWMBRPILTCRD-UHFFFAOYSA-M 2-methylheptanoate Chemical compound CCCCCC(C)C([O-])=O NKBWMBRPILTCRD-UHFFFAOYSA-M 0.000 description 6
- VIJFDNKQXWCYTH-UHFFFAOYSA-N 3-bromocyclopentene-1-carbonitrile Chemical compound BrC1CCC(C#N)=C1 VIJFDNKQXWCYTH-UHFFFAOYSA-N 0.000 description 6
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 6
- UIIAPRKTDBEFAO-UHFFFAOYSA-N BrC1=C(CCC1=O)C#N Chemical compound BrC1=C(CCC1=O)C#N UIIAPRKTDBEFAO-UHFFFAOYSA-N 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- BKIMMITUMNQMOS-UHFFFAOYSA-N Nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 6
- RCVPUWWTYXQZFF-HXUWFJFHSA-N O=C1NC(=CN2C=CC=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N Chemical compound O=C1NC(=CN2C=CC=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)C#N RCVPUWWTYXQZFF-HXUWFJFHSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- FOBSIYAPELUICT-LJQANCHMSA-N [N+](=O)([O-])C1=C(NC(C=2C=CC=NC1=2)=O)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound [N+](=O)([O-])C1=C(NC(C=2C=CC=NC1=2)=O)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 FOBSIYAPELUICT-LJQANCHMSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- AFKDWBNXXRTISI-NVJADKKVSA-N Cl.Cl.C#CC1=C[C@@H](CC1)N1CCNCC1 Chemical compound Cl.Cl.C#CC1=C[C@@H](CC1)N1CCNCC1 AFKDWBNXXRTISI-NVJADKKVSA-N 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- KIHJGHQZZAFOLA-GOSISDBHSA-N FC=1C=C(C#N)C=CC=1N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound FC=1C=C(C#N)C=CC=1N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O KIHJGHQZZAFOLA-GOSISDBHSA-N 0.000 description 5
- OQXRCISZYORQBS-GOSISDBHSA-N O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=NC=C(C#N)C=C1 Chemical compound O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C1=NC=C(C#N)C=C1 OQXRCISZYORQBS-GOSISDBHSA-N 0.000 description 5
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N XPhos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 4
- VPCVHKCFRQNUDJ-UHFFFAOYSA-N C(#N)C(C)C1=C(C(=O)O)C=CC=N1 Chemical compound C(#N)C(C)C1=C(C(=O)O)C=CC=N1 VPCVHKCFRQNUDJ-UHFFFAOYSA-N 0.000 description 4
- IHZIXTJKZXPUKF-CYBMUJFWSA-N C(=O)C1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(=O)C1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C IHZIXTJKZXPUKF-CYBMUJFWSA-N 0.000 description 4
- LEQUWXBNDAXBIQ-LJQANCHMSA-N C1(=C(C=CC=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O)C Chemical compound C1(=C(C=CC=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O)C LEQUWXBNDAXBIQ-LJQANCHMSA-N 0.000 description 4
- CZIXBUQHCXXTIB-OGFXRTJISA-N Cl.N[C@@H]1CCC(=C1)C#C Chemical compound Cl.N[C@@H]1CCC(=C1)C#C CZIXBUQHCXXTIB-OGFXRTJISA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- DOVYLXGJAUNVCL-UHFFFAOYSA-N FC1=CC=C(C=C1)N1CCN(CC1)C1C=C(CC1)C=O Chemical compound FC1=CC=C(C=C1)N1CCN(CC1)C1C=C(CC1)C=O DOVYLXGJAUNVCL-UHFFFAOYSA-N 0.000 description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-N Isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 4
- ZMDMALYQOGTELZ-OAQYLSRUSA-N O=C1OC(=CC=2C=NC=CC=21)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound O=C1OC(=CC=2C=NC=CC=21)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 ZMDMALYQOGTELZ-OAQYLSRUSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N SPhos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- UEMSQRPTTZYVPP-MRLFYKGRSA-N (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;dihydrochloride Chemical compound Cl.Cl.O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 UEMSQRPTTZYVPP-MRLFYKGRSA-N 0.000 description 3
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 3
- TXOBWOBAIVXLOV-UHFFFAOYSA-N 3-(2-trimethylsilylethynyl)cyclopent-2-en-1-ol Chemical compound C[Si](C)(C)C#CC1=CC(O)CC1 TXOBWOBAIVXLOV-UHFFFAOYSA-N 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- JVYOUWLWRZEFBQ-YFKPBYRVSA-N BrC1=C(CC[C@@H]1O)C#N Chemical compound BrC1=C(CC[C@@H]1O)C#N JVYOUWLWRZEFBQ-YFKPBYRVSA-N 0.000 description 3
- QLECNRIIIJJSFQ-GOSISDBHSA-N C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 QLECNRIIIJJSFQ-GOSISDBHSA-N 0.000 description 3
- ZIOXNWGUADRVFY-TTZKSVMKSA-N C(=O)C1=CC(CC1)N1[C@@H]2CN([C@H](C1)C2)C(=O)OC(C)(C)C Chemical compound C(=O)C1=CC(CC1)N1[C@@H]2CN([C@H](C1)C2)C(=O)OC(C)(C)C ZIOXNWGUADRVFY-TTZKSVMKSA-N 0.000 description 3
- AIKUXPKZHBCXDB-CQSZACIVSA-N C(C)(=O)C1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(C)(=O)C1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C AIKUXPKZHBCXDB-CQSZACIVSA-N 0.000 description 3
- PARRPTLSBCGIJT-GFCCVEGCSA-N C(C)(=O)O[C@H]1C=C(CC1)C#C[Si](C)(C)C Chemical compound C(C)(=O)O[C@H]1C=C(CC1)C#C[Si](C)(C)C PARRPTLSBCGIJT-GFCCVEGCSA-N 0.000 description 3
- QILRTGAPKUAMOL-UHFFFAOYSA-N COC(=O)c1cccnc1C(C)C#N Chemical compound COC(=O)c1cccnc1C(C)C#N QILRTGAPKUAMOL-UHFFFAOYSA-N 0.000 description 3
- KQUXSPGLWNERSF-UHFFFAOYSA-N COC1=C2C=CC=NC2=C(C(=N1)C1=CC(CC1)=O)C Chemical compound COC1=C2C=CC=NC2=C(C(=N1)C1=CC(CC1)=O)C KQUXSPGLWNERSF-UHFFFAOYSA-N 0.000 description 3
- KUPICDOHGIBCAV-UHFFFAOYSA-N COC1=NC(Cl)=C(C)C2=NC=CC=C12 Chemical compound COC1=NC(Cl)=C(C)C2=NC=CC=C12 KUPICDOHGIBCAV-UHFFFAOYSA-N 0.000 description 3
- COIJMPDPCWRTJW-QGZVFWFLSA-N C[Si](C)(C)C#CC1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound C[Si](C)(C)C#CC1=C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C COIJMPDPCWRTJW-QGZVFWFLSA-N 0.000 description 3
- GAMUANYDZLEGLV-LJQANCHMSA-N ClC1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound ClC1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O GAMUANYDZLEGLV-LJQANCHMSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- AMHLLXMCQPWXNQ-UHFFFAOYSA-N Fc1ccc(cc1)N1CCN(CC1)C1CCC(=C1)C#N Chemical compound Fc1ccc(cc1)N1CCN(CC1)C1CCC(=C1)C#N AMHLLXMCQPWXNQ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229940119837 Isopropyl Alcohol Drugs 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 229940040461 Lipase Drugs 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- TTXQCRKMQSVTGC-LJQANCHMSA-N OC(=O)C1=CC=C(C=C1)N1CCN(CC1)[C@@H]1CCC(=C1)C1=CC2=NC=CC=C2C(=O)N1 Chemical compound OC(=O)C1=CC=C(C=C1)N1CCN(CC1)[C@@H]1CCC(=C1)C1=CC2=NC=CC=C2C(=O)N1 TTXQCRKMQSVTGC-LJQANCHMSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229910007568 Zn—Ag Inorganic materials 0.000 description 3
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- PSBABBDEUFNFKJ-UHFFFAOYSA-N cyclopent-2-en-1-ol Chemical compound OC1CCC=C1 PSBABBDEUFNFKJ-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- WXQSFECXTRCYSG-UHFFFAOYSA-N dimethyl-[methyl(trimethylsilyl)amino]silicon;lithium Chemical compound [Li].C[Si](C)N(C)[Si](C)(C)C WXQSFECXTRCYSG-UHFFFAOYSA-N 0.000 description 3
- 238000010931 ester hydrolysis Methods 0.000 description 3
- NUCWDCRUEIUKPN-UHFFFAOYSA-J ethane-1,2-diamine;palladium(2+);phosphonato phosphate Chemical compound [Pd+2].[Pd+2].NCCN.NCCN.[O-]P([O-])(=O)OP([O-])([O-])=O NUCWDCRUEIUKPN-UHFFFAOYSA-J 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 102000004882 lipase Human genes 0.000 description 3
- 108090001060 lipase Proteins 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutic aid Substances 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HWRIZWZEFLQAHE-CYBMUJFWSA-N tert-butyl 4-[(1R)-3-cyanocyclopent-2-en-1-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1[C@H]1C=C(C#N)CC1 HWRIZWZEFLQAHE-CYBMUJFWSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- OBCUSTCTKLTMBX-SECBINFHSA-N (2R)-2-acetyloxy-2-phenylacetic acid Chemical compound CC(=O)O[C@@H](C(O)=O)C1=CC=CC=C1 OBCUSTCTKLTMBX-SECBINFHSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- RVLWYJGGNGVULN-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one;hydrate Chemical compound O.O=C1C=CC=C2NNN=C12 RVLWYJGGNGVULN-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- UIMPAOAAAYDUKQ-UHFFFAOYSA-N 1-methoxy-4-(4-methoxyphenyl)benzene Chemical group C1=CC(OC)=CC=C1C1=CC=C(OC)C=C1 UIMPAOAAAYDUKQ-UHFFFAOYSA-N 0.000 description 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
- LMKPHJYTFHAGHK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 description 2
- OBCUSTCTKLTMBX-UHFFFAOYSA-M 2-acetyloxy-2-phenylacetate Chemical compound CC(=O)OC(C([O-])=O)C1=CC=CC=C1 OBCUSTCTKLTMBX-UHFFFAOYSA-M 0.000 description 2
- BZKFMUIJRXWWQK-UHFFFAOYSA-N 2-cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 102000036638 BRCA1 Human genes 0.000 description 2
- 108010042977 BRCA1 Protein Proteins 0.000 description 2
- 102000002280 BRCA2 Protein Human genes 0.000 description 2
- 108010000750 BRCA2 Protein Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- AGMDJRFFLKBYNP-UHFFFAOYSA-N C(#N)CC1=C(C(=O)OC)C=CC=N1 Chemical compound C(#N)CC1=C(C(=O)OC)C=CC=N1 AGMDJRFFLKBYNP-UHFFFAOYSA-N 0.000 description 2
- CGOHWZKMNNEDEE-SECBINFHSA-N C(=O)C1=C[C@@H](CC1)NC(OC(C)(C)C)=O Chemical compound C(=O)C1=C[C@@H](CC1)NC(OC(C)(C)C)=O CGOHWZKMNNEDEE-SECBINFHSA-N 0.000 description 2
- YNSVBPKBYQQKNR-LJQANCHMSA-N C1(=CC=CC=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound C1(=CC=CC=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O YNSVBPKBYQQKNR-LJQANCHMSA-N 0.000 description 2
- HWRIZWZEFLQAHE-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC1)C1CCC(=C1)C#N Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)C1CCC(=C1)C#N HWRIZWZEFLQAHE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- VYLVYHXQOHJDJL-UHFFFAOYSA-K Cerium(III) chloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- 206010070976 Craniocerebral injury Diseases 0.000 description 2
- 231100001074 DNA strand break Toxicity 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N Decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- KHALDTXVYPNZNH-UHFFFAOYSA-N FC1=CC=C(C=C1)N1CCN(CC1)C1CCC(=C1)C#C Chemical compound FC1=CC=C(C=C1)N1CCN(CC1)C1CCC(=C1)C#C KHALDTXVYPNZNH-UHFFFAOYSA-N 0.000 description 2
- WEBWNYRNLHJOOA-LJQANCHMSA-N FC1=CC=C(C=C1)N1CCN(CC1)[C@@H]1CCC(=C1)C1=CC2=NC=CC=C2C(=O)N1 Chemical compound FC1=CC=C(C=C1)N1CCN(CC1)[C@@H]1CCC(=C1)C1=CC2=NC=CC=C2C(=O)N1 WEBWNYRNLHJOOA-LJQANCHMSA-N 0.000 description 2
- GMOMATCRSUBFAB-MRXNPFEDSA-N FC=1C=C(C#N)C=CC=1N1CCN(CC1)[C@H]1C=C(CC1)C1=CC2=C(C(N1)=O)SC=N2 Chemical compound FC=1C=C(C#N)C=CC=1N1CCN(CC1)[C@H]1C=C(CC1)C1=CC2=C(C(N1)=O)SC=N2 GMOMATCRSUBFAB-MRXNPFEDSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N Methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 208000010125 Myocardial Infarction Diseases 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- SBEDWZGXXQVCMD-OAHLLOKOSA-N O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C=1SC(=CN=1)C#N Chemical compound O=C1C=2C=CC=NC=2C=C(N1)C1=C[C@@H](CC1)N1CCN(CC1)C=1SC(=CN=1)C#N SBEDWZGXXQVCMD-OAHLLOKOSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229940083599 Sodium Iodide Drugs 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N Trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L Zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229910000090 borane Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- XBVZRFXCDCYXAX-UHFFFAOYSA-N cyclopentene-1-carbonitrile Chemical compound N#CC1=CCCC1 XBVZRFXCDCYXAX-UHFFFAOYSA-N 0.000 description 2
- UOPIRNHVGHLLDZ-UHFFFAOYSA-L dichlororhodium Chemical compound Cl[Rh]Cl UOPIRNHVGHLLDZ-UHFFFAOYSA-L 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000009906 meningitis Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical compound O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 125000002097 pentamethylcyclopentadienyl group Chemical group 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- FMLPQHJYUZTHQS-MRVPVSSYSA-N tert-butyl (3R)-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-MRVPVSSYSA-N 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- UKHJNJFJCGBKSF-WHFBIAKZSA-N (1S,4S)-2,5-diazabicyclo[2.2.1]heptane Chemical compound C1N[C@]2([H])CN[C@@]1([H])C2 UKHJNJFJCGBKSF-WHFBIAKZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-Trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- AVGHIQUXSVAJBC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.1]heptane Chemical compound C1C2CCN1NC2 AVGHIQUXSVAJBC-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- JYUXDXWXTPSAEL-UHFFFAOYSA-N 1,4-dioxane;oxolane Chemical compound C1CCOC1.C1COCCO1 JYUXDXWXTPSAEL-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- HWIVGBQUEUPWHG-UHFFFAOYSA-N 1-thia-2,3-diazacyclopent-2-en-4-yne Chemical group S1N=NC#C1 HWIVGBQUEUPWHG-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N 2,3-dihydro-1H-indole Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004565 2,3-dihydrobenzofuran-4-yl group Chemical group O1CCC2=C1C=CC=C2* 0.000 description 1
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N 2-Pentanone Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- QEROMHXUKREOCB-UHFFFAOYSA-N 2-bromo-3-ethoxycyclopent-2-en-1-one Chemical compound CCOC1=C(Br)C(=O)CC1 QEROMHXUKREOCB-UHFFFAOYSA-N 0.000 description 1
- TZALTHQYRONLQA-UHFFFAOYSA-N 2-bromo-5-nitropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CN=C1Br TZALTHQYRONLQA-UHFFFAOYSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-L 2-sulfobutanedioate Chemical class OS(=O)(=O)C(C([O-])=O)CC([O-])=O ULUAUXLGCMPNKK-UHFFFAOYSA-L 0.000 description 1
- BQTWGGGLMLASSY-UHFFFAOYSA-N 2H-pyrrolo[1,2-c]pyrimidin-1-one Chemical compound OC1=NC=CC2=CC=CN12 BQTWGGGLMLASSY-UHFFFAOYSA-N 0.000 description 1
- YZYQQJHFYIVWPS-UHFFFAOYSA-N 3,4,5,6-tetradehydrothiopyran Chemical group [CH]1SC#CC#C1 YZYQQJHFYIVWPS-UHFFFAOYSA-N 0.000 description 1
- BTBFCBQZFMQBNT-UHFFFAOYSA-N 3,4-difluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1F BTBFCBQZFMQBNT-UHFFFAOYSA-N 0.000 description 1
- CGTGLMSBJLJNCL-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-one Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(=O)CC1 CGTGLMSBJLJNCL-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- SSEJSSNDPMMWBQ-UHFFFAOYSA-M 3-methylpiperazine-1-carboxylate Chemical compound CC1CN(C([O-])=O)CCN1 SSEJSSNDPMMWBQ-UHFFFAOYSA-M 0.000 description 1
- VDPIEHNUNDVINZ-UHFFFAOYSA-N 4-[bis(2-chloroethyl)amino]benzonitrile Chemical compound ClCCN(CCCl)C1=CC=C(C#N)C=C1 VDPIEHNUNDVINZ-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- VRLVOMUVHHHJHB-UHFFFAOYSA-N 6-fluoropyridine-3-carbonitrile Chemical compound FC1=CC=C(C#N)C=N1 VRLVOMUVHHHJHB-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- PQLAYKMGZDUDLQ-UHFFFAOYSA-K Aluminium bromide Chemical compound Br[Al](Br)Br PQLAYKMGZDUDLQ-UHFFFAOYSA-K 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108009000276 Base Excision Repair Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000311499 Bos grunniens x Bos taurus Species 0.000 description 1
- DLEUTYUKWDGNGV-MRXNPFEDSA-N C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C1=C(C=C(C#N)C=C1)F Chemical compound C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C1=C(C=C(C#N)C=C1)F DLEUTYUKWDGNGV-MRXNPFEDSA-N 0.000 description 1
- KHALDTXVYPNZNH-QGZVFWFLSA-N C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)F Chemical compound C(#C)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C=C1)F KHALDTXVYPNZNH-QGZVFWFLSA-N 0.000 description 1
- NJYBIBAIZUFZLB-SNVBAGLBSA-N C(#C)C1=C[C@@H](CC1)NC(OC(C)(C)C)=O Chemical compound C(#C)C1=C[C@@H](CC1)NC(OC(C)(C)C)=O NJYBIBAIZUFZLB-SNVBAGLBSA-N 0.000 description 1
- STCLZNCJVGRSCU-ZGTCLIOFSA-N C(=O)C1C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(=O)C1C[C@@H](CC1)N1CCN(CC1)C(=O)OC(C)(C)C STCLZNCJVGRSCU-ZGTCLIOFSA-N 0.000 description 1
- MNTULAOHQCBAAI-OAQYLSRUSA-N C(C)(=O)C1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound C(C)(=O)C1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O MNTULAOHQCBAAI-OAQYLSRUSA-N 0.000 description 1
- MOTHUBJOUGRFPE-UHFFFAOYSA-N C12CC2CCCC21CCCC2 Chemical compound C12CC2CCCC21CCCC2 MOTHUBJOUGRFPE-UHFFFAOYSA-N 0.000 description 1
- FQPYRSGBGNUITN-UHFFFAOYSA-M C1CN2N(C(=O)[O-])CC1C2 Chemical compound C1CN2N(C(=O)[O-])CC1C2 FQPYRSGBGNUITN-UHFFFAOYSA-M 0.000 description 1
- LIHISFLBPLXITM-UHFFFAOYSA-N CC(C)(C)C(=O)ONC(=O)N1C=CC=C1 Chemical compound CC(C)(C)C(=O)ONC(=O)N1C=CC=C1 LIHISFLBPLXITM-UHFFFAOYSA-N 0.000 description 1
- AJUKGKFBUGZGSW-UHFFFAOYSA-M CC(C)(C)C(=O)O[NH3+].[O-]S(=O)(=O)C(F)(F)F Chemical compound CC(C)(C)C(=O)O[NH3+].[O-]S(=O)(=O)C(F)(F)F AJUKGKFBUGZGSW-UHFFFAOYSA-M 0.000 description 1
- KYYWEUNSFOYUGT-SECBINFHSA-N CC(C)(C)OC(=O)N[C@@H]1CCC(=C1)C#N Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCC(=C1)C#N KYYWEUNSFOYUGT-SECBINFHSA-N 0.000 description 1
- IVYZFDKKVMMORR-UHFFFAOYSA-N CC1=C(Cl)N=C(Cl)C2=CC=CN=C12 Chemical compound CC1=C(Cl)N=C(Cl)C2=CC=CN=C12 IVYZFDKKVMMORR-UHFFFAOYSA-N 0.000 description 1
- JRYMSXIWKLARPS-OAQYLSRUSA-N CC1=CC=C2C(=N1)C=C(OC2=O)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound CC1=CC=C2C(=N1)C=C(OC2=O)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 JRYMSXIWKLARPS-OAQYLSRUSA-N 0.000 description 1
- WZUCGBWCWKAVTM-LJQANCHMSA-N CN1N=CC=2C(NC(=CC=21)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1)=O Chemical compound CN1N=CC=2C(NC(=CC=21)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1)=O WZUCGBWCWKAVTM-LJQANCHMSA-N 0.000 description 1
- MLKJHUVIMBAHRX-HXUWFJFHSA-N CNC1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound CNC1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O MLKJHUVIMBAHRX-HXUWFJFHSA-N 0.000 description 1
- IKNAVMJIUIYTFO-LJQANCHMSA-N COC1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound COC1=CC=C(C=C1)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O IKNAVMJIUIYTFO-LJQANCHMSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N Chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 210000003483 Chromatin Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M Copper(I) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N Cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940052303 Ethers for general anesthesia Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- LUIOZBYYOZBLFS-LJQANCHMSA-N FC(F)(F)c1ccc(cc1)N1CCN(CC1)[C@@H]1CCC(=C1)c1cc2ncccc2c(=O)[nH]1 Chemical compound FC(F)(F)c1ccc(cc1)N1CCN(CC1)[C@@H]1CCC(=C1)c1cc2ncccc2c(=O)[nH]1 LUIOZBYYOZBLFS-LJQANCHMSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 241000132446 Inula Species 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 244000232488 Jessenia polycarpa Species 0.000 description 1
- 235000002407 Jessenia polycarpa Nutrition 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940050176 Methyl Chloride Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N N,N-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 101710017472 NT5C3A Proteins 0.000 description 1
- 102100011518 NT5C3A Human genes 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N Norcarane Chemical compound C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- YUQIIMSPSLOXFW-OAQYLSRUSA-N O=C1NC(=CC2=CC=NC=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 Chemical compound O=C1NC(=CC2=CC=NC=C12)C1=C[C@@H](CC1)N1CCN(CC1)C1=CC=C(C#N)C=C1 YUQIIMSPSLOXFW-OAQYLSRUSA-N 0.000 description 1
- MHJPVYSZJYTXFJ-GOSISDBHSA-N O=C1NCC2=CC(=CC=C12)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O Chemical compound O=C1NCC2=CC(=CC=C12)N1CCN(CC1)[C@H]1C=C(CC1)C=1NC(C=2C=CC=NC=2C=1)=O MHJPVYSZJYTXFJ-GOSISDBHSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100017733 PARP2 Human genes 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N Phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N Phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N Phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O Pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040070 Septic shock Diseases 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M Silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N Spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N Thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100017881 USP11 Human genes 0.000 description 1
- 101700043628 USP11 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VKYBQFWSQQZDLX-UHFFFAOYSA-N acetic acid;palladium;triphenylphosphane Chemical compound [Pd].CC(O)=O.CC(O)=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VKYBQFWSQQZDLX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- AWYMFBJJKFTCFO-UHFFFAOYSA-N bicyclo[3.2.0]heptane Chemical class C1CCC2CCC21 AWYMFBJJKFTCFO-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical compound C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000002051 biphasic Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002140 halogenating Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-O hydron;urea Chemical compound NC([NH3+])=O XSQUKJJJFZCRTK-UHFFFAOYSA-O 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- YWOITFUKFOYODT-UHFFFAOYSA-N methanol;sodium Chemical compound [Na].OC YWOITFUKFOYODT-UHFFFAOYSA-N 0.000 description 1
- UWRNYQBIUUVTGB-UHFFFAOYSA-N methyl 2-bromo-6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C)N=C1Br UWRNYQBIUUVTGB-UHFFFAOYSA-N 0.000 description 1
- RAFFKXWNTXTTFO-UHFFFAOYSA-N methyl 2-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1Br RAFFKXWNTXTTFO-UHFFFAOYSA-N 0.000 description 1
- FASOJOLGUAUEPU-UHFFFAOYSA-N methyl 3-bromopyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1Br FASOJOLGUAUEPU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- ZPJZSEHCMJYUPI-UHFFFAOYSA-N methyl piperazine-1-carboxylate Chemical compound COC(=O)N1CCNCC1 ZPJZSEHCMJYUPI-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-M oxolane-2-carboxylate Chemical compound [O-]C(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-M 0.000 description 1
- KONSZQMWMWAJKU-UHFFFAOYSA-N palladium(2+);triphenylphosphane Chemical compound [Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 KONSZQMWMWAJKU-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- FOEYMRPOKBCNCR-UHFFFAOYSA-N spiro[2.5]octane Chemical compound C1CC11CCCCC1 FOEYMRPOKBCNCR-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- UXAWXZDXVOYLII-YUMQZZPRSA-N tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1NC2 UXAWXZDXVOYLII-YUMQZZPRSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical group CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Abstract
Disclosed are compounds of fomula (1), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1 -R5 , X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, of salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARD enzyme of a subject.
Description
Lupin Limited
HETEROARYL DERIVATIVES AS PARP INHIBITORS
FIELD OF THE INVENTION
The present invention relates to heteroaryl dérivatives, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, combinations with suitable médicament, pharmaceutical compositions containing them, methods of making of heteroaryl dérivatives, and their use as PARP inhibitors.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of Indian Provisional Patent Application Number 3111/MUM/2015, filed on 17* August 2015, Indian Provisional Patent Application Number 3588/MUM/2015, filed on 21« September 2015, and Indian Provisional Patent Application Number 201621000832, filed on 8* January 2016, the disclosures of which are incorporated herein by reference in their entirety for ail purposes.
BACKGROUND OF THE INVENTION
Poly (ADP-ribose) Polymerase (PARP; 113 kDa) is an enzyme that catalyzes the addition of ADP-ribose residues to varions target proteins. The reaction requires NAD* as substrate. As many as 18 isoforms of PARP are known. PARP1 and PARP2 are the closest relatives [60% identical in PARP1 is activated by SSB (single-strand breaks) in DNA]. ADP-ribosylation occurs at the carboxylate groups of glutamic acid or aspartic acid residues in acceptor proteins and results in the modulation of catalytic activity and protein-protein interactions of the target proteins (e.g., modulation of chromatin structure, DNA synthesis, DNA repair (Base Excision Repair or BER), transcription, and/or cell cycle progression. PARP-binds to DNA single strand as well as double strand breaks. The binding of PARP to damaged DNA leads to activation of the enzyme. PARP carries out ADP ribosylation of proteins involved in DNA repair (e.g., BER) including itself. Automodification of PARP results in its release from DNA which allows the DNA repair machinery to access the DNA damage site and cany out the repair process.
Overactivation of PARP leads to necrotic cell death as a resuit of NAD+ and ATP déplétion. Cancer patients who hâve undergone radiotherapy or hâve been treated with chemotherapeutic agents that damage DNA (e.g., cisplatin, irinotecan, temozolomide) harbour DNA strand breaks. Activation of PARP in such cases allows the repair of the damaged DNA, thus leading to an undesirable résistance to the chemotherapeutic agents (and the conséquent ineffîcacy). In such a scénario, treatment with a PARP inhibitor is expected to make the repair process inefficient and cause cell death.
BRCA1 and BRCA2 play an important rôle in HR (Homologous Recombination). DNA breaks arising during DNA réplication can only be repaired by HR. Continuous exposure of BRCA1/BRCA2 déficient cells to PARP inhibitor results in accumulation of DNA DSB, followed by apoptosis (Synthetic Lethality). Triple Négative Breast Cancers (TNBC) are also acutely sensitive to PARP since they also harbor defects in the DNA repair machinery. Recently, cancer cells déficient in USP11 and endométrial cancer cells déficient in PTEN hâve also been shown to be sensitive to PARP inhibitors. PARP inhibitors thus hâve immense potential to be used for anticancer chemotherapy. [Biochem. J., (1999) 342, 249268; Ann. Rev. Biochem., 1977, 46:95-116; E. Journal Cancer 4 6 (2010) 9-20].
Additionally, PARP has been implicated in a number of disease conditions other than cancer. These include disorders such as stroke, traumatic brain injury, Parkinson’s disease, meningitis, myocardial infarction, ischaemic cardiomyopathy and other vasculature-related disorders. In animal experiments, PARP-/-mice demonstrated improved motor and memory function after CCI (Controlled Cortical Impact) versus PARP +/+ mice (J Cereb Blood Flow Metab. 1999, Vol. 19. No.8, 835).
While attempts hâve been made to develop PARP inhibitors for treating cancer and other diseases, satisfactory treatment has not been achieved.
Therefore, there exîsts an unmet need for new PARP inhibitors and treatment regimen therewith.
International patent application publications W02002/090334, W02002/036576, WO 2003/055865, W02002/094790, W02003/063874, 5 WO2013/143663, W02014/009872 and WO2016/012956 describe certain PARP inhibitors.
BRIEF SUMMARY OF THE INVENTION
In one aspect, the présent invention provides a compound of formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable sait, its 10 combination with suitable médicament, its pharmaceutical composition and its use as PARP inhibitor,
wherein, is either a single or a double bond;
X and Y independently represent carbon or nitrogen;
ring Ar is selected from
a) 6 membered heteroaromatic ring containing 1 to 2 nitrogen atoms, with X and Y being carbon; and
b) 5 membered heteroaromatic ring containing 1 to 2 heteroatoms selected ’° from nitrogen, oxygen, and sulphur, wherein both X and Y are not selected as nitrogen at the same time;
R1 is independently selected at each occurrence from halogen, nitro, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, substituted- or unsubstitutedcyclopropyl, -NH2, -N(H)CH3, -OH, and -OCH3;
R2 is selected from hydrogen, halogen, nitro, cyano, -NH2, -N(H)CH3, -OH, -OCH3> substituted- or unsubstituted- cyclopropyl, and substituted- or unsubstitutedalkyl;
R3 is independently selected at each occurrence from halogen, and substitutedor unsubstituted- alkyl, or two R3 on the same carbon form an oxo (=O), or two R3 groups together with the carbon atom(s) to which they are attached form a substituted- or unsubstituted- carbocycle;
R4 is independently selected at each occurrence as substituted- or unsubstitutedalkyl, or two R4 on the same carbon form an oxo (=0), or two R4 groups together with the carbon atom(s) to which they are attached form a substituted- or unsubstituted- carbocycle or substituted- or unsubstituted- heterocycle;
ring B is selected from çycloalkyl, heterocyclyl, aryl, and heteroaryl;
R3 is independently selected at each occurrence from halogen, nitro, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, C(=O)Ria, -C(=O)ORib, C(=O)NRibR‘c, -NRIdRie, and -ORlf;
R'“ is selected from substituted- or unsubstituted- alkyl, and substituted- or unsubstituted- çycloalkyl;
Ri” and Ru are each independently selected from hydrogen, substituted- or unsubstituted- alkyl, and substituted- or unsubstituted- çycloalkyl;
Rld and R^ are each independently selected from hydrogen, -C(=O)alkyl, substituted- or unsubstituted- alkyl, and substituted- or unsubstitutedcycloalkyl;
R’fis selected from hydrogen, -C(=O)alkyl, substituted- or unsubstituted- alkyl, perhaloalkyl, and substituted- or unsubstituted- çycloalkyl;
p is selected from 0, 1, and 2;
q is selected from 0, 1, 2, and 3;
r is selected from 0, 1, 2, and 3; and s is selected from 0, 1, 2, and 3.
In a second aspect, the invention provides a pharmaceutical composition comprising the compound of formula (I) and a pharmaceutically acceptable carrier.
In a third aspect, the invention provides a method of treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering 10 therefrom, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I).
DETAILED DESCRIPTION OF THE INVENTION
The présent invention provides a compound of the general formula (I), its tautomenc form, its stereoisomer, its pharmaceutically acceptable sait, its 15 combination with suitable médicament, its pharmaceutical composition, process and intermediates for the préparation of the above compound,
wherein, is either a single or a double bond;
X and Y independently represent carbon or nitrogen;
ring Ar is selected from
a) 6 membered heteroaromatic ring containing 1 to 2 nitrogen atoms, with X and Y being carbon; and
b) 5 membered heteroaromatic ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein both X and Y are not selected as nitrogen at the same time;
R1 is independently selected at each occurrence from haiogen, nitro, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, substituted- or unsubstitutedçyclopropyl, -NH2, -N(H)CH3, -OH, and -OCH3;
R2 IS selected from hydrogen, haiogen, nitro, cyano, -NH2, -N(H)CH3, -OH, -OCH3, substituted- or unsubstituted- cyclopropyl, and substituted- or unsubstitutedalkyl;
R3 is independently selected at each occurrence from haiogen, and substitutedor unsubstituted- alkyl, or two R3 on the same carbon form an oxo (=O), or two 15 R3 groups together with the carbon atom(s) to which they are attached form a substituted- or unsubstituted- carbocycle;
R4is independently selected at each occurrence as substituted- or unsubstitutedalkyl, or two R4 on the same carbon form an oxo (=O), or two R4 groups together with the carbon atom(s) to which they are attached form a substituted- or 20 unsubstituted- carbocycle or substituted- or unsubstituted- heterocycle;
nng B is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R5 is independently selected at each occurrence from haiogen, nitro, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, C(=O)R1a, -C(=O)ORlb C(=O)NRlbR>c, -NR^R'fj and -ORlf;
Ria is selected from substituted- or unsubstituted- alkyl, and substituted- or unsubstituted- cycloalkyl;
R1” and Rie are each independenüy selected from hydrogen, substituted- or unsubstituted- alkyl, and substituted- or unsubstituted- cycloalkyl;
Rld and Rie each independenüy selected from hydrogen, -C(=O)alkyl, substituted- or unsubstituted- alkyl, and substituted- or unsubstituted5 cycloalkyl;
Rifis selected from hydrogen, -C(=O)alkyl, substituted- or unsubstituted- alkyl, perhaloalkyl, and substituted- or unsubstituted- cycloalkyl;
p is selected from 0, 1, and 2;
q is selected from 0, 1, 2, and 3;
r is selected from 0, 1, 2, and 3;
s is selected from 0, 1, 2, and 3;
when ‘alkyl’ is substituted, it is substituted with 1 to 3 substituents independently selected from oxo (=O), halogen, nitro, cyano, perhaloalkyl, cycloalkyl, cycloalkenyl, heterocyclyl, -OR6b, -SO2R6a, -C(=O)ORba, -OC(=O)Rba, 15 C(=O)N(H)R6, -C(=O)N(alkyl)Rû, -N(H)C(=O)Rba, -N(H)R6, and -N(alkyl)R6;
when ‘cycloalkyl’ and ‘carbocycle’ are substituted, each is substituted with 1 to 3 substituents independenüy selected from oxo (=O), halogen, nitro, cyano, alkyl, alkenyl, perhaloalkyl, heterocyclyl, -OR*”, -SO2R6a, -C(=O)0R6a, -OC(=O)Rfa _ C(=O)N(H)R&, -C(=O)N(aIkyl)R*, -N(H)C{=O)R6a, -N(H)R6, and -N(alkyl)R*;
when the ‘heterocycle’ is substituted, it is substituted either on one or more ring carbon atoms or on one or more ring hetero atoms, and when it is substituted on nng carbon atom(s), it is substituted with 1 to 3 substituents independenüy selected from oxo (=O), halogen, cyano, alkyl, alkenyl, perhaloalkyl, -OR&, SCti(alkyl), -C(=O)O(alkyl), -C(=O)N(H)R6, -C(=O)N(alkyl)R&, -N(H)C(=O)(alkyl), 25 N(H)R6, and -N(alkyl)2; and when the heterocyclic group is substituted on ring nitrogen atom(s), it is substituted with a substituent or substituents independently selected from alkyl, alkenyl, cycloalkyl, cycloalkenyl, -SO2(alkyl), C(=O)(aIkyl), C(=O)O(alkyl)· -C(=O)N(H)R&, and -C(=O)N(alkyl)R6;
each R6 is independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, and heterocyclyl;
each R6a is independenüy selected from alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl; and
R6b is selected from hydrogen, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl.
In an embodiment, ring Ar is
wherein a and b represent the points of attachment of the C=O and CR2 moieties of the adjoining dihydropyridinone ring.
In any of the above embodiments, R> is independenüy selected at each occurrence from halogen, substituted- or unsubstituted- alkyl, and -NH2.
In another embodiment, Ri is independenüy selected at each occurrence from fluorine, methyl, and amino.
In any of the above embodiments, p is 0 or 1.
In any of the above embodiments, R2 is selected from hydrogen, nitro, and substituted- or unsubstituted- alkyl.
In another embodiment, R2 is selected from hydrogen, nitro, and methyl.
In any of the above embodiments, q is 0.
In any of the above embodiments, R4 is independently selected at each occurrence as substituted- or unsubstituted- alkyl, or two R4 on the same carbon 5 form an oxo (=0), or two R4 groups together with the carbon atoms to which they are attached form a substituted- or unsubstituted- heterocycle.
In another embodiment, R4 is independently selected at each occurrence as methyl, or two R4 on the same carbon form an oxo (=O), or two R4 groups together with the carbon atoms to which they are attached form a 2,510 diazabicyclo[2.2.1]heptane.
In any of the above embodiments, r is selected from 0, 1, and 2.
In any of the above embodiments, ring B is selected from aiyl and heteroaryl.
In an embodiment, ring Bis selected from phenyl, pyridinyl, thiazolyl, 2,315 dihydro-indene-5-yl, 2,3-dihydro-l-indenone-5-yI, l-isoindolinone-5-yl, and 2,3dihydro-1 -isobenzofuranone-5-yl.
More particularly, ring B is selected from
In any of the above embodiments, R5 is independently selected at each occurrence from halogen, cyano, perhaloalkyl, substituted- or unsubstitutedalkyl, C(=O)Ri% -C(=O)OR11’, -C(=O)NRibRi<-, -nriüru and -ORif, wherein Ria js substituted- or unsubsütuted- alkyl; Rib and Rlc are each independently selected from hydrogen, and substituted- or unsubstituted- alkyl; Rid and R‘« are each independently selected from hydrogen, and substituted- or unsubstituted- alkyl; and Riris substituted- or unsubstituted- alkyl.
In another embodiment, R5 is independently selected at each occurrence from fluorine, chlorine, cyano, trifluoromethyl, methyl, -C(=O)CH3, C(=O)OCH2CH3, -C(=O)NHCH3j -C(=O)NH2, -NHCH3j and -OCH3.
In any of the above embodiments, s is selected from 0, 1, and 2.
In another embodiment, ring Ar is
wherein a and b represent the points of attachaient of the C=O and CR2 moieties of the adjoining dihydropyridinone ring;
R1 is independently selected at each occurrence from halogen, substitutedor unsubstituted- alkyl, and -NH2;
R2 is selected from hydrogen, nitro, and substituted- or unsubstitutedalkyl;
R4 is independently selected at each occurrence as substituted- or unsubstituted- alkyl, or two R4 on the same carbon form an oxo (=0), or two R4 groups together with the carbon atoms to which they are attached form a substituted- or unsubstituted- heterocycle;
ring B is selected from aryl and heteroaryl;
R° is independently selected at each occurrence from halogen, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, C(=O)Rla, -C(=O)ORlb, C(=O)NRlbRlc, -NRldR>% and -OR]f, wherein Rla is substituted- or unsubstitutedalkyl; Rlb and Rlc are each independently selected from hydrogen, and 5 substituted- or unsubstituted- alkyl; R*d and Rie are each independently selected from hydrogen, and substituted- or unsubstituted- alkyl; and Rifis substitutedor unsubstituted- alkyl;
p is 0 or 1;
q is 0;
10 r is selected from 0, 1, and 2; and s is selected from 0, 1, and 2.
In yet another embodiment, ring Ar is
wherein a and b represent the points of attachment of the C=O and CR2 moieties of the adjoining dihydropyridinone ring;
R1 is independently selected at each occurrence from fluorine, methyl, and amino;
R2 is selected from hydrogen, nitro, and methyl;
R4 is independently selected at each occurrence as methyl, or two R4 on 20 the same carbon form an oxo (=O), or two R4 groups together with the carbon atoms to which they are attached form a 2,5-diazabicyclo[2.2. l]heptane;
ring B is selected from phenyl, pyridinyl, thiazolyl, 2,3-dihydro-indene-5yl, 2,3-dihydro-l-indenone-5-yl, 2,3-dihydro-l-isobenzofuranone-5-yl, and 1isoindolinone-5-yl;
R’ is independently selected at each occurrence from fluorine, chlorine, 5 cyano, trifluoromethyl, methyl, -C(=O)CH3, -C(=O)OCH2CH3, -C(=O)NHCH3, C(=O)NH2, -NH(CH3), and -OCH3;
p is 0 or 1;
q is 0;
r is selected from 0, 1, and 2; and 10 s is selected from 0, 1, and 2.
In a further embodiment, the compound of formula (I) has the structure of formula (la):
wherein R‘-R=, rmg Ar, ring B, X, Y, p, q, r and s are as defined in formula (I).
In another embodiment, the compound of formula (I) has the structure of formula (Ib):
wherein R1-R5, ring Ar, ring B, X, Y, p, q, r and s are as defined in formula (I).
General terms used in formula can be defined as follows; however, the meaning stated should not be interpreted as limiting the scope of the term per se.
The term ‘alkyl’, as used herein, means a straight chain or branched hydrocarbon containing from 1 to 20 carbon atoms. Preferably, the alkyl group contains 1 to 10 carbon atoms. More preferably, the alkyl group contains up to 6 carbon atoms. Représentative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tertbutyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
The term ‘substituted alkyl’, as defined hereinabove refers to an alkyl group which is substituted with 1 to 3 substituents independently selected from oxo (=O), halogen, nitro, cyano, perhaloalkyl, cycloalkyl, cycloalkenyl, heterocyclyl, -OR** -SO2R6a, -C(=O)OR6a, -OC(=O)R6a, -C{=O)N(H)R<\ C(=O)N(aIkyl)R6, -N(H)C(=O)R<» -N{H)R6, and -N(alkyl)R6; each R(ï is independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, and heterocyclyl; each R&a is independently selected from alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl; and Rûb is selected from hydrogen, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl.
The term ‘perhaloalkyl’, as used herein, means an alkyl group as defined hereinabove wherem ail the hydrogen atoms of the said alkyl group are substituted with halogen. The perhaloalkyl group is exemplified by trifluoromethyl, pentafluoroethyl, and the like.
The term ‘cycloalkyl’ and ‘carbocycle’ as used herein, means a monocyclic, bicyclic, or tricyclic non-aromatic ring system containing from 3 to 14 carbon atoms, preferably monocyclic cycloalkyl ring containing 3 to 6 carbon atoms. Examples of monocyclic ring Systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Bicyclic ring Systems include monocycfic nng system fused across a bond with another cyclic system which may be an alicyclic ring or an aromatic ring. Bicyclic rings also include spirocyclic Systems wherein the second ring gets annulated on a single carbon atom. Bicyclic ring Systems are also exemplifîed by a bridged monocyclic ring System in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge. Représentative examples of bicyclic ring Systems include, but are not limited to, biçyclo[3.1.1]heptane, bicyclo[2.2.ljheptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3. l]nonane, and bicyclo[4.2. IJnonane, bicyclo[3.3.2]decane, bicyclo[3. l.OJhexane, bicyclo[4.1.0]heptane, bicyclo[3.2.0]heptanes, octahydro-lH-indene, spiro[2.5]octane, spiro[4.5]decane, spiro[bicyclo[4.1.0]heptane-2,1 ’-cyclopentane], hexahydro-2'H-Spiro[Cyciopropane-l,r-pentalene], Tricyclic ring Systems are the Systems wherein the bicyclic Systems as described above are further annulated with third ring, which may be an alicyclic ring or aromatic ring. Tricyclic ring Systems are also exemplifîed by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge. Représentative examples of tricyclic-ring Systems include, but are not limited to, tricyclo[3.3.1.03 7]nonane, and tricyclo[3.3.1.137]decane (adamantane).
The term ‘alkenyl’, as used herein, means an alkyl group containing at least one carbon-carbon double bond. The term ‘cycloalkenyl’, as used herein, means a cycloalkyl group containing at least one carbon-carbon double bond.
The term substituted cycloalkyl’, or ‘substituted carbocycle’ as defined heremabove is a cycloalkyl group which is substituted with 1 to 3 substituents independently selected from oxo (=O), halogen, nitro, cyano, alkyl, alkenyl, perhaloalkyl, heterocyclyl, -OR6b, -SO2R^, -C(=O)OR6a, -OC(=O)R6a, -C(=O)N(H)Rû, -C(=O)N(alkyl)R6, -N(H)C(=O)R*a, -N(H)R<\ and -N(alkyl)R6; each R& is independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, and heterocyclyl; each Rûa is independently selected from alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl; and R<* is selected from hydrogen, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl.
The term lieterocycle’ or heterocyclic’ as used herein, means a ‘cycloalkyl’ group wherein one or more of the carbon atoms replaced by heteroatom selected is from N, S and O. The heterocycle may be connected to the parent molecular moiety through any carbon atom and/or any nitrogen atom contained within the heterocycle. Représentative examples of monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1.1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. Représentative examples of bicyclic heterocycle include, but are not limited to, l,2,3,4-tetrahydroisoquinolin-2-yl, 1,2,3,4tetrahydroquinolin-1-yl, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-l,4benzodioxinyl, 2,3-dihydro-l-benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3dihydro-IH-indolyl, and 1,2,3,4-tetrahydroquinolinyl. The term Tieterocycle’ or ‘heterocyclic also includes bridged and spiro heterocyclic Systems such as azabicyclo[3.2.1] octane, azabicyclo[3.3.l]nonane, 8-oxa-3-azabicyclo[3.2.ljoctan-
3- yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yI, 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl, 8- azabicyclo[3.2.1]octan-8-yl, 3-azabicyclo[3.2.1]octan-3-yl, 3azabicyclo[3.1.0]hexan-3-yl, 6-azaspiro[2.5]octan-6-yl, 5-azaspiro[2.5]octan-5-yl,
4- azaspiro[2.4]heptan-4-yl, 2,5-diazabicyclo[2.2. l]heptane and the like.
The tenri substituted heterocycle’ or ‘substituted heterocyclic’ as defined hereinabove, each of them is substituted either on a ring carbon atoms or on a ring hetero atoms, and when it is substituted on a ring carbon atom(s), it is substituted with 1 to 3 substituents independently selected from oxo (=0), halogen, cyano, alkyl, alkenyl, perhaloalkyl, -OR&, -SO2(alkyl), -C{=O)O(alkyl), C(=O)N(H)R6, -C(=O)N(alkyl)R6, -N(H)C(=O)(alkyl), -N(H)R&, and -N(alkyl)2; and when the heterocyclic group is substituted on a ring nitrogen atoms(s), it is substituted with one or more substituents independently selected from alkyl, alkenyl, cycloalkyl, cycloalkenyl, -SO2(alkyl), -C(=O)(alkyl), C(=O)O(alkyI)· 18697
C( O)N(H)R5, and -C(-0)N(alkyl)R6; wherein each Rs is independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, and heterocyclyl.
The term ‘aryl’, as used herein, refers to a monovalent monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring system. Examples of aryl groups include 5 phenyl, naphthyl, anthracenyl, fluorenyl, îndenyl, azulenyl, and the like. The term ‘aryl’ as used herein, also includes partially saturated bicyclic and tricyclic aromatic hydrocarbons optionally substituted with oxo (=0), e.g., tetrahydronaphthalene, 2,3-dihydro-indene-5-yl, and 2,3-dihydro-l-indenone-5-yl.
The term ‘heteroaryl’, as used herein, refers to a 5-14 membered 10 monocyclic, bicyclic, or tricyclic ring System having 1-4 ring heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated), wherein at least one ring in the ring System is aromatic. Thus the term heteroaryl’ as used herein, also includes a 514 membered partially saturated bicyclic and tricyclic aromatic ring System 15 having 1-4 ring heteroatoms selected from O, N, or S, and the said heteroaryl is optionally substituted with oxo (=O). Examples of heteroaryl groups include, but not limited to, pyridyl, 1-oxo-pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyndazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, 20 benzoxazolyl, benzofuranyl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, azaindolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3Jpyrimidinyl, pyrazolo[3,4]pyrimidinyl, and benzo(b)thienyl, 2,3-thiadiazolyl, lH-pyrazolo[5,l-
c]-1,2,4-triazolyl, pyrrolo[3,4-d]-1,2,3-triazolyl, cyclopentatriazolyl, 3H- pyrrolo[3,4-c] isoxazolyl, 2,3-dihydro-benzo[l,4]dioxin-6-yl, 2,3-dihydrobenzo[ 1,4]dioxm-5-yl, 2,3-dihydro-benzofuran-5-yl, 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro-benzofuran-6-yl, 2,3-dihydro-benzofuran-6-yl, 2,3-dihydroisobenzofuran-5-yl, 2,3-dihydro-l-isobenzofuranone-5-yl, 2,3-dihydro-lH-indol-
5-yl, 2,3-dihydro-lH-indol-4-yl, 2,3-dihydro-lH-indol-6-yl, 2,3-dihydro-lH30 indol-7-yI, l-isoindolinone-5-yl, benzof 1,3]dioxol-4-yl, benzo[ 1,3]dioxol-5-yl,
1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 2,3dihydrobenzothien-4-yl, 2-oxoindolin-5-yl and the like.
The terni ‘oxo’ means a divalent oxygen (=O) attached to the parent group. For example, an oxo attached to carbon forms a carbonyl, an oxo substituted on cyclohexane forms a cyclohexanone, and the like.
The term ‘annulated’ means the ring system under considération is either annulated with another ring at a carbon atom(s) of the cyclic system or across a bond of the cyclic system as in the case of fused or spiro ring Systems.
The term ‘bndged’ means the ring system under considération contain an alkylene bridge having 1 to 4 methylene units joining two non-adjacent ring atoms.
Whenever a range of the number of atoms in a structure is indicated (e.g., a C, to C20 alkyl, C2 to C20 alkenyl etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used. Thus, for instance, the recitation of a range of 1-6 carbon atoms (e.g., Ci to C6), 2-6 carbon atoms (e.g., C2 to C6), 3-6 carbon atoms (e.g., C3 to C0), as used with respect to any Chemical group (e.g., alkyl, alkenyl, etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, and/ or 6 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms,1-6 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms,2-6 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms,4-5 carbon atoms, 4-6 carbon atoms as appropriate).
In accordance with an embodiment, the invention provides a compound, its tautomeric form, its stereoisomers, racemates, and pharmaceutically acceptable sait thereof as described hereinabove wherein the compound of general formula (I) is selected from:
(R)-4’(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 1);
(R)-4-(4-(3-(3-fluoro-5-oxo-5,6-dihydro-lJ6-naphthyridin-7-yl)cycIopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 2);
(R) -7-(3-(4-(o-tolyl)piperazin-1 -yljcyclopent-1 -en-1 -yl) -1,6-naphthyridin5(6H)-one (Compound 3);
(S) -4-(4-(3-(5-oxo-5J6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 4);
(S)-4-(4-(3-(3-fluoro-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl}cyclopent-2en-l-yl)piperazin-l-yl)benzomtrile (Compound 5);
(R)-4-(4-(3-(2-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 6);
(R)-4-(4-(3-(3-amino-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 7);
(R)-4-(4-(3-(8-nitro-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 8);
(R) -4-(4-(3-(8-methyl-5-oxo-5)6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 9);
(S) -4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yi)benzonitrile (Compound 10);
4-(4-(( 1 R,3S/3R)-3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7yl)cyclopentyl)piperazin-l-yl)benzonitrîle (Compound 11);
4-(4-(( 1 R,3R/3S)-3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7yl)cyclopentyl)piperazm-l-yl)benzonitrile (Compound 12);
(R)*4-(2-oxo-4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-enl-yl)piperazïn-l-yl)benzonitrile (Compound 13);
4-((R)-3-methyl-4-((R/S)-3-(5-oxo-5,6-dihydro-ll6-naphthyridin-7yl)cycIopent-2-en-l-yl)piperazin-l-yI)benzonitrile (Compound 14);
4-((R)-3-methyl-4-((S/R)-3-(5-oxo-5,6-dihydro-1,6-naphthyridîn-7yl)cyclopent-2-en-l-yl)piperazin-I-yl)benzonitriIe (Compound 15);
4-((lS,4S)-5-((R/S)-3-(5-oxo-5J6-dihydro-l)6-naphthyridin-7-yl)cyclopent-2en-l-yl)-2,5-diazabicydo[2.2.l]heptan-2-yl)benzonitrile (Compound 16);
4-(( 1 S,4S)-5-((S/R)-3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyciopent-2en-l-yl)-2,5-diazabicyclo[2.2. l]heptan-2-yl)benzonitrile (Compound 17);
(R)-N-methyl-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yI)cyclopent-2en-l-yl)piperazin-l-yl)benzamide (Compound 18);
(R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzamide (Compound 19);
Ethyl(R)-4-(4-(3-(5-oxo-5,6-dihydro-l>6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzoate (Compound 20);
(R)-7-(3-(4-phenylpiperazin-1 -yl)cyclopent-1 -en-1 -yl)-1, 6-naphthyridin5(6H)-one (Compound 21);
(R)-7-(3-(4-(4-fluorophenyl)piperazin-1 -yljcyclopent-1 -en-1 -yl)-1,6naphthyndin-5(6H)-one (Compound 22);
(R)-3-fluoro-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 23);
(R)-7-(3-(4-(4-chlorophenyl)piperazin-l-yl)cyclopent-l-en- 1-yl)-1,6naphthyridin-5(6H)-one (Compound 24);
(R)-7-(3-(4-(4-methoxyphenyl)piperazin- l-yl)cy dopent-1 -en- 1-yl)-1,6naphthyridin-5(6fl)-one (Compound 25);
(R)-7-(3-(4-(p-tolyI)piperazin-l-yl)cyclopent-l-en-l-yl)-l,6-naphthyridin5(6H)-one (Compound 26);
(R)-7-(3-(4-(4-(methylamino)phenyl)piperazin-1 -yljcydopent-1 -en-1 -yl)-1,6naphthyridin-5(6H)-one (Compound 27);
(R)-7-(3-(4-(4-acetylphenyl)piperazin-1 -yljcydopent-1 -en-1 -yl)-1,6naphthyridin-5(6H)-one (Compound 28);
(R)-7-(3-(4-( 1-oxo-2,3-dihydro-177-inden-5-yl)piperazin-1 -yljcydopent-1 -enl-yl)-l,6-naphthyridin-5(6/l)-one (Compound 29);
(R)-7-(3-(4-(2,3-dihydro-I7f-inden-5-yl)piperazin-l-yljcydopent-1-en-1-yl)l,6-naphthyridin-5(6H)-one (Compound 30);
(R)-7-(3-(4-( 1 -oxo-1,3-dihydroisobenzofuran-5-yl)piperazin-1 -yljcydopent-1 en-l-yl)-l,6-naphthyridin-5(6H)-one (Compound 31);
(R)-7-(3-(4-(l-oxoisoindolin-5-yl)piperazin-l-yljcydopent-1-en-1-yl)-1,6naphthyridin-5(6H)-one (Compound 32);
(R)-7-(3-(4-(4-(trifluoromethyl)phenyl)piperazin-1 -yljcydopent-1 -en- 1-yl)-1,6naphthyridin-5(6H)-one {Compound 33);
(R)-6-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yI)cyclopent-2-en-lyl)piperazin-l-yl)nicotinonitrile (Compound 34);
(R)-2-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)thiazole-5-carbonitrile (Compound 35);
(R)-4-(4-(3-( 1 -oxo-1,2-dihydro-2,6-naphthyridin-3-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 36);
(R)-4-(4-(3-(8-oxo-7,8-dihydro-1,7-naphthyridin-6-yI)cydopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 37);
(R)-4-(4-(3-(l-oxo-l,2-dihydro-2,7-naphthyridin-3-yl)cydopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 38);
(R)-7~(3-(4-(2,4-difluorophenyl)piperazin-1 -yljcyclopent-1 -en-1 -yl)-1,6naphthyndin-5(6H)-one (Compound 39);
(R)-4-(4-(3-(5-oxo-5J6-dihydropyrido[4,3-d]pyrimidm-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 40);
(R)-4-(4-(3-(5-oxo-5,6-dihydropyrido[3,4-b]pyrazin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 41);
(R)-4-(4-(3-(4-oxo-4,5-dihydrothieno[3i2-c]pyridin-6-yl)cycIopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 42);
(R)-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[5,4-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 43);
(R) -4-(4-(3-(4-oxo-4,5-dihydrothiazolo[4J5-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 44);
(S) -4-(4-(3-(4-oXo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 45);
(S)-4-(4-(3-(4-oxo-4J5-dihydrothiazolo(5J4-c]pyridin-6-yl)cyclopent-2-en-lyljpiperazm- l-yl)benzonitrile (Compound 46);
(R)-6-(3-(4-(4-fluorophenyl)piperazin-1 -yl)cy dopent-1 -en- l-yl)thieno[3,2c]pyndin-4(5/J)-one (Compound 47);
(R)-6-(3-(4-phenylpiperazin-l-yl)cydopent-l-en-l-yl)thieno[3>2-c]pyridin4(5H)-one (Compound 48);
(R)-N-methyl'4-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cyclopent-
2-en-l-yl)piperazin-l-yl)benzamide (Compound 49);
(R)-6-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)nicotinonitrile (Compound 50);
(R)-6-(3-(4-(thiazol-2-yl)piperazin-1 -yljcyclopent- 1-en-1 -yl)thieno[3,2c]pyridin-4(5H)-one (Compound 51);
(R)-3-fluoro-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[5,4-c]pyridin-6-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 52);
(R)-4-(4-(3-( 1 -methyl-4-oxo-4,5-dihydro-1 H-pyrazolo(4,3-c]pyridin-6yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 53);
(R) - 4-(4-(3-( I -oxo-1,2-dihydropyrrolo[ 1,2-c]pyrimidin-3-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 54);
(R) -3-(3-(4-(4-fluorophenyl)piperazin- l-yl)cyclopent-1 -en-1 -yl)pyrrolo[ 1,2c]pyrimidin-1 (2H)-one (Compound 55); and (R)-4-(4-(3-(l -oxo- l,2-dihydropyrrolo[ 1,2-a]pyrazin-3-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 56).
According to an embodiment of the present invention, the compounds of general formula (I) where ail the symbols are as defined earlier, can be prepared by 20 methods given in Schemes 1-15 and the examples. Représentative procedures are shown below, however; these synthetic methods should not be construed as limiting the invention in any way, which lies in the whole genus described by the compound of formula (I) as disclosed hereinabove.
(la)
Wherein στ— is a double bond;
R2 Is hydrogen;
q=0;
X and Y are carbon.
Scheme 1
Scheme 1 shows a method of préparation of the compounds of formula represented as (la) in accordance with an embodiment. The compounds of 5 formula (la), wherein R2 is hydrogen, q = 0, === is double bond, X and Y are carbon, and ail other symbols are as defined under formula (I), can be prepared from compounds of formula (ΙΙΙ-a), wherein R4 and R5 are as defined under formula (I).
The compounds of formula (II), wherein, L is halogen or 10 trifluoromethanesulfonate (OTf), and ail other symbols are as defined under formula (I), are subjected to Sonogashira coupling with compounds of formula (III-a) wherein R4 and R5 are defined earlier in formula (I), followed by in situ cyclization to obtain the compounds of formula (IV). Sonogashira coupling can be carried out under different coupling conditions and in a suitable solvent or 15 solvents, for example, a halogenated hydrocarbon such as dichloromethane or chloroform, an aromatic hydrocarbon such as xyiene, toluene, or benzene, an ether type solvent such as diethyl ether, tetrahydrofuran or 1,4-dioxane, an aproüc solvent such as dimethylformamide, dimethylsulfoxide, acetonitrile, or Nmethyl-2-pyrrolidinone, in the presence of a suitable base such as potassium carbonate, triethylamine, diethylisopropylamine, diisopropylethylamine or the like, and a palladium catalyst such as bis(triphenylphosphine)palladium (II) dichlonde [(PPhahPdCh], bis(triphenylphosphine)palladium (II) diacetate [(PPh3)2Pd(OAc)2] combined with a co-catalytic amount of copper(I)iodide (Cul), as well known in the art (Review article by R. Chinchilla and C. Nejera; Chem. Soc. Rev., 2011, 40, 5084) at a température of 0-120°C over a period of 1-12 hr to give compounds of formula (IV). Preferably, the Sonogashira reaction is carried out in anhydrous acetonitrile in the presence of bis(triphenylphosphine)palladium (II) chloride, using diisopropylethylamine or triethylamine as base at 60 -65DC under nitrogen for 3 hr.
The compounds of formula (IV), where ail symbols are as defined under formula (I), can be treated with ammonia to obtain compounds of formula (la); where R2 is hydrogen, q = 0, ===== is double bond, X and Y are carbon, and ail other symbols are as defined under formula (I). Preferably, the reaction is carried out in the presence of methanolic ammonia at 85°C for 3 h.
The compounds of formula (Ib), wherein R2 is hydrogen, q = 0, :_____is double bond, X and Y are carbon, and ail other symbols are as defined under formula (I), can be prepared from compounds of formula (ΙΙΙ-b), wherein R4 and R3 are as defined under formula (I), using similar process as described in Scheme-1.
Where Ak is methyl or ethyl L is Halogen or OTf
(R1), (h)
Where crm is a double bond:
R2 is hydrogen;
Q=0:
X and Y are carbon.
Scheme 2
Scheme 2 shows a method of préparation of compounds of formula (la) in accordance with an embodiment. Compounds of formula (la), where R2 is 5 hydrogen, q = 0, ™ is double bond? χ γ carbon( symbols are as defined under formula (I), can be prepared from compounds of formula (ΠΙ-a), where R4 and R* are as defined under formula (I).
The compounds of formula (V), wherein L is halogen, or trifluoromethanesulfonate (OTf), and ail other symbole are as defined under 10 formula (I), are subjected to Sonogashira coupling with compound of formula (IIIa), where R4 and R5 are defined earlier in formula (I), to obtain compounds of formula (VI). Preferably, the Sonogashira reaction is carried out in anhydrous acetomtrile in the presence of bis(triphenylphoSphine)paUadium (II) chloride, using diisopropylethyl amine or triethylamine as base at 60-80’C under nitrogen 15 for 3-18 hours .
The compounds of formula (VI), where ail symbols are as defined under formula (I), are hydrolyzed using sodium hydroxide in water and methanol to obtain compounds of formula (VII); and ftrrther cyclized to obtain compounds of formula (IV) using lewis acid such as trifluoromethane sulphonic acid.
The compounds of formula (IV). where ail symbols are as defined under formula (I), can be treated with ammonia to obtain compounds of formula (la);
where R2 is hydrogen, q = 0, = 1S douWe bond> x and y carbon.
other symbols are as defined under formula (I). Preferably, the reaction is carried out in the presence of methanolic ammonia at 85°C for 3 h.
The compounds of formula (Ib), wherein R2 is hydrogen, q = 0, ~ is double bond, X and Y are carbon, and ail other symbols are as defined under 10 formula (I), can be prepared from compounds of formula (ΙΙΙ-b), wherein R4 and R3 are as defined under formula (I), using similar process as described in Scheme 2.
(XXX)
Scheme 3
Scheme 3 shows a method of préparation of enantiopure compounds of formula (Ill-a). The compounds of formula (ΙΙΙ-a), wherein r = 0 and ail other symbols are as defined under compounds of formula (I), can be prepared from a compound (IX). The compound (IX) is prepared from compound (XXX) and (VIII) according to the procedure reported in W020149872.
Racemic compound of formula (IX) can be subjected to préparative chiral HPLC to separate two enantiomers compound (X-b) and compound (X-a). 5 Enantiopure compound of formula (ΙΙΙ-a) can be synthesized starting from enantiopure compound of formula (X-a).
Compound of formula (X-a) can be treated with diisobutyl aluminium hydride (DIBAL-H) in a suitable solvent or mixture of solvents, for example, tetrahydrofuran, toluene, chloroform, dichloromethane or the like, at a 10 température of -78°C to 50°C over a period of 1-16 hr to give a compound of formula (Xl-a).
The compound of formula (ΧΙ-a) can be treated with trimethylsilyldiazomethane solution (2M in diethyl ether or in hexane) in a suitable solvent, for example, tetrahydrofuran or the like, in the presence of base 15 n-butyl lithium or the like at a température of -78°C to 50°C over a period of 120 hr to give a compound of formula (XH-a).
The compound of formula (Xll-a) is subjected to deprotection of Nprotecüng group to obtain a compound of formula (ΧΙΙΙ-a). Deprotection reaction of N-protecting groups can be carried out using standard procedures generally 20 used m synthetic organic chemistry or well known in the literature e.g., Greene T.W. et al., 1999. Preferably, reaction is carried out in dichloromethane using hydrochloric acid in 1,4-dioxane.
The compound of formula (ΧΙΙΙ-a) is reacted with the compounds of formula (XIV), where X= F, Cl, Br, I, or OTf, either in nucleophilic substitution 25 reaction condition or Buchwald coupling method to obtain the compounds of formula (ΙΙΙ-a), wherein r=0 and ail other symbols are as defined under compounds of formula (I). The reaction may be carried out in a suitable solvent such as dimethylsulfoxide, Ν,Ν-dimethylformamide, 1,4-dioxane, acetonitrile, dichloromethane, methanol, or éthanol in the presence of a base such as potassium carbonate, sodium bicarbonate, triethylamine or the like, at a température of 25°C-150°C over a period of 30 min to 20 hr to obtain the compounds of formula (ΠΙ-a). Preferably, reaction is carried out in N,Ndimethylformamide using potassium carbonate as base. On the other hand, Buchwald coupling can be carried out in a solvent such as toluene, tert-butanol, dimethylformamide, iso-propyl alcohol, 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofuran, and/or acetonitrile, in the presence of a base such as potassium phosphate, potassium carbonate, sodium tert-butoxide, césium carbonate, lithium hexamethyl disilazane or the like, palladium catalysts such as palladium (II) acetate (Pd(OAc)2), tris(dibenzyllideneacetone)dipalladium (0), [Pd2(dba)3], at a température of 50-160 °C and ligand such as 2,2'Bis(diphenylphosphino)-1, Γ-binaphthyl (BINAP), 2-Dîcyclohexylphosphino2',4',6'-triisopropylbiphenyl (XPhos), 2-Dicyclohexylphosphino-2'-(N,iVdimethylaminojbiphenyl (DavePhos), (2-Biphenyl)di-tert-butylphosphine (JohnPhos), 2-Dicyclohexylphosphino-2',6’-dimethoxybiphenyl (SPhos), 2Dicyclohexylphosphino-2 -methylbiphenyl (MePhos) or the like.
Enantiopure compound of formula (ΠΙ-b), wherein r=0 and ail other symbols are as defined under compounds of formula (I) can be synthesized from enantiopure compound of formula (X-b). Enantiopure compound of formula (X-b) is synthesized by following methods described in the Scheme 3 which can be further converted to a compound of formula (ΙΙΙ-b), wherein r = 0 and ail other symbols are as defined under compounds of formula (I); by following methods described m Scheme 3 for the synthesis of enantiopure compound of formula (IIIa).
TMSCN
Znl2
R-CBS
BHj.DMS
DCC.
DMAP
OHC (XV) (xvi)
(XXI)
...NHBoc
DIBAL-H
Zn/Ag
(XIX)
(XVII)
TMSNj, nBuLi
HCl
...NHBoc
0) DPPA, DBU, TPP (il) (Boc)2O. TEA
wtiere:n r=O or two R4 togeiher form oxo
Scheme 4
Scheme 4 shows a method of préparation of the compound of formula (III5 a), wherein r = O or two R4 together can form oxo and ail other symbols are as defined under the compounds of formula (I), from a compound of formula (XV). The compound of formula (XV) can be prepared according to the procedure described in Journal of Médicinal Chemistry, 1999, 42, 7, 1274-1281.
The compound of formula (XV) is reacted with trimethylsilylcyanide 10 (TMSCN) and zinc iodide, in the presence of an acid or zinc iodide in dichloromethane to obtain a compound of formula (XVI). The compound of formula (XVI) is reacted with (R)-l,3a-dimethyI-3,3diphenylhexahydropyrrolo[l,2c][l,3,2]oxaborole (R-CBS) (IM solution in toluene) and Borane dimethyl sulphide complex (BH3.DMS) in Tetrahydrofuran (THF) to 15 obtain a compound of formula (XVII) with an enantiomeric excess - 94.0%.
The compound of formula (XVII) as obtained in the previous step is subjected to coupling with (2R)-2-acetoxy-2-phenylacetic acid to obtain a compound of formula (XVIII) to enrich the enantiomeric excess. The coupling reaction can be carried out according to the conditions known for converting carboxylic acids to esters, to a person skilled in the art. The reaction may be carried out in an organic solvent, for example, Ν,Ν-dimethyl formamide, tetrahydrofuran, a halogenated hydrocarbon such as chloroform or dichloromethane, an aromatic hydrocarbon such as xylene, benzene, toluene, or mixtures thereof, or the like, in the presence of suitable base such as triethylamine, diisopropylethylamine, pyridine, dimethyl amino pyridine or the like at a température of 0-50°C using reagents such as l-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1 3dicyclohexylcarbodiimide (DCC), and auxiliary reagents such as l-hydroxy-7azabenzotriazole (HOAT), hydroxybenzotriazole hydrate (HOBT) or the like. Preferably, the coupling is carried out in dichloromethane using DCC and dimethyl amino pyridine as base. Further ester hydrolysis of the compound (XVIII) using LiOH in THF-water provides a compound of formula (XVII) with enantiomeric excess -98.5%.
The compound of formula (XVII) is reacted with Zn-Ag couple to obtain the de-brominated product as a compound of formula (XIX). The compound of formula (XIX) is reacted with [azido(phenoxy)phosphoryl]oxybenzene in tetrahydrofuran; the resulting intermediate is treated with triphenyl phospine, Boc-anhydride and triethylamine to obtain a compound of formula (XX).
The compound of formula (XX) is subjected to réduction using di-isobutyl aluminium hydride (DIBAL-H) in dichloromethane to obtain a compound of formula (XXI); which in turn is treated with trimethylsilyldiazomethane and nbutyl lithium in tetrahydrofuran to obtain a compound of formula (XXII).
The compound of formula (XXII) is treated with hydrochloric acid in dichloromethane or dioxane to obtain a compound of formula (XXIII) as hydrochloride sait; which in tum is reacted with a compound of formula (XXIV); wherein r = 0 or two R4 together can form oxo and ail other symbols are as defined under compounds of formula (I) and X is halogen, tosylate (OTs), mesylate (OMs), or any other leaving group, to obtain the compounds of formula (ΙΙΙ-a); wherein r = 0 or two R4 together can form oxo and ail other symbols are as defined under compounds of formula (I).
Wherein r=0
Scheme 5
Scheme 5 shows a method of préparation of the compounds of formula (ΙΙΙ-a); wherein r = 0 and ail other symbols are as defined under compounds of 10 formula (I), from a compound represented by formula (XXV). The compound of formula (XXV) is commercially available.
The compound of foi inula (XXV) is reacted with Trimethylsilylacetylene in the presence of a base such as n-butyl lithium in tetrahydrofuran to obtain a compound of formula (XXVI). The compound of formula (XXVI) is treated with 15 aqueous sulphuric acid to obtain a migrated product as (XXVII).
The compound of formula (XXVII) as obtained in the previous step is subjected to enantioselective acylation reaction with vinyl acetate in the presence of an enzyme such as Lipase PS “Amano” SD to obtain a compound of formula (XXVIII).
The compound of formula (XXVIII) is reacted with piperazine dérivative in presence of a palladium catalyst such as TetrakiS(triphenyl phosphine) Pd(O) to 5 obtain the coupled product as compound of formula (XXIX),
The compound of formula (XXIX) is subjected to deprotection reaction using tetrabutyl ammonium fluoride (TBAF) to obtain the compound of formula (XH-a). The compound of formula (ΧΙΙ-a) can be converted into the compound of formula (ΙΙΙ-a) by following the procedure described in Scheme 3.
Wherein R4 is Methyl
Ring Θ is Phenyl. R£ is cyano
(XXXIII-b)
ÎXXXIV-al
(XXXIV-bJ
Scheme 6
Scheme 6 shows a method of préparation of compounds of formula (III-a) and (ΠΙ-b), wherein R4 is methyl, Ring B is phenyl and R5 is cyano and ail other symbols are as defined under the compounds of formula (I) from a compound of formula (XXX).
The compound of formula (XXX) is reacted with tert-butyl (R)-3methylpiperazîne-l-carboxylate in the presence of a base such as potassium 5 carbonate in acetonitrile as a solvent to obtain the compound as diastereomeric mixture. The mixture of compounds is separated by column chromatography to obtain two diastereomers of compound of formulas (XXXI-a) and (XXXI-b). The compounds of formula (Ill-a) and (ΙΙΙ-b), where R4 is methyl, Ring B is phenyl and R° is cyano and ail other symbols are as defined under compound of formula (I), 10 can be synthesized following the methods described in Scheme 3, starting from compounds of formula (XXXI-a) and compound of formula (XXXI-b) respectively.
(XXX)
(lll-a)
X is halogen or -OTf
(lll-b) wherein two R4 together form heterocyde;
Ring B is Phenyl, Rs is cyano.
Scheme 7
(XXXVIII)
Scheme 7 shows a method of préparation of compounds of formula (Ilia) 15 and (ΙΙΙ-b), wherein two R4 together form bridged heterocyde ring, Ring B is phenyl and R5 is cyano and ail other symbols are as defined under compound of formula (I), from the compound of formula (XXX).
The compound of formula (XXX) is reacted with tert-butyl (lS,4S)-2,5diazabicyclo[2.2. l]heptane-2-carboxylate in the presence of a base such as 5 potassium carbonate, m acetonitrile as a solvent to obtain the compound as diastereomeric mixture (XXXV). The compounds of formula (ΙΠ-a) and (III-b); where two R4 together form (lS,4S)-2,5-diazabicyclo[2.2.1]heptane bridged heterocycle ring, Ring B is phenyl and R5 is cyano and ail other symbols are as defmed under compound of formula (I); can be synthesized starting from 10 compounds of formula (XXXV); following the methods described in Scheme 3 and séparation by chiral HPLC.
(R3), (la) wherei π ζττζτ is a double bond:
Ring Ar is Pyridyl,
X and Y are carbon, p. q, r are 0;
R2 is hydrogen,
Ring B is Phenyl, Rs is -CONR1bRT
Scheme 8
Scheme 8 shows a method of préparation of the compounds of formula (la) wherein R2 is hydrogen, p, q, and r = 0, is double bond, Ring Ar is Pyridyl, X and Y are carbon, Ring B is Phenyl, R° is —CONRlbRIc, from a compound of formula (XXXIX). The compounds of formula (XXXIX) can be prepared by the method described in Scheme 1.
The compound of formula (XXXIX) can be converted to a compound of formula (XXXX) according to reaction conditions known in the art for converting carboxylic esters to carboxylic acids. Preferably, the reaction is carried out using sodium hydroxide as a base and water-ethanol as a solvent.
The compound of formula (XXXX) is reacted with alkylamine hydrochloride. The reaction can be carried out using the conditions generally used for synthesis of amides from acids. The reaction may be carried out in suitable solvents such as dimethyl sulfoxide (DMSO), N,N-dimethylformamide, tetrahydrofuran, chloroform, dichloromethane, xylene, benzene or mixtures thereof or the like in the presence of a base such as methylamine, triethylamine, diisopropylethylamine, pyndine or the like at a température between 0-100 °C using reagent(s) such as thionyl chloride, phosphorous chloride, oxalyl chloride, alkyl chloroformate, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), N,Ndicyclohexylcarbodiimide (DCC), auxiliary reagents such as Hydroxybenzotriazole (HOBt), l-hydroxy-7-azabenzotriazole (HOAt), N,N,N',N-Tetramethyl-O-(1Hbenzotriazol-l-yl)uronium hexafluorophosphate (HBTU), (1[Bis(dimethylamino)methylene]-IH-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) or the like. Preferably, the coupling is carried out in DMSO using HATU and Diisopropyl ethyl amine (DIPEA) as base.
The compounds of foimula (Ib), wherein R2 is hydrogen, p, q, and r = 0, is double bond, Ring Ar is Pyridyl, X and Y are carbon, Ring B is Phenyl, Rs is -CONRibRic can be prepared from compounds of formula (ΙΙΙ-b), wherein q = 0, r = 0, Ring B is Phenyl, R5 is -COOEt, using similar process as described in Scheme-8.
Where rrrr: is a double bond;
Ring Arts Pyndyl;
X and Y are cadran, p, q, r are 0;
(h)
Where ..... is a double bond,
X is haiogen or -QTi
Ring Ar is Pyridyi.
X and Y are carbon, p, q. r are 0, R2 is Nitro.
Scheme 9
Scheme 9 shows a method of préparation of the compound of formula (la);
wherein R2 is hydrogen, p, q, and r are 0,-----is double bond, Ring Ar is Pyridyl,
X and Y are carbon, and ail other symbols are as defined under compound of formula (I), from the compound of formula (ΧΙΙ-a). The compound of formula (XIIa) can be prepared by the method described in the Scheme 3 or Scheme 5.
The compound of formula (ΧΙΙ-a) is subjected to Sonogashira coupling with 10 2-bromonicotinic acid, followed by in situ cyclization to obtain a compound of formula (XXXXI). Preferably, the Sonogashira coupling reaction is carried out in anhydrous acetonitrile in the presence of bis(triphenylphosphine)palladium (II) chloride, using diisopropylethylamine or triethylamine as a base at 60-85°C under nitrogen for 3-16 hr.
The compounds of formula (XXXXI) can be treated with ammonia to obtain a compound of formula (XXXXII). PreferaMy, the reaction is carried out in the presence of methanolic ammonia at 85°C for 3 - 24 hrs.
The compound of formula (XXXXII) is subjected to deprotection of the N5 protecting group to obtain a compound of formula (XXXXIII). The deprotectîon reaction of N-protecting groups can be carried out using standard procedures generally used in synthetic organic chemistry or well known in the literature e.g., Greene T.W. et al., 1999. Preferably, the reaction is carried out in dichloromethane using hydrochloric acid in 1,4-dioxane.
The compound of formula (XXXXIII) is reacted with the compounds of formula (XIV), wherein X = F, Cl, Br, I, or OK, either in nucleophilic substitution reaction condition or Buchwald coupling method to obtain the compounds of formula (la), wherein R2 is hydrogen, p, q, r = 0, Ring Ar is Pyridyl, X and Y are carbon, and ail other symbols are as defined under the compounds of formula (I).
The reaction may be carried out in a suitable solvent such as dimethylsulfoxide, Ν,Ν-dimethylformannde, 1,4-dioxane, acetonitrile, dichloromethane, methanol, or éthanol in the presence of a base such as potassium carbonate, sodium bicarbonate, triethylamine or the like, at a température of 25°C-150°C over a penod of 30 min to 20 hr to obtain compound of formula (I). Preferably, the nucleophilic substitution reaction is carried out in Ν,Ν-dimethylformamide using potassium carbonate as base. On the other hand, Buchwald coupling can be carried out in a solvent such as toluene, tert-butanol, dimethylformamide, isopropyl alcohol, 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofuran, and/or acetonitrile, in the presence of a base such as potassium phosphate, potassium carbonate, sodium tert-butoxide, césium carbonate, lithium hexamethyl disilazane or the like, palladium catalysts such as palladium (II) acetate (Pd(OAc)2), tris(dibenzyllideneacetone)dipalladium (0), [Pd2(dba)3], at a température of 50-160 °C and ligand such as 2,2'-Bis(diphenylphosphino)-l,l'bmaphthyl (BINAP), 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), 2-Dicyclohexylphosphino-2'-(7V,JV-dimethylamino)biphenyl (DavePhos), (2-Biphenyl)di-tert-butylphosphine (JohnPhos), 2-Dicyclohexylphosphino-2',6’18697 dimethoxybiphenyl (SPhos), 2-Dicyclohexylphosphino-2'-methylbiphenyI (MePhos) or the like.
The compound of formula (ΧΧΧΧΠ) is reacted with sulphuric acid and nitric acid to obtaîn the compound of formula (XXXXIV); which on deprotection and coupling with the compounds of formula (XIV), where X = F, Cl, Br, I, or OTf, either m a nucleophilic substitution reaction condition or Buchwald coupling method, to give the compounds of formula (la), wherein p, q, and r are 0, R2 is nitro, ===== is double bond, Ring Ar is Pyridyl, X and Y are carbon, and ail other symbols are as defined under compound of formula (I).
The compounds of formula (Ib), wherein R2 is hydrogen or nitro, p, q, and r are 0, ===== is double bond, Ring Ar is Pyridyl, X and Y are carbon, and ail other symbols are as defined under compound of formula (I), from the compound of formula (ΧΙΙ-b). The compound of formula (ΧΙΙ-b) can be prepared by the method described in the Scheme 3.
(XXXXXl)
(XXXXXIII) (R\ (I)
Where ==τττ: is a double bond;
Ring Ar is Pyridyl. X and Y carbon, p, q. r are O.
R2 is alkyl;
Ring B is Phenyl; and R5 is cyano
Scheme 10
Scheme 10 shows a method of préparation of the compounds of formula (I), wherein p, q, r are 0, R2 is alkyl,-----is double bond, Ring Ar is Pyridyl, X and Y are carbon, Ring B is Phenyl and R5 is cyano, from a compound of formula (XXXXVI). The compound of formula (XXXXVI) can be prepared according to the procedure described in W02015/200677.
The compound of formula (XXXXVI) is reacted with a halide of formula (XXXXXIV); where R2 is alkyl, and X is halogen; in the presence of a base like sodium ethoxide, sodium hydride, potassium t-butoxide, potassium carbonate, or césium carbonate in solvents such as acetonitrile, DMF, THF, or acétone to obtain the compounds of formula (XXXXVII), where R2 is alkyl. Preferably, the alkylation reaction is carried out in DMF in the presence of sodium hydride as base.
Ester hydrolysis of the compounds of formula (XXXXVII) gives the compounds of formula (XXXXVIII). Ester hydrolysis may be carried out using standard procedure generally used in synthetic organic chemistry or well known m the art with reagents such as sodium hydroxide, potassium hydroxide, lithium hydroxide or the like in solvents such as alcohol, THF, water or the like or a mixture thereof. Preferably, an aqueous solution of sodium hydroxide and methanol is used for the reaction.
The compounds of formula (XXXXVIII) so obtained are reacted with phosphoryl chloride or phosphorus pentachloride to obtain the dichlorinated compounds of formula (XXXXIX) under heating conditions; the resulting Products treated with sodium methoxide in methanol to obtain the compounds of formula (XXXXX). Reactions can be carried out using procedures reported in the literature (e.g., US2004199024 and WO201387805).
The compounds of formula (XXXXX) obtained in the previous step are subjected to Suzuki coupling with boronic ester (prepared according to the procedure reported in the literature, US2012/77814) represented by formula (XXXXXV), to obtain compounds of formula (XXXXXI). Suzuki coupling with boronic ester can be carried out by following procedures well known in the art.
The compounds of formula (XXXXXI) as obtained in the previous step are 5 treated with reducing agents such as sodium borohydride in the presence of Cenum(III) chloride, followed by acylation using acetic anhydride in the presence of base such as triethyl amine and DMAP (4-Dimethylaminopyridine) to obtain the compounds of formula (XXXXXII).
The compounds of formula (XXXXXII) as obtained are reacted with 4(piperazin-l-yl)benzonitrile in the presence of Palladium catalyst such as Tetrakis(triphenylphosphine}Pd(0) (Pd(PPh3)4) to obtain the coupled product as compounds of formula (ΧΧΧΧΧΙΠ).
The compounds of formula (XXXXXIII) so obtained in the previous step are reacted with trimethylsilyl chloride (TMS-Cl) and sodium iodide to obtain the compounds of formula (I); wherein p, q, and r are 0, Ra is alkyl, Ring Ar is Pyridyl, X and Y are carbon, ™ is double bondj β is phenyl> R. cyano.
NC
(X-a) ^n'Boc ,„N.___J
NC <n'Boc
OHC
r.Boc N
N, J (XXXXXVi)
(XXXXXX)
(Rs),
<r5), (XIV)
(XXXXXIX) (xxxxxvii)
(XXXXXVIII) ,Boc N
X is halogen or -OTf
(la) (R3)q
Where_____ is a single bond;
R2 is hydrogen; q=0, r=0; X and Y are carbon.
Scheme 11
Scheme 11 shows a method of préparation of the compounds of formula (la), where R2 is hydrogen, q= 0, r = 0, X and Y are carbon, ===== is single bond, and ail other symbols are as defined in general formula (I), from the compound of formula (X-a). The compound of formula (X-a) can be prepared according to the procedure described in Scheme 3.
The compound of formula (X-a) is reduced to a compound of formula (XXXXXVI). The compound of formula (XXXXXVI) is further converted to the compounds of formula (la), wherein R2 is hydrogen, q = 0 r = 0, X and Y are carbon, ===== is single bond, and ail other symbols are as defined in general formula (I), by following the procedures described in Schemes 2 and 3.
The compounds of formula (Ib), where R2 is hydrogen, q = 0, r = 0, X and Y are carbon, —— is single bond, and ail other symbols are as defined in general formula (I), from the compound of formula (X-b). The compound of formula (X-b) can be prepared according to the procedure described in Scheme 3.
(XXXXXXIV)
(la)
Where is double hond
X il Nitrogen and Y il Carbon;
R: il hydrogen;
P.Q.r=O;
Ring Ar il Pyrrote
Scheme 12
Scheme 12 shows a method of préparation of compounds of formula (la) in accordance with an embodiment. The compounds of formula (la), wherein X is nitrogen, Y is carbon, R2 is hydrogen, p, q, and r are 0, — is double bond, Ring Ar is Pyrrole and ail symbols are as defined under formula (I), can be prepared from compounds of formula (ΙΠ-a), wherein ring B, Rs and s are as defined under formula (I). The compounds of formula (Ill-a) can be prepared by the procedures described in Scheme 3.
The compounds of formula (XXXXXXIV) are subjected to Rh(III) catalyzed coupling with compound of formula (ΙΙΙ-a), where ail symbols are as defined under formula (I), to obtain the compounds of formula (la). The reaction may be carried out in the presence of an organic solvent, for example, methanol, acetomtrile, Ν,Ν-dimethyl formamide, tetrahydrofuran, a halogenated hydrocarbon such as chloroform or dichloromethane, an aromatic hydrocarbon such as xylene, benzene, toluene, or the like or mixtures thereof. Preferably, the coupling reaction is carried out in methanol in the presence of bis[(pentamethylcyclopentadienyl)dichloro-rhodium], using césium acetate at 30°C under nitrogen.
The compounds of formula (Ib), wherein X is nitrogen, Y is carbon, R2 js hydrogen, p, q, and r are 0, is double bond, Ring Ar is Pyrrole and ail symbols are as defined under formula (I), can be prepared from compound of formula (ΙΙΙ-b), wherein ring B, R5 and s are as defined under formula (I). The 5 compounds of formula (ΙΙΙ-b) can be prepared by the procedures described in Scheme 3.
(X-.)
(XXXXXXVI) (XX.XXXXV1I)
1,ert - · - i» double bond
X ïs Carbon and Y « Nürogen;
R* is hydrogen;
p. q» r =0;
Ring Ar b Py rrole;
Scheme 13
Scheme 13 shows a method of préparation of compounds of formula (la) in 10 accordance with an embodiment. The compounds of formula (I), wherein X is carbon, Y is nitrogen, R2 is hydrogen, p, q, and r are 0, = is double bond, Ring Ar is Pyrrole and ail symbols are as defined under formula (I), can be prepared from the compound of formula (X-a), The compound of formula (X-a) can be prepared by the procedures described in Scheme 3.
The compound of formula (X-a) is reacted with methyl lithium in THF to obtain a compound of formula (XXXXXXV). The compound of formula (XXXXXXV) so obtained is reacted under halogénation condition generally used m the synthetic organic chemistry using halogenating agents such as N bromosuccinimide, N-chlorosuccinimide, bromine, phosphorous tribromide and aluminium tribromide. In an embodiment, chlorination is carried out using Nchlorosuccinimide, in tetrahydrofuran to obtain compounds of formula (XXXXXXVI) wherein X is halogen. The compounds of formula (XXXXXXVI) as obtained in the previous step are reacted with ethyl lH-pyrrole-2-carboxylate in the presence of base such as césium carbonate in DMF as solvent to obtain a compound of formula (XXXXXXVII).
The compound of formula (XXXXXXVII) so obtained is reacted with ammonia in methanol to obtain the cyclized product as compound of formula (XXXXXXVIII). The compound of formula (XXXXXXVIII) as obtained in the previous step is subjected to deprotection in HCl in dioxane and dichloromethane to obtain a compound of formula (XXXXXXIX). The compound of formula (XXXXXXIX) is reacted with the compounds of formula (XIV), wherein X= F, Cl, Br, I, or OTf, and ail other symbols are as defined under formula (I), either in nucleophilic substitution reaction condition or Buchwald coupling method to obtain the compounds of formula (la) wherein X is carbon, Y is nitrogen, R2 is hydrogen, p, q and r = 0, is double bond and ail symbols are as defmed under formula (I). The reaction is carried out depending on nature of X and R5 in compound of formula (XIV) in a suitable solvent such as dimethyl suif oxide, N,Ndimethylformamide, 1,4-dioxane, acetonitrile, dichloromethane, methanol, or éthanol in the presence of a suitable base such as potassium carbonate, sodium bicarbonate, triethylamine or the like at température between 25°C - 150°C over a period of 30 min to 20 hr to obtain the compounds of formula (I). On the other hand, Buchwald coupling can be carried out under reaction conditions known in the art. Preferably, the Buchwald coupling is carried out in a solvent such as toluene, tert-butanol, dimethylformamide, iso-propyl alcohol, 1,4-dioxane, 1,2dimethoxyethane, tetrahydrofuran, and/or acetonitrile, in the presence of a base such as potassium phosphate, potassium carbonate, sodium tert-butoxide, césium carbonate, lithium hexamethyl disilazane or the like, and a palladium catalyst such as palladium (II) acetate (Pd(OAc)2), tris(dibenzyllideneacetone)dipalladium (0), [Pd2(dba)3], at a température between
50-160 °C and a ligand such as 2,2'-Bis(diphenylphosphino)-l,r-binaphthyl (BINAP), 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), 2Dicyclohexylphosphino-2'-(lV,A-dimethylamino)biphenyl (DavePhos), (2Biphenyljdi-tert-butylphosphine (JohnPhos), 2-Dicyclohexylphosphino-2')6'5 dimethoxybiphenyl (SPhos), 2-DicycloheXylphoSphino-2’-methylbiPheLyl (MePhos) or the like.
The compounds of formula (Ib), wherein X is carbon, Y is nitrogen, R2 is hydrogen, p, q, and r are 0, = is double bond, Ring Ar is Pyrrole and ail symbols are as defined under formula (I), can be prepared from the compound of 10 formula (X-b). The compound of formula (X-b) can be prepared by the procedures described in Scheme 3.
wherein r = 0, Ring 0 js phenyl and R* Is fluoro
Scheme 14
The enantiopure compound of formula (Ilia and ΙΙΙ-b), wherein r = 0, Ring 15 B is phenyl and R5 is fluoro, and ail other symbols are as defined under compounds of formula (I), can be synthesized from a compound of formula (XXXXXXX). Compounds of formula (XXXXXXX) can be synthesized by following methods described in literature (WO20149872); which can be further converted to a compound of formula (ΙΠ-a and ΙΠ-b), wherein r = 0, Ring B is phenyl and R5 20 is fluoro, and ail other symbols are as defined under compounds of formula (I), by following methods described in Scheme 3 for the synthesis of enantiopure compound of formula (ΙΠ-a) followed by chiral séparation using chiral préparative HPLC.
(R3), (la) “>(Rs), 8 /
(XXXXXXXII)
Where----- is a double bond;
R1 is -NH2, R2 is hydrogen;
q=0. r=0;
X and Y are carbon, Ring B is Phenyl and Rs is cyano
Scheme 15
Scheme 15 shows a method of préparation of the compounds of formula represented as (la) in accordance with an embodiment. The compounds of formula (la), wherein R* is -NH2, R3 is hydrogen, q = 0, r = 0, ~ — is double bond, X and Y are carbon, Ring B is phenyl and R* is cyano, and ail other symbols are as defined under formula (I), can be prepared from compound of formula (XXXXXXXII), which can be prepared according to the method described in Scheme 1.
Compound of formula (XXXXXXXII) is converted to compounds of formula (la), wherein R‘ is -NH2, R3 is hydrogen, q = 0, r = 0, ===== is double bond, X and Y are carbon, Ring B is phenyl and R5 is cyano, and ail other symbols are as defined under formula (I), by réduction of the nitro group to amino group using iron and acetic acid in éthanol.
The intermediates and the compounds of the present invention can be obtained m a pure form in a manner known per se, for example, by distilling off the solvent m vacuum and/or re-ciystallizing the residue obtained from a suitable solvent, such as pentane, dîethyl ether, isopropyl ether, chloroform, dichloromethane, ethyl acetate, acetone or their combinations or subjecting them to one of the purification methods, such as column chromatography (e.g. flash chromatography) on a suitable support material such as alumina or silica gel using an eluent such as dichloromethane, ethyl acetate, hexane, methanol, acetone and their combinations. Préparative LC-MS method can also be used for the purification of molécules described herein.
Unless otherwise stated, work-up includes distribution of the reaction mixture between the organic and aqueous phases indicated within parenthèses, 5 séparation of layers and drying the organic layer over sodium sulphate, filtration and évaporation of the solvent. Purification, unless otherwise mentioned, includes purification by silica gel chromatographie techniques, generally using a mobile phase with suitable polarity.
Salts of compound of formula (I) can be obtained by dissolving the 10 compound in a suitable solvent, for example in a chlorinated hydrocarbon, such as methyl chloride or chloroform or a low molecular weight aliphatic alcohol, for example, éthanol or isopropanol, which was then treated with the desired acid or base as described in Berge S.M. et al., “Pharmaceutîcal Salts, a review article in Journal of Pharmaceutîcal sciences volume 66, page 1-19 (1977)” and in 15 “Handbook of Pharmaceutîcal Salts - Properties, Sélection, and Use,” by P. H.
Einrich Stahland Camille G.wermuth, Wiley- VCH (2002). Lists of suitable salts can also be found in Remington’s Pharmaceutîcal Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445, and Journal of Pharmaceutîcal Science, 66, 2-19 (1977). For example, the sait can be of an alkali métal (e.g., 20 sodium or potassium), alkaline earth métal (e.g., calcium), or ammonium.
The compound of the invention or a composition thereof can potentially be administered as a pharmaceutically acceptable acid-addition, base nentraior addition sait, formed by reaction with inorganic acids, such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and 25 phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base, such as sodium hydroxide, potassium hydroxide. The conversion to a sait is accomplished by treatment of the base compound with at least a stoichiometric 30 amount of an appropriate acid. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, éthanol, methanol, and the like, and the acid is added in a similar solvent. The mixture is maintained at a suitable température (e.g., between 0 °C and 50 °C). The resulting sait précipitâtes spontaneously or can be brought out of solution with a less polar solvent.
The stereoisomers of the compounds of formula (I) of the present invention may be prepared by stereospecific synthèses or resolution of racemic compound using an optically active amine, acid or complex forming agent, and separating the diastereomeric salt/complex by fractional crystallization or by column chromatography.
The compounds of formula (I) of the present invention can exist in tautomenc forms, such as keto-enol tautomers. Such tautomeric forms are contemplated as an aspect of the present invention and such tautomers may be in equilibrium or prédominant in one of the forms.
The present invention further provides a pharmaceutical composition, containing the compounds of the general formula (I) as defined above, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts in combination with one or more of pharmaceutically acceptable carriers, diluents, excipients, and the like.
The pharmaceutically acceptable carrier or excipient is preferably one that is chemically inert to the compound of the invention and one that has no detrimental side effects or toxicity under the conditions of use. Such pharmaceutically acceptable carriers or excipients include saline (e.g., 0.9% saline), Cremophor EL® (which is a dérivative of castor oil and ethylene oxide available from Sigma Chemical Co., St. Louis, MO) (e.g., 5% Cremophor EL/5% ethanol/90% saline, 10% Cremophor EL/90% saline, or 50% Cremophor EL/50% éthanol), propylene glycol (e.g., 40% propylene glycol/10% ethanol/50% water), polyethylene glycol (e.g., 40% PEG 400/60% saline), and alcohol (e.g., 40% ethanol/60% water). A preferred pharmaceutical carrier is polyethylene glycol, such as PEG 400, and particularly a composition comprising 40% PEG 400 and 60% water or saline. The choice of carrier will be determined in part by the particular compound chosen, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable 5 formulations of the pharmaceutical composition of the présent invention.
The following formulations for oral, aérosol, parentéral, subcutaneous, intravenous, intraarterial, întramuscular, intrathecal, intraperitoneal, rectal, and vaginal administration are merely exemplary and are in no way limiting.
The pharmaceutical compositions can be administered parenterally, e.g., 10 mtravenously, intraarterially, subcutaneously, intradermally, intrathecally, or mtramuscularly. Thus, the invention provides compositions for parentéral administration that comprise a solution of the compound of the invention dissolved or suspended in an acceptable carrier suitable for parentéral administration, including aqueous and non-aqueous, isotonie stérile injection 15 solutions.
Overall, the requirements for effective pharmaceutical carriers for parentéral compositions are well known to those of ordinaiy skill in the art. See Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on 20 Injectable Drugs, Toissel, 4th ed„ pages 622-630 (1986). Such compositions include solutions containing anti-oxidants, buffers, bacteriostats, and solutés that render the formulation isotonie with the blood of the intended récipient, and aqueous and non-aqueous stérile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The 25 compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a stérile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as éthanol, isopropanol (for example in topical applications), or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, dimethylsulfOχide,, 30 glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
Oils useful in parentéral formulations include petroleum, animal, vegetable, and synthetic oils. Spécifie examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and minerai oil. Suitable fatty acids for use in parentéral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
Suitable soaps for use in parentéral formulations include fatty alkali métal, ammonium, and triethanolamine salts, and suitable détergents include (a) cationic détergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic détergents such as, for example, alkyl, aryl, and olefîn sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic détergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric détergents such as, for example, alkyl-β-aminopropionates, and 2alkyl-imidazoline quatemaiy ammonium salts, and (e) mixtures thereof.
The parentéral formulations typically will contain from about 0.5% or less to about 25% or more by weight of a compound of the invention in solution. Preservatives and buffers can be used. In order to minimize or eliminate irritation at the site of injection, such compositions can contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobie base, formed by the condensation of propylene oxide with propylene glycol. The parentéral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vîals, and can be stored in a freeze-dried (lyophilîzed) condition requiring only the addition of the stérile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from stérile powders, granules, and tablets.
Topical formulations, including those that are useful for transdermal drug release, are well known to those of skill in the art and are suitable in the context of the présent invention for application to skin.
Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of a compound of the invention dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a pre-determined amount of the compound of the invention, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable émulsions. Liquid formulations can include diluents, such as water and alcohols, for example, éthanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and comstarch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloïdal Silicon dioxide, croscarmellose sodium, talc, magnésium stéarate, calcium stéarate, zinc stéarate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise the compound ingrédient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising a compound of the invention in an inert base, such as gelatin and glycerin, or sucrose and acacia, émulsions, gels, and the like containing, in addition to the compound of the invention, such excipients as are known in the art.
A compound of the présent invention, alone or in combination with other suitable components, can be made into aérosol formulations to be administered 5 via inhalation. A compound or epimer of the invention is preferably supplied in fmely divided form along with a surfactant and propellant. Typical percentages of the compounds of the invention can be about 0.01% to about 20% by weight, preferably about 1% to about 10% by weight. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Représentative of such 10 surfactants are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, hnolenic, olestenc and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides can be employed. The surfactant can constitute from about 0.1% to about 20% by 15 weight of the composition, preferably from about 0.25% to about 5%. The balance of the composition is ordinarily propellant. A carrier can also be included as desired, e.g., lecithin, for intranasal delivery. These aérosol formulations can be placed into acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also can be 20 formulated as pharmaceuticals for non-pressured préparations, such as in a nebulizer or an atomizer. Such spray formulations can be used to spray mucosa.
Additionally, the compound of the invention can be made into suppositoires by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration can be 25 presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, m addition to the compound ingrédient, such carriers as are known in the art to be appropriate.
The concentration of the compound in the pharmaceutical formulations can vary, e.g., from less than about 1% to about 10%, to as much as about 20% 30 to about 50% or more by weight, and can be selected primarily by fluid volumes, and viscosities, in accordance with the particular mode of administration selected.
For example, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of stérile Ringer’s solution, and 100 5 mg of at least one compound of the invention. Actual methods for preparing parenterally administrable compounds of the invention will be known or apparent to those sküled in the art and are described in more detail in, for example, Remington’s Pharmaceutical Science (17* ed., Mack Publishing Company, Easton, PA, 1985).
It will be appreciated by one of ordinaiy skill in the art that, in addition to the afore-described pharmaceutical compositions, the compound of the invention can be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes. Liposomes can serve to target a compound of the invention to a particular tissue, such as lymphoid tissue or cancerous hepatic 15 cells. Liposomes can also be used to increase the half-life of a compound of the invention. Many methods are available for preparing liposomes, as described in, for example, Szoka et al., Ann. Rev. Biophys. Bioeng., 9, 467 (1980) and U.S. Patents 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
The compounds of the invention can be administered in a dose sufficient 20 to treat the disease, condition or disorder. Such doses are known in the art (see, for example, the Physidans’ Desk Reference (2004)). The compounds can be administered using techniques such as those described in, for example, Wasserman et al., Cancer, 36, pp. 1258-1268 (1975) and Physidans> Desk Reference, 58th ed., Thomson PDR (2004).
Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinaiy skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound of the présent invention. Thereafter, the dosage is increased by small incréments until the optimum effect under the circumstances is reached.
The présent method can involve the administration of about 0.1 pg to about 50 mg of at least one compound of the invention per kg body weight of the individual. For a 70 kg patient, dosages of from about 10 pg to about 200 mg of the compound of the invention would be more commonly used, depending on a patient’s physiological response.
By way of example and not intending to limit the invention, the dose of the pharmaceutically active agent(s) described herein for methods of treating or preventing a disease or condition as described above can be about 0.001 to about 1 mg/kg body weight of the subject per day, for example, about 0.001 mg, 0.002 mg, 0.005 mg, 0.010 mg, 0.015 mg, 0.020 mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.1 mg, 0.15 mg, 0.2 mg, 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg/kg body weight per day. The dose of the pharmaceutically active agent(s) described herein for the described methods can be about 1 to about 1000 mg/kg body weight of the subject being treated per day, for example, about 1 mg, 2 mg, 5 mg, 10 mg, 15 mg, 0.020 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 500 mg, 750 mg, or 1000 mg/kg body weight per day.
PARP inhibitors of the présent invention can be used for the treatment of diseases and/or disorders that include but are not limited to cancer, stroke, traumatic brain injury, Parkinson’s disease, meningitis, myocardial infarction, ischaemic cardiomyopathy, vascular disease, septic shock, ischémie injury, reperfusion injuiy, neurotoxicity, inflammatory disease, and haemorrhagic shock. PARP inhibitors mentioned herein can be used as single agents and/or in combination with other chemotherapeutic agents so that they can potentiate the effects of the standard chemotherapeutic agents.
Cancers that can be treated with PARP inhibitors include but are not, limited to breast cancer, glioblastoma, pancreatic cancer, ovarian cancer, prostate cancer, melanoma, colon cancer, leukaemia and lymphoma.
The terms “treat,” “prevent,” “ameliorate,” and “inhibit,” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complété treatment, prévention, amelioration, or inhibition. Rather, there are varying degrees of treatment, prévention, amelioration, and inhibition of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the disclosed methods can provide any amount of any level of treatment, prévention, amelioration, or inhibition ofthe disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, may be reduced by, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%. Furthermore, the treatment, prévention, amelioration, or inhibition provided by the inventive method can include treatment, prévention, amelioration, or inhibition of one or more conditions or symptoms of the disorder, e.g., cancer. Also, for purposes herein, “treatment,” “prévention,” “amelioration,” or “inhibition” can encompass delaying the onset of the disorder, or a symptom or condition thereof.
The terms effective amount or therapeutically effective amount, as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. In some embodiments, the resuit is a réduction and! or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological System. For example, an effective amount for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. In some embodiments, an appropriate effective amount in any individual case is determined using techniques, such as a dose escalation study.
The terms potentiation or potentiating,'' as used herein, means to increase or prolong either in potency or duration a desired effect. Thus, in regard to potentiating the effect of therapeutic agents/regimen, the term potentiating refers to the abiiity to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a System.
In accordance with the invention, the term subject includes an “animal” which m tum includes a mammal such as, without limitation, the order Rodentia, such as mice, and the order Lagomorpha, such as rabbits. In one aspect, the mammals are from the order Camivora, including Felines (cats) and 5 Canines (dogs). In another aspect, the mammals are from the order Artiodactyla, including Bovines (cows) and Swine (pigs) or of the order Perssodactyla, including Equmes (horses). In a further aspect, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoïde (humans and apes). In yet another aspect, the mammal is human.
The term patient encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animais such as cattle, horses, sheep, goats, swine; domestic animais such as rabbits, dogs, and cats; laboratoïy animais including 15 rodents, such as rats, mice and guînea pigs, and the like. Examples of nonmammals include, but are not limited to, birds, fish and the like. In one embodiment of the methods and compositions provided herein, the mammal is a human.
Another aspect of the present invention is a pharmaceutical composition 20 of compound of formula (I) in combination with at least one other known anticancer agent, or a pharmaceutically acceptable sait of said agent.
Any suitable anticancer agent can be used. In an embodiment, the anticancer agent used in combination is selected from the group consisting of busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, 25 temozolomide, bendamustine, cisplatin, mitomycin C, bleomycin, carboplatin,’ camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-iluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, 30 Vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel’ docetaxel, campath, imatinib, gelitinib, erlotinib, lapatinib, sorafenib, sunitinib, nüotinib, dasatinib, pazopanib, teœsirolimus, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant. mitoguazone, octreotide, reünoic acid, arseni/ trioxide, zoledromc acid, bortezomib, thalidomide and lenalidomide.
In another embodiment, the invention provides a method of treatment or prévention of a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom, comprising administering to the mammal in need of such treatment or prévention, an effective amount of a compound of formula (I).
In an embodiment, the disorder as stated above is cancer, which includes hver cancer, melanoma, Hodgkin s disease, non-Hodgkin's lymphomas, acute or chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms’ tumor, cervical carcinoma, testicular carcinoma, soft-üssue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primaiy brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, chorio carcinoma, mycosis fungo ide, head or neck carcinoma, ostéogénie sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinaiy carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, rénal cell carcinoma, endométrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, or prostatic carcinoma.
The invention further provides a method of potentiating the efficacy of chemotherapeutic regimen for a patient undergoing chemotherapeutic treatment comprising co-administering to the patient an effective amount of a compound of the present invention, wherein, the compound of the invention may be co adminîstered simultaneously, sequentially, or cyclically with the anticancer agent.
The chemotherapeutic agent mentioned above is selected form busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, 5 bendamustîne, cis-platin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, Vinblastine, vincristine, 10 vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, campath, panitumumab, ofatumumab, bevacizumab, trastuzumab, adalimumab, imatimb, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolunus, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, 15 zoledronic acid, bortezomib, thalidomide or lenalidomide.
Overactivation of PARP leads to necrotic cell death as a resuit of NAD and ATP déplétion. Cancer patients who hâve undergone radiotherapy or hâve been treated with chemotherapeutic agents that damage DNA harbour DNA strand breaks. Activation of PARP in such cases allows the repair of the damaged DNA, 20 thus leading to an undesirable résistance to the chemotherapeutic agents (and the conséquent inefficacy). In such a scénario, treatment with a PARP inhibitor is expected to make the repair process inefficient and cause cell death.
In a further embodiment, the invention provides a method for sensitizing a patient who has developed or likely to develop résistance for chemotherapie 25 agents compnsing administering an effective amount of a compound of the présent invention.
EXAMPLES
The following examples further illustrate a method of préparation of représentative compounds embodied in formula (I); however, the same should not be constructed as limiting the scope of the invention.
Example 1: Synthesis of (R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzomtrile (Compound 1)
Step 1: 2-bromo-3-oxocyclopent-l-enecarbonitrile (Compound la)
Br
To a stirred solution of 2-bromo-3-ethoxycyclopent-2-enone (Prepared according to the procedure reported in Journal of Médicinal Chemistry, 1999, 42, 7, 1274-1281, 185.00 g, 0.90 mol) in dichloromethane (1200 ml) was added zinc lodide (28.80 g, 0.09 mol) and trimethylsilyl cyanide (179.00 g, 242.0 ml, 1.80 mol) under nitrogen atmosphère at 0°C and reaction mixture was stirred at 25°C for 0.5 hr and at room température for 18 hr. The progress of the reaction was monîtored by TLC. The reaction mixture was slowly quenched with aqueous IM hydrochloric acid solution (500 ml). The organic layer was separated and washed with aqueous sodium bicarbonate solution (2 x 500 ml). The organic layer was dned over sodium sulphate and was concentrated to obtain crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 25/o ethyl acetate in hexane as an eluent to obtain the title compound (128.00 g, 76.0%).
•H NMR (400 MHz, CDC13) δ 2.91 (t, J= 6.8 Hz, 2H), 2.71 (t, J= 6.8 Hz, 2H)
MS: m/z 186 (M+l).
Step 2: (S)-2-bromo-3-hydroxycyclopent-l-enecarbonitrile (Compound 1b)
Br
To a stirred solution of 2-bromo-3-oxocyclopent-l-enecarbonitrile (Compound la, 110.00 g, 0.59 mol) in tetrahydrofuran (700 ml) was added (R)1.3a-dimethyl-3,3-diphenylhexahydropyrrolo[l,2c][l,3,2]oxaborole (118.0 ml IM solution m Toluene, 0.12 mol) under nitrogen atmosphère at 0°C. Stirring was continued over a period of 20 min. Borane dimethylsulfîde complex (31.4 gm, 39.3 ml, 0.41 mol) was added to the reaction mixture at 0°C in drop wise manner in 20 min and reaction mixture was stirred at 0°C for 1 hr. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with methanol (50 ml). The organic layer was dried over sodium sulphate and was concentrated to obtain crude product. A column of silica gel (100-200 mesh) was loaded in hexane and crude compound was adsorbed over silica gel (100 - 200 mesh). The eluent used for column was hexane to 25% ethyl acetate and the desired product was eluted in 20-22 % ethyl acetate in hexane to obtain the title compound (93.4 g, 84.0 %, %ee = 94.0% confirmed by chiral HPLC).
*H NMR {400 MHz, CDC13) 6 4.83-4.85 (m, 1H), 2.69-2.74 (m, 1H), 2.51-2.56 (m, 2H), 2.48 (brs-exchanges with D2O, 1H), 1.96-2.04 (m, 1H).
MS: m/z 188.2 (M+l).
Step 3: (R)-(S)-2-bromo-3-cynocyclopent-2-en-l-yl 2-acetoxy-2-phenylacetate (Compound le)
To a stirred solution of (S)-2-bromo-3-hydroxycyclopent-l-enecarbomtrile (Compound lb, 145.0 g, 0.77 mol) in dichloromethane (1000 ml) was added (2R)-2-acetoxy-2-phenylacetic acid (150.0 g, 0.77 mol) and dimethyl amino pyridine (4.7 g, 38.6 mmol) at O°C. To this N, N’-Dicyclohexyl dicarbodiimide (175.0 g, 0.85 mol) was added in portions at O’C. The reaction mixture was stirred over a period of 4 hr at room température (white solid séparâtes out). The progress of the reaction was monitored by TLC. The reaction mixture was filtered 5 and organic layer was washed with 5% aqueous hydrochloric acid, saturated aqueous sodium bicarbonate solution and was dried over sodium sulphate. The organic layer was concentrated to obtain crude product which was again dissolved in ether (1500 ml) and filtered; filtrate was concentrated up to 200 ml of ether and then triturated with hexane (3000 ml) to form the precipitated off 10 white title product (232.0 g, 82.0 %).
Ή NMR (400 MHz, CDC13) δ 7.47-7.50 (m, 2H), 7.38-7.42 (m, 3H), 5.93 (s, 1H), 5.83-4.86 (m, 1H), 2.22 (s, 3H), 2.47-2.64 (m, 3H), 1.74-1.77 (m, 1H).
MS: m/z 366.1 (M+l).
Step 4: (S)-2-bromo-3-hydroxycyclopent-1 -enecarbonitrile (Compound Id)
Br
NC-Z7 ] 15 vJ
To a stirred solution of (R)-(S)-2-bromo-3-cynoçyclopent-2-en-l-yl 2acetoxy-2-phenylacetate (Compound le, 115.0 g, 0.30 mol) in tetrahydrofuran: Water (600:300 ml) was added lithium hydroxide (22.6 g, 0.94 mol) and the réaction mixture was stirred at room température for 2 hr. The progress of the 20 reaction was monitored by TLC. The reaction mixture was quenched with water {300 ml) and extracted with dichloromethane (2 x 500 ml). The organic layer was separated and washed with aqueous 10% hydrochloric acid (300 ml). The organic layer was dried over sodium sulphate and was concentrated to obtain title product (45.0 g, Yield = 76.0 %, %ee = 98.5% confïrmed by chiral HPLC).
Ή NMR (400 MHz, CDCh) δ 4.83-4.85 (m, 1H), 2.69-2.74 (m, 1H), 2.51-2.56 (m, 2H), 2.48 (bs-exchanges with D2O, 1H), 1.96-2.04 (m, 1H).
MS: τη/ζ 188 (M+I).
Step 5: (S)-3-hydroxycyclopent-l-enecarbonitrile (Compound le)
Aqueous 10% hydrochloric acid (750 ml) was added to zinc (272.0 g, 4.10 mol) with stirring at room température. After 5 min, hydrochloric acid was decanted and zinc was washed with acetone (2 x 100 ml), and diethyl ether (2x 100 ml). Zinc was dried under vacuum (vacuum was released under nitrogen); free flowing zinc was added to a suspension of silver acetate in boiling acetic acid. After 1 mm supematant was decanted and the black Zn-Ag couple was washed with aceüc acid (200 ml), ether (4x 100 ml) and methanol (2x 100 ml). To a moist Zn-Ag couple was added a solution of (S)-2-bromo-3-hydroxycyclopent-lenecarbonitrile (Compound Id, 130.0 g, 0.69 mol) in methanol (600 ml) at 25°C and was stirred at 25°C for 24.0 hr. The progress ofthe reaction was monitored by TLC. The reaction mixture was fïltered and washed with methanol (50 ml), filtrate was concentrated and then portioned between ether {1000 ml) and 30% aqueous hydrochloric acid (300 ml). The ether layer was separated, dried over sodium sulphate and concentrated to obtain a crude product. The crude product was purified by column chromatography over silica gel (100-200 mesh) using 2022% ethyl acetate in hexane as an eluent to obtain the title compound (64.1 g, 85.0%).
’H NMR (400 MHz, CDC13) 6 6.64(s, 1H), 4.99-5.03 (m, 1H), 2.74-2.79 (m, 1H) 2.51-2.56 (m, 1H), 2.46-2.49 (m, 1 H), 1.95 (bs-exchanges with D2O, 1H), 1.831.87 (m, 1 H).
MS: m/z 108 (M+l).
Step 6: (R)-tert-butyl (3-cyanocyclopent-2-en-l-yl)Carbamate (Compound If)
NC
‘iNHBoc
To a stirred solution of (S)-3-hydroxycyclopent-l-enecarbonitrile (Compound le, 64.0 g, 0.58 mol) in tetrahydrofuran (500 ml), was added (azido(phenoxy)phosphoryl]oxybenzene (210.0 g, 164.9 ml, 0.76 mol) at 0°C in drop wise manner. The reaction mixture was stirred at 0°C for 10 min and 1,8diazabicyclo[5.4.0]undec-7-ene (116.0 g, 115.0 ml, 0.76 mol) was added to reaction mixture at 0°C. The reaction mixture was allowed to stir at 0°C for 2 hr. The progress of the reaction was monitored by TLC. Triphenyl phosphine (169.0 g, 0.64 mol) and water (140 ml) were added at 0°C and reaction mixture was stirred at room température for 18 hrs. The progress of the reaction was monitored by TLC. Boc anhydride (141.0 g, 150 ml, 0.64 mol) was added to the reaction mixture at 0°C followed by addition of triethyl amine (89.0 g, 123.0 ml, 0.88 mol), the reaction mixture was gradually warmed to room température, and stirred for 3 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 ml). The reaction mixture was concentrated; and to the residue saturated aqueous ammonium chloride solution (100 ml) was added and extracted with ethyl acetate (2 x 250 ml). The organic layer was separated, dried over sodium sulphate and concentrated to obtain the crude product; which was purifîed by flash column chromatography using 10% ethyl acetate in hexane as an eluent to obtain the title compound (0.14 g, 45.0%).
iH NMR (400 MHz, CDCh) Ô 6.57 (s, 1H), 4.88-4.90 (m, 1H), 4.63 (brsexchangable with D2O, 1H), 2.45-2.70 (m, 3H), 1.65-1.69 (m, 1H), 1.46 (s, 9H).
MS: m/z 207 (M+l).
Step 7: (R)-tert-butyl (3-formylcyclopent-2-en-l-yl)carbamate (Compound 1g) ,NHBoc
OHC
To a stirred solution of (R)-tert-butyl (3-cyanocyclopent-2-en-lyljcarbamate (Compound lf, 10.0 g, 48.0 mmol) in dichioromethane (100 ml), diisobutyl aluminium hydride (72 ml IM solution in toluene, 72.0 mmol) was added at -40°C. A cooling bath was removed and reaction mixture was allowed to warm up to room température and stirred for 2 hr. The progress of the reaction was monitored by TLC. The reaction mixture was re-cooled to 0°C and was quenched with saturated aqueous ammonium chloride solution (30 ml) at 0°C. The reaction mixture was diluted with 10% methanol in dichioromethane (100 ml) and stirred for 10 min and filtered through a Celite bed. The Celite bed was washed with 10% methanol in dichioromethane (100 ml). The combined fîltrate was concentrated under reduced pressure to obtain crude product; which was purified by flash column chromatography using 25% ethyl acetate in hexane as an eluent to obtain the title compound (0.050 g, 43.1%).
*H NMR (400 MHz, CDC13) ô 9.83 (s, 1H), 6.75 (s, 1H), 4.89-4.92 (m, 1H), 4.60 (brs-exchangable with D2O, 1H), 2.62-2.65 (m, 1H), 2.40-2.51 (m, 2H), 1.64-1.67 (m, 1H), 1.49 (s, 9H).
Step 8: (R)-tert-butyl (3-ethynylcyclopent-2-en-l-yl)carbamate (Compound Ih)
JIHBoc
To the stirred solution of trimethylsilyldiazomethane (12.3 ml 2M solution in diethyl ether, 24.6 mmol) in tetrahydrofuran (15 ml) was added n-Butyl lithium (15.5 ml, 1.6 M solution in hexane) at -78°C in drop wise manner and stirred for 30 min. (R)-tert-butyl (3-formylcyclopent-2-en-l-yl)carbamate (Compound lg, 4.0 g, 18.9 mmol) in tetrahydrofuran (15 ml) was added to the reaction mixture and stirred for 10 min. The cooling bath was removed and reaction mixture was allowed to stir at room température for 2 hr. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (100 ml), organic layer was washed with water (20 ml) and dried over anhydrous sodium sulphate. The organic layer was concentrated under reduced pressure to obtain crude product; which was purified by flash column chromatography using 15% ethyl acetate in hexane as an eluent to obtain the title compound (2.8 g, 70.5%).
S ·Η NMR (400 MHz, CDC1,) δ 6.04 (q, J - 2.1 Hz, 1H), 4.91 - 4.72 (m, 1H), 4.56 (bs, exchanges with D2O, 1HJ, 3.07 (s, 1H), 2.62 - 2.48 (m, 1H), 2.48 - 2.32 (m, 2H), 1.71 - 1.53 (m, 1H), 1.40 (s, 9H).
MS: m/z207 (M+l).
Step 9: (R)-3-ethynylcyclopent-2-enamine hydrochloride (Compound li)
,.nh2hci
To a stirred solution of (R)-tert-butyl (3-ethynylcyclopent-2-en-lyl)carbamate (Compound Ih, 1.5 g, 7.24 mmol) in dichloromethane (10 ml), hydrochloric acid (2.2 ml 4M solution in dioxane, 72.4 mmol) was added at 0°C. The reaction mixture was stirred at room température for 1 hr. The progress of 15 the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure to dzyness. A residue was co-evaporated with toluene to obtain the title product (0.95 gm, 95.5%).
H NMR (400 MHz, DMSO-d6) ô 8.26 (bs-exchanges with D2O, 2H), 6.05 (s, 1H), 4.24-4.26 (m, 1H|, 3.40 (s, 1H), 2.59-2.62 (m, 1H|, 2.41-2.42 (m, 1H), 2.24-2.27 20 (m, 1H), 1.79-1.82 (m, 1H).
Step 10: (R)-4-(4-(3-ethynylcyclopent-2-en-l-yl)piperazin- l-yl)benzonitrile (Compound Ij)
To the (R)-3-ethynylcyclopent-2-enamine hydrochloride (Compound li, 6.8 g, 47.3 mmol) and 4-(bis(2-chloroethyl)amino)benzonitrile (Prepared according to the procedure reported in US6455528, 14.53 g, 61.6 mmol) were added sodium bicarbonate (19.9 g, 237.0 mmol), potassium iodide (19.6 g, 118.0 mmol), and nS butanol (70 ml) at room température under nitrogen atmosphère. The reacüon mixture was heated at 1WC for 18 hrs under nitrogen atmosphère on preheated oil bath. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température and diluted with ethyl acetate (50 ml). The reaction mixture was ffltered through Celite, and washed with ethyl acetate 10 (40 ml). The combined filtrate was concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography using 15% ethyl acetate in hexane as an eluent to obtain the title compound (10.5 g, 82.0%).
H NMR (400 MHz, CDCh) 6 7.56 - 7.47 (m, 2H). 6.91 - 6.84 (m, 2H), 6.18 (q, J15 2.2 Hz, 1H), 4.00 - 3.88 (m, 1H), 3.41 - 3.26 (m, 4H), 3.08 (s, 1H), 2.74 - 2 61 (m, 4H), 2.62 - 2.42 (m, 2H), 2.14 - 1.85 (m, 2H).
MS: m/z 278 (M+l).
Step 11; (R)-4-(4-(3-(5-oxo-5!6-dihydro-lJ6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 1)
O
To a solution of 2-bromonicotinic acid (0.947 g, 4.69 mmol) in anhydrous acetomtnle (10 ml, degassed by nitrogen gas) was added bis(triphenylphosphine) palladium (II) chloride (0.253 g, 0.361 mmol) at 25-C. The reaction mixture was 25 heated and stirred at 70 °C for 10 min and to this wanned reacüon mixture was added diisopropylethylamine (3.78 ml, 21.63 mmol) followed by the addition of a solution of (R)-4-(4-(3-ethynylcyclopent-2-en-1 -yl)piperazin- l-yl)benzonitrile (Compound Ij, 1.0 g, 3.61 mmol) in acetonitrile (5 ml) and the reaction mixture was heated at same température for 3 hrs. The progress of the reaction was momtored by TLC. The reaction mixture was cooled to room température and diluted with ethyl acetate (200 ml), washed with water (100 ml). The aqueous layer was again extracted with ethyl acetate (100 ml) and the combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give crude intermediate; which was dissolved in anhydrous tetrahydrofuran (10 ml). To this solution of crude intermediate was added ammonia m methanol (50 ml 7M solution in methanol, 361.0 mmol) at 25°C and was heated at 90°C for 2 hr. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température, filtered and fîltrate was concentrated under reduced pressure to obtain crude product which was purified by flash column chromatography over silica gel (100 - 200 mesh) using 0-5% methanol in dichloromethane as eluent to obtain title compound (0.110 g, 7.68% yield).
H NMR (400 MHz, DMSO-de) δ 11.47 (brs-exchangeable with D2O, 1H), 8.90 (dd, d= 8.8, 2.0 Hz, 1H), 8.47 (dd, J= 8.0, 2.0 Hz, 1H), 7.59 (d, J= 8.8 Hz, 2H), 7.48 (dd, J= 8.0, 2.0 Hz, 1H), 7.04 (d, J= 8.8 Hz, 2H), 6.96 (d, J= 2.0 Hz, 1H), 6.59 (s, 1H), 3.97 - 3.86 (m, 1H), 3.43 - 3.35 (m, 4H), 2.82 - 2.70 (m, 1H), 2.68 - 2.55 (m, 4H), 2.15-2.01 (m, 1H), 1.98- 1.80 (m, 1H), 1.38-1.13 (m, 1H).
MS: m/z 398.3 (M+l).
Step 12: (R)-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 1-hydrochloride sait)
2HCI
A solution of (R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 1, 90 mg, 0.226 mmol) in tetrahydrofuran (2 ml) and methanol (2 ml) was heated at 65°C and was added hydrochloric acid in methanol (0.830 ml, 0.498 mmol, 3M solution) at same température in small portions over a period of 5 min. The reaction mixture was then stirred for 30 min at 25°C. The reaction mixture was cooled to room température, diluted with diethyl ether (10 ml), and product was collected upon filtration. The resulting solid was washed with diethyl ether (10 ml) and dried under reduced pressure for 3 hr at 40°C to obtain the title compound (0.095 g, 89 % yield).
!H NMR (400 MHz, DMSO-da) 6 11.73 (brs-exchangeable with D2O, 1H), 11.49 (brs-exchangeable with D2O, 1H), 9.00 (dd, J= 8.8, 2.0 Hz, 1H), 8.62 (dd, J= 8.0, 2.0 Hz, 1H), 7.68 (d, J= 8.8 Hz, 2H), 7.62 (dd, J = 8.0, 2.0 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.89 (d, J= 2.0 Hz, 1H), 6.82 (s, 1H), 4.73-4.53 (m, 2H), 4.15 (d, J = 12.4 Hz, 2H), 3.59 (t, J = 11.6 Hz, 2H), 3.35 (t, J= 11.6 Hz, 2H), 3.12 (dd, J = 20.0, 9.6 Hz, 2H), 2.90 (q, J= 7.6 Hz, 2H), 2.40 (q, J =7.6 Hz, 2H).
MS: m/z 398.2 (M+l).
The following compounds were prepared using the procedure described above in Example 1 with appropriate changes to the reactants and reaction conditions.
(R) -7-(3-(4-phenylpiperazin-1 -yl)çy dopent-1 -en-1 -yl)-1,6-naphthyridin-5(6H)-one (Compound 21-hydrochloride sait)
O
H NMR (400 MHz, DMSO-de) δ 11.75 (brs-exchangeable with D2O, 1H), 11.16 (brs-exchangeable with D2O, 1H), 9.03 - 8.95 (m, 1H), 8.65 - 8.57 (m, 1H), 7.66
7.57 (m, 1H), 7.28 (t, J= 7.8 Hz, 2H), 7.03 (d, J =8.2 Hz, 2H), 6.92 (s, 1H), 6.88 (t, J =7.2 Hz, 1H), 6.85 - 6.79 (m, 1H), 4.69 (s, 1H), 3.92 - 3.84 (m, 2H), 3.64 3.54 (m, 2H), 3.27 - 3.08 (m, 4H), 2.94 - 2.87 (m, 2H), 2.46 - 2.35 (m, 2H).
MS: m/z 373.0 (M+l).
(R)-7-(3-(4-(o-tolyl)piperazin-1 -yl)cyclopent-1 -en-1 -yl)-1,6-naphthyridin-5(6H)-one (Compound 3)
Ή NMR (400 MHz, DMSO-cfc) δ 11.49 (brs-exchangeable with D2O, 1H) 8.95 8.87 (m, 1H), 8.52 - 8.44 (m, 1 H), 7.52 - 7.44 (m, 1H), 7.21 - 7.13 (m, 2H), 7.06 6.91 (m, 3H), 6.60 (s, 1H), 3.99 - 3.83 (m, 1H), 2.95 - 2.81 (m, 4H), 2.80 - 2.56 (m, 6H), 2.26 (s, 3H), 2.14-2.05 (m, 1H), 1.98- 1.88 (m, 1H).
MS: m/z 386.8 (M+l).
(R)-4-(2-oxo-4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 13-hydrochloride sait)
NMR (400 MHz, DMSO-cZ&) δ 12.45 (brs-exchangeable with D2O, 1H), 11.69 (s brs-exchangeable with D2O, 1H), 8.99 (dd, J= 4.8, 1.7 Hz, 1H), 8.61 (dd, J = 8.1, 1.7 Hz, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.66 - 7.58 (m, 3H), 6.87 (s, 1H), 6.83 (s, 1H), 4.73 - 4.61 (m, 2H), 4.35 - 4.22 (m, 1H), 4.12 (s, 2H), 4.00 - 3.85 (m, 1H), 3.65 - 3.48 (m, 1H), 3.03 - 2.86 (m, 2H), 2.47 - 2.36 (m, 2H).
MS: m/z412.1 (M+l).
(R)-7-(3-(4-(4-fluorophenyl)piperazin- l-yl)cyclopent-1 -en-1 -yl)-1,6-naphthyridin5(6H)-one (Compound 22-hydrochloride sait)
‘H NMR (400 MHz, OMSO-cfe) ô 11.89 (brs-exchangeable with D2O, 1H), 11.52 (brs-exchangeable with D2O, 1H), 9.04 (s, 1H), 8.73 (d, J = 8.0 Hz, 1H), 7.70 (dd, J = 8.0, 5.0 Hz, 1H), 7.14-7.10 (m, 2H), 7.07-7.03 (m, 3H), 6.96 (s, 1HJ.6.88 (s,
1H), 4.69 (s, 1H), 3.84-3.75 (m, 2H), 3.62-3.54 (m, 2H), 3.30 - 3.11 (m, 4H)’
2.94-2.86 (m, 2H), 2.44-2.38 (m, 2H).
MS: m/z 391.2 (M+l) (R) -7-(3-(4-(4-chlorophenyl)piperazin-1 -yl)cyclopent-1 -en-1 -yl) -1,6-naphthyridin5(6H)-one (Compound 24-hydrochloride sait)
’H NMR (400 MHz, DMSO-dô) δ 11.79 (brs-exchangeable with D2O, 1H), 11.43 (brs-exchangeable with D2O, 1H), 9.01 (d, J = 4.8 Hz, 1H), 8.65 (d, J = 8.0 Hz, 20 1H), 7.65 (dd, J = 8.0, 4.8 Hz, 1H), 7.31 (d, J = 8.6 Hz, 2H), 7.05 (d, J = 8.6 Hz,’
2H), 6.93 (s, 1H), 6.84 (s, 1H), 4.69-4.67 (m, 1H), 3.90-3.87 (m, 2H), 3.60-3.55 (m, 2H), 3.26-3.12 (m, 4H), 2.98-2.83(m, 2H), 2.44-2.36 (m, 2H).
MS: m/z 407.1 (M+l) (R) -7-(3-(4-(4-methoxyphenyl)piperazin-1 -yl)cyclopent-1 -en- 1-yl)-1,6naphthyridin-5(6H)-one (Compound 25-hydrochloride sait)
Ή NMR (400 MHz, DMSO-cfe) 511.96 (brs-exchangeable with DaO, 1H), 11.62 (brs-exchangeable with D2O, 1H), 9.06 (d, J = 5.0 Hz, 1H), 8.77 (d, J = 8.0 Hz, 1H), 7.73 (dd, J = 8.0, 5.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 2H), 6.99 (s, 1H), 6.91 6.81 (m, 3H), 4.70 (s, 1H), 3.70 (s, 3H), 3.64 - 3.50 (m, 2H), 3.33 - 3.14 (m, 2H), 10 3.12 - 3.02 (m, 2H), 2.93 - 2.87 (m, 2H), 2.49 - 2.42 (s, 2H), 2.37 - 2.31 (m, 2H).
MS: m/z 403.1 (M+l).
(R)-7-(3-(4-(p-tolyl)piperazin-1 -yl)cy dopent-1 -en- 1-yl)-1,6-naphthyridin-5(6H) -one (Compound 26-hydrochloride sait)
‘H NMR (400 MHz, DMSO-de) 5 11,80 (brs-exchangeable with D2O, 1H), 11.34 (brs-exchangeable with D2O, 1H), 9.02 (d, 4.8 Hz, 1H), 8.66 (d, J= 8.0 Hz,
1H), 7.65 (dd, J= 8.1, 4.8 Hz, 1H), 7.09 (d, J= 8.2 Hz, 2H), 6.96 -6.91 (m, 3H), 20 6.84 (s, 1H), 4.67-4.65 (m, 1H), 3.81-3.79 (m, 2H), 3.59-3.55 (m, 2H), 3.28 - 3.08 (m, 4H), 2.94-2.85 (m, 2H), 2.44 - 2.31 (m, 2H), 2.23 (s, 3H).
MS: m/z 387.1 (M+l).
(R)-7-(3-(4-(2,3-dihydro-1 H-inden-5-yl)piperazin-1 -yl)cy dopent-1 -en-1 -yl) -1,6 naphthyridin-5(6H)-one (Compound 30-hydrochloride sait)
.2HCI ’H NMR (400 MHz, DMSO-de) ô 11.81 (brs-exchangeable with D2O, 1H) , 11.31 (brs-exchangeable with D2O, 1H) , 9.02 (s, 1H), 8.66 (d, J = 7.8 Hz, 1H), 7.74 7.56 (m, 1H), 7.12 (d, J= 8.4 Hz, 1H), 6.94-6.92 (m, 2H), 6.83 - 6.80 (m, 2H), 4.86 (s, 1H), 4.68 (s, 1H), 3.79-3.76 (m, 2H), 3.59-3.56 (m, 2H), 3.28-3.11 (m, 5H), 2.97-2.84 (m, 2H), 2.83-2.71 (m, 3H), 2.41-2.39 (m,lH), 2.09 - 1.92 (m, 2H).
MS: m/z 414.2 (M+l).
(R) -7-(3-(4-(2,4-difluorophenyl)piperazin-1 -yljcydopent-1 -en-1 -yl) -1,6naphthyridin-5(6H)-one (Compound 39-hydrochloride sait)
>H NMR (400 MHz, DMSO-dc,) Ô 11.79 (brs-exchangeable with D2O, 1H), 11.45 (brs-exchangeable with D2O, 1H), 9.01 (dd, J= 4.5, 1.5 Hz, 1H), 8.65 (d, J= 8.0 Hz, 1H), 7.63 - 7.66 (m, 1H), 7.26 - 7.32 (m, 1H), 7.15 - 7.21 (m, 1H), 7.08 - 7.03 (m, 1H), 6.93 (s, 1H), 6.83 (s, 1H), 4.72 (s, 1H), 3.60 - 3.54 (m, 2H), 3.48 - 3.45 (m, 3H), 3.15-3.32 (m, 4H), 2.99-2.85 (m, 2H), 2.43 - 2.38 (m, 2H).
MS: m/z 409.1 (M+l).
^^’6'(3‘(4-phenylpiperazm-l-yl)cyclopent-l-en-l-yl)thieno[3)2-c]pyridin-4(5H) one (Compound 48-hydrochloride sait)
Ή NMR (400 MHz, DMS0-A) 6 n,41 (brs.exchmgeab,e u (brs-exchangeable with DzO, 1H), 7.69 (d, J - 5.3 Hz, 1H), 7.51 (d J. 5 3 Hz
1H), 7.28 (t, J = „ HZ, 2H), 7.10 (s. 1H), 7.03 (d, J =8.2 Hz, 2H), 6.88 (t, σ- 7 3
Hz, 1H), 6.79 (s, 1H), 4.63 (s, 1H), 3.92-3.80 (m. 2H), 3.64 - 3.49 (m, 2H) 3 263.09 (m, 4H), 2.94-2.74 ( m, 2H), 2.41-2.32 (m, 2H).
MS: m/z 378.1 (M+l).
Example 2, Synthesis of dD^-fluoro^.^SoxodS.SHUhydro-l ,6 aaphthyndm-7-yl)cyelopent-2-en-l.yl)pipemzin-l-yl)ben2onitrile (Compound 23)
Step 1: 3-bromocyclopent-1 -enecarbonitrile (Compound 23a)
To a stirred solution of cyclopent-l-enecarbonitrile (50 g, 537 mmol) in tetrachloromethane (400 ml) at 25°C was added N-bromosuccinimide (96 g, 537 mmol) under nitrogen atmosphère. The resulting mixture was refluxed for 2 hr. The progress of reaction was monitored by TLC. The reaction mixture was cooled to 25°C and filtered through Celite. The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography over silica gel (100 - 200 mesh) using 1% ethyl acetate in hexane as an eluent to obtain the tîtle compound (60.0 g, 65%).
‘HNMR (400MHz, CDC13): ô 6.77-6.73 (m, 1H), 5.12-5.09 (m, 1H) 2.95-2.86 (m, 1H) 2.67-2.42 (m, 3H).
Step 2: tert-butyl 4-(3-cyanocyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 23b)
N NBoc
To a stirred solution of tert-butyl piperazine-l-carboxylate (59.5 g, 320 mmol) in dimethyl formamide (400 ml) was added triethylamine (134 ml, 959 mmol) at 25°C and stirred the reaction mixture for 10 minutes. To the above mixture was added 3-bromocyclopent-l-enecarbonitrile (Compound 23a, 55 g, 320 mmol) and the reaction mixture was stirred for 3 hr. The progress of the reaction was monitored by TLC. The reaction mixture was then concentrated under reduced pressure. The residue obtained was diluted with water (250 ml) and extracted with ethyl acetate (3 x 250 ml). The combined organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced pressure to obtain a crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 40% ethyl acetate in hexane as an eluent to obtain the title compound (35.0 g, 39.5%yield).
Ή NMR (400MHz, CDCb): fi 6.66-6.64 (m, 1H) 3.97-3.93 (m, 1H), 3.45-2.42 (m, 4H), 2.65-2.57(m, 2H), 2.50-2.40 (m, 4H), 2.11-2.04 (m, 1H) 1.97-1.89 (m, 1H)
1.47 (s, 9H).
A chiral séparation of racemic tert-butyl 4-(3-cyanocyclopent-2-en-l5 yl)piperazine-l-carboxylate (Compound 23b-racemiCj 30 g) was carried out using chiral column to obtain (R) tert-butyl 4-(3-cyanocyclopent-2-en-l-yl)Piperazine-l-carboxylate (Compound 23b’; 12 g)
Z___
NBoc »H NMR (400MHz, CDCb): δ 6.66-6.64 (m, 1H) 3.97-3.93 (m, 1H), 3.45-2.42 (m, 4H), 2.65-2.57(m, 2H), 2.50-2.40 (m, 4H), 2.11-2.04 (m, 1H) 1.97-1.89 (m,lH)
1.47 (s, 9H).
and (S) tert-butyl 4-(3-cyanocyclopent-2-en-l-yl)piperazine-l-carboxyIate (compound
23b”; 11.5 g)
NC\ /__
NBoc
NMR (400MHz, CDC13): fi 6.66-6.64 (m, 1H) 3.97-3.93 (m, 1H), 3.45-2.42 (m, 4H), 2.65-2.57(m, 2H), 2.50-2.40 (m, 4H), 2.11-2.04 (m,lH) 1.97-1.89 (m,lH)
1.47 (s, 9H).
Step 3: tert-butyl (R)-4-(3-formylcyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 23c)
NBoc
To a stirred solution of (R) tert-butyl 4-(3-cyanocyclopent-2-en-lyl)piperazine-l-carboxylate (Compound 23b', 10 g, 36.1 mmol) in dry dichloromethane (100 ml) was added di-isobutyl aluminium hydride (DIBAL-H) (43.3 ml, IM solution in toluene, 43.3 mmol) under nitrogen atmosphère at -78 °C over a period of 30 min. The reaction mixture was slowly warmed to room température and stirred over a period of 16 hr. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (250 ml), quenched with saturated aqueous ammonium chloride solution (100 ml) and the reaction mixture was stirred for 15 min. The reaction mass was fïltered through a Celite bed and the residue was washed with ethyl acetate (100 ml). The separated organic layer was dried over sodium sulfate, and fïltered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by flash column chromatography over silica gel (100 - 200 mesh) using 35 - 40% ethyl acetate in hexane as an eluent to obtain the titie compound (4.0 g, 39.6%).
Ή NMR (400 MHz, CDCh): 6 9.84 (s, 1H), 6.85 (s, 1H), 3.99 (dt, J= 6.4, 3.2 Hz, 1H), 3.46 (t, J= 4.8 Hz, 4H), 2.66 - 2.38 (m, 6H), 2.19 - 2.06 (m, 1H), 2.00 - 1.85 (m, 1H), 1.47 (s, 9H).
Step 4: tert-butyl (R)-4-(3-ethynylcyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 23d)
N NBoc
To a stirred solution of trimethylsilyldiazomethane (10.70 ml, 21.40 mmol) m dry tetrahydrofuran (10 ml) was added n-butyl lithium (8.56 ml, 21.40 mmol, 1.6 M solution in hexane) under nitrogen atmosphère at -78 °C . The resulting mixture was stirred for 30 min. To this reaction mixture a solution of tert-butyl (R)-4-(3-formylcyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 23c, 5.0 g, 17.83 mmol) in tetrahydrofuran (25 ml) was added slowly at the same température. The reaction mixture was allowed to stir at room température for
h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (50 ml) and was washed with water (10 ml). The organic layer was dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product which was 5 purified by flash column chromatography over silica gel (100 - 200 mesh) using 45 50 /o ethyl acetate in hexane as an eluent to obtain the title compound (2 5 g 50.7%).
‘H NMR (400 MHz, CDC13): δ 6.15 (q, J= 2.2 Hz, 1H), 3.95 - 3.85 (m, 1H), 3.52 (s, 4H), 3.06 (s, 1H), 2.61 - 2.38 (m, 6H), 2.05 - 1.82 (m, 2H), 1.47 (s, 9H).
Step 5: (R)-l-(3-ethynylcycIopent-2-en-l-yl)piperazine hydrochloride (Compound 23e)
To a solution of tert-butyl (R)-4-(3-ethynylcyclopent-2-en-l-yl)piperazine1-carboxylate (Compound 23d, 2 g, 7.24 mmol) in dry dichloromethane (250 mi) 15 was added hydrochloric acid (12.06 ml, 36.2 mmol, 4M solution in 1,4-dioxane) in a drop-wise manner at 0-5 °C. The reaction mixture was stirred at room température for 1-2 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The residue was washed with diethyl ether (10 ml), and dried under reduced pressure to obtain 20 the title compound.
Ή NMR (400 MHz, DMSO-*): 6 12.19 (brs-exchangeable with D2O, 1H), 9.73 (brs-exchangeable with D/J. 1H), 6.23 (q, J - 2.1 Hz, 1H), 4.58 - 4.49 (m, 1H), 3.79 - 3.20 (m, 9H), 2.72 - 2.60 (m, 1H), 2.51 - 2.39 (m, 1H), 2.35 - 2.11 (m’ 2H).
Step 6: (R)-4-(4-(3-ethynylcyclopent-2-en-l-yl)piperazin-l-yl)-3-nuorobenzonitrile 25 (Compound 23f)
To a solution of (R)-l-(3-ethynylcyclopent-2-en-l-yl)piperazine hydrochloride (Compound 23e, 2.5 g, 14.18 mmol) in Ν,Ν-dimethylformamide (20 ml) were added 3,4-difluorobenzonitrile (1.960 g, 14.18 mmol) in Ν,Νdimethylformamide (5 ml) and potassium carbonate (5.88 g, 42.6 mmol) at room température. The reaction mixture was heated at 120 - 125 °C for 18-20 hr under a nitrogen atmosphère. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température and quenched with water (50 ml). The aqueous layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain crude product which was purified over flash chromatography over silica gel (100 -200 mesh) using 20-30% ethyl acetate as an eluent to obtain the title compound (1.2 g, 30.5%).
>H NMR (400 MHz, DMSO-ck) δ 7.74-7.66 (m, 1H), 7.61-7.55 (m, 1H), 7.117-7.08 (m, 1H), 6.18 (d, J= 2.0 Hz, 1H), 4.12 (s, 1H), 3.86 - 3.78 (m, 1H), 3.20-3.11 (m, 4H), 2.64-2.52 (m, 4H), 2.46 - 2.29 (m, 2H), 2.00 - 1.87 (m, 1H), 1.86-1.75 (m, 1H).
MS: m/z296 (M+l).
Step 7: (R)-3-fluoro-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 23)
O
To a solution of 2-bromonicotinic acid (0.947 g, 4.69 mmol) in anhydrous acetonitrile (10 ml, degassed by nitrogen gas) was added bis (triphenylphosphine) palladium (II) chloride (0.253 g, 0.361 mmol) at 25°C. The reaction mixture was heated and stirred at 70 C for 10 min and to this warmed reaction mixture was 5 added diisopropylethylamine (3.78 ml, 21.63 mmol) followed by the addition of a solution of (R)-4-(4-(3-ethynylcyclopent-2-en-l-yl)piperazin-l-yl)-3fluorobenzonitrile (Compound 23f, 1.0 g, 3.61 mmol) in acetonitrile (5 ml) and the reaction mixture was heated at same température for 3 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room 10 température and diluted with ethyl acetate (200 ml), washed with water (100 ml).
The aqueous layer was again extracted with ethyl acetate (100 ml) and the combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give crude intermediate; which was dissolved in anhydrous tetrahydrofuran (10 ml). To this solution of crude intermediate was 15 added ammonia in methanol (50 ml, 361.0 mmol) at 25°C and was heated at 90°C for 2 hr. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température, filtered and filtrate was concentrated under reduced pressure to obtain crude product which was purified by flash column chromatography over silica gel (100 - 200 mesh) using 0-5% methanol in 20 dichloromethane as eluent to obtain title compound (0.110 g, 7.68% yield).
MS: m/z 415 (M+l).
Step 8: (R)-3-fluoro-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 23-hydrochloride sait)
.2HCI
A solution of (R)-3-fluoro-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 23, 90 mg, 0.226 mmol) in tetrahydrofuran (2 ml) and methanol (2 ml) was heated at 65°C and was added hydrochloric acid in methanol (0.830 ml, 0.498 mmol, 3M solution) at 5 same température in small portions over a period of 5 min. The reaction mixture was then stirred for 30 min at 25°C. The reaction mixture was cooled to room température, diluted with diethyl ether (10 ml), and product was collected upon filtration. The solid was washed with diethyl ether (10 ml) and dried under reduced pressure for 3 hr at 40°C to obtain the title compound (0.095 g, 89 % 10 yield).
‘H NMR (400 MHz, DMSO-de) Ô 11.86 (brs-exchangeable with D2O, 2H), 9.04 (dd, J= 5.0, 1.7 Hz, 1H), 8.84 - 8.60 (m, 1H), 7.80 (dd, J= 13.1, 1.9 Hz, 1H), 7.69 (dd, J = 8.1, 5.0 Hz, 1H), 7.64 (dd, J = 8.4, 1.9 Hz, 1H), 7.27 (t, J =8.7 Hz, 1H), 6.95 (d, J= 2.6 Hz, 1H), 6.87 (s, 1H), 4.70 (s, 1H), 3.76-3.73 (m, 2H), 3.61-3.55 15 (m, 2H), 3.46-3.40 (m, 2H), 3.31-.16 (m, 2H), 2.98-2.81 (m, 2H), 2.44-2.38 (m,
2H).
MS: m/z 415.9 (M+l).
The following compounds were prepared using the procedure described above in Example 2 with appropriate changes to the reactants, if required 20 stereoisomer (compound 23b”) and to the reaction conditions.
(R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 1-hydrochloride sait)
NH .2HCI
Ή NMR (400 MHz, DMSO-dô) 6 11.73 (brs-exchangeable with D2O, 1H), 11.49 25 (brs-exchangeable with D2O, 1H), 9.00 (dd, J= 8.8, 2.0 Hz, 1H), 8.62 (dd, J= 8.0,
2.0 Hz, 1H), 7.68 (d, J- 8.8 Hz, 2H), 7.62 (dd, J = 8.0, 2.0 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.89 {d, J= 2.0 Hz, 1H), 6.82 (s, 1H), 4.73-4.53 (m, 1H), 4.15 (d, J = 12.4 Hz, 2H), 3.59 (t, J = 11.6 Hz, 2H), 3.35 (t, J = 11.6 Hz, 2H), 3.12 (dd, J = 20.0, 9.6 Hz, 2H), 2.90 (q, J= 7.6 Hz, 2H), 2.40 (q, J= 7.6 Hz, 2H).
MS: m/z 398.3 (M+l).
(S)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-l yl)piperazin-l-yl)benzonitrile (Compound 4-hydrochloride sait)
Ή NMR (400 MHz, DMSO-dô) δ 11.73 (brs-exchangeable with D2O, 1H), 11.49 (brs-exchangeable with D2O, 1H), 9.00 (dd, J= 8.8, 2.0 Hz, 1H), 8.62 (dd, J= 8.0, 2.0 Hz, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.62 (dd, J= 8.0, 2.0 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.89 (d, J= 2.0 Hz, 1H), 6.82 (s, 1H), 4.73-4.53 (m, 2H), 4.15 (d, J = 15 12.4 Hz, 2H), 3.59 (t, J= 11.6 Hz, 2H), 3.35 (t, J= 11.6 Hz, 2H), 3.12 (dd, J =
20.0, 9.6 Hz, 2H), 2.90 (q, J= 7.6 Hz, 2H), 2.40 (q, J= 7.6 Hz, 2H).
MS: τη/z 398.1 (M+l).
Ethyl (R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-l yl)piperazin-l-yl)benzoate (Compound 20-hydrochloride sait)
COOCH2CH3
Ή NMR (400 MHz, DMSO-dt,) 6 11.71 (brs-exchangeable with D2O, 1H), 11.28 (brs-exchangeable with D2O, 1H), 8.99 (dd, J= 4.8, 1.8 Hz, 1H), 8.61 - 8.59 (m,
1H), 7.85 (d, J= 8.5 Hz, 2H), 7.61 (dd, J= 8.1, 4.8 Hz, 1H), 7.10 (d, J= 8.5 Hz, 2H), 6.89 (s,lH), 6.81 (s, 1H}, 4.69 (s, 1H), 4.26 (q, J= 7.0 Hz, 2H), 4.12 (d, J = 13.0 Hz, 2H), 3.60 (t, J= 10.5 Hz, 2H), 3.41-3.13 (m, 4H), 2.91 (d, J= 7.0 Hz, 2H), 2.40 (m, 2H), 1.30 (t, 7.0 Hz, 3H).
MS: τη/z 445.1 (M+l).
(R)-7-(3-(4-(l -oxo-2,3-dihydro-1 H-inden-5-yl)piperazin- l-yl)cyclopent-1 -en-1 -yl) l,6-naphthyridin-5(6H)-one (Compound 29-hydrochloride sait)
*H NMR (400 MHz, DMSO-da) S 11.76 (brs-exchangeable with D2O, 1H) , 11.52 (brs-exchangeable with D2O, 1H) , 9.01 (d, J= 4.8 Hz, 1H), 8.64 (d, J= 8.0 Hz, 1H), 7.64 (dd, J = 8.0, 4.8 Hz, 1H), 7.51 (d, J= 8.8 Hz, 1H), 7.09 (m, 2H), 6.91 (s, 1H), 6.83 (s, 1H), 4.69 (s, 1H), 4.51 (s, 1H), 4.19-4.16 (m, 1H), 3.62-3.56 (m, 2H), 3.42-3.35 (m, 2H), 3.20-3.11( m, 2H), 3.00-2.87 (m, 2H), 2.90-2.87(m, 2H), 2.572.55 (m, 2H), 2.45 - 2.32 (m, 2H).
MS: m/z 427.3 (M+l).
(R)-7-(3-(4-( 1-oxo-1,3-dihydroisobenzofuran-5-yl)piperazin-1 -yl) cyclopent-1 -en-1 yl)-l,6-naphthyridin-5(6H)-one (Compound 31-hydrochloride sait)
2HCI
Ή NMR (400 MHz, DMSO-ds) δ 11.66 (brs-exchangeable with D2O, 1H), 11.12 (brs-exchangeable with D2O, 1H), 9.02 - 8.95 (m, 1H), 8.57 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.59 (dd, J = 8.0, 4.0 Hz, 1H), 7.25 (d, J = 9 Hz, 1H), 7.19 (s, 1H), 6.88 (s, 1H), 6.80 (s, 1H), 5.31 (s, 2H), 4.70 (s, 1H), 3.62 (t, J = 12 Hz, 2H), 3.34 (t, J = 12 Hz, 2H), 3.24 - 3.16 (m, 2H), 2.95 - 2.88 (m, 2H), 2.58 2.54 (m, 2H), 2.46 - 2.37 (m, 2H).
MS: m/z 429.1 (M+l).
(R)-7-(3-(4-( 1 -oxoisoindolin-5-yl)piperazin-1 -yl)cyclopent-1 -en-1 -yl) -1,6naphthyridin-5(6H)-one (Compound 32-hydrochloride sait)
Ή NMR (400 MHz, DMSO-cfc) ô 11.58 (brs-exchangeable with D2O, 1H), 10.40 (brs-exchangeable with D2O, 1H), 8.96 (s, 1H), 8.52 (d, J= 8.1 Hz, 1H), 8.27 (s, 1H), 7.63 - 7.51 (m, 2H), 7.11-7.17 (m, 1H), 6.87 (s, 1H), 6.80 (s, 1H), 4.71 (s, 1H), 4.30 (s, 2H), 4.07 (d, J= 12.2 Hz, 2H), 3.63 (s, 2H), 3.11-3.19 (m, 4H), 2.93 (s, 2H), 2.41-2.44 (m, 2H).
MS: m/z 428.1 (M+I).
(R) -7-(3-(4-(4-(trifluoromethyl)phenyl)piperazin-1 -yl)cyclopent-1 -en-1 -yl) -1,6naphthyridin-5(6H)-one (Compound 33-hydrochloride sait)
.2HCI *H NMR (400 MHz, DMSO-ck) Ô 11.69 (brs-exchangeable with D2O, 1H), 11.30 (brs-exchangeable with D2O, 1H), 8.99 (d, J = 4.5 Hz, 1H), 8.59 (d, J= 8.0 Hz, 1H), 7.64-7.54 (m, 3H), 7.18 (d, J = 8.5 Hz, 2H), 6.89 (s, 1H), 6.81 (s, 1H), 4.9 4.61 (m, 1H), 4,11 - 4.07 (m, 2H), 3.68-3.54 (m, 2H), 3.34 - 3.30 (m, 2H), 3.22 3.12 (m, 2H), 2.92-2.82 (m, 2H), 1.54- 1.52 (m, 2H).
MS: m/z 441.3 (M+l).
(R)-6-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cyclopent-2-en-Iyl)piperazin-l-yl)nicotinonitrile (Compound 50-hydrochloride sait)
‘H NMR (400 MHz, DMSO-cfc) ô 11.56 (brs-exchangeable with D2O, 1H), 11.35 (brs-exchangeable with D2O, 1H), 8.58 (d, J = 2.0Hz, 1H), 7.99 (dd, J= 8.0, 2.0 Hz, 1H), 7.69 (d, J= 5.0 Hz, 1H), 7.51 (d, J= 5.0Hz, 1H), 7.10 (d, 8.0 Hz, 2H),
6.73 (s, 1H), 4.68- 4.61 (m, 3H), 3.61-3.45 (m,4H), 3.17-3.00 (m, 2H), 2.89-2.7( m, 2H),2.39- 2.37 (m, 2H).
MS: m/z 404.3 (M+l)
Example 3: Synthesis of (R)-N-methyl-4-(4-(3-(5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzamide (Compound 18)
CONHCH3
Step 1: (R) -4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzoic acid (Compound 18a)
To the stirred solution of ethyl (R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzoate (Compound 20, 1.6 5 g, 3.60 mmol) in éthanol (20 ml), tetrahydrofuran (3 ml) was added NaOH (0.576 g, 14.40 mmol) in water (5 ml) and the reaction mixture was stirred at room température for 15 min and heated at 70°C for 16 h. The progress of the reaction was monitored by TLC. The reaction was cooled to room température and the solvent was evaporated under vacuum. Water (10 ml) was added to the reaction 10 followed by 10% HCl (till acidic pH). The solid obtained was filtered. The residue was washed with water and azeotropped with toluene to afford 1g (66 %) of the titled compound as white solid.
MS: m/z 417 (M+l).
Step 2: (R)-N-methyl-4-(4-(3-(5-oxo-5,6-dihydro- l,6-naphthyridin-7-yl)cyclopent2-en-l-yI)piperazin-l-yl)benzamide (Compound 18)
CONHCH3
To the cooled (10 °C) and stirred solution of (R)-4-(4-(3-(5-oxo-5,6-dihydrol,6-naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzoic acid (Compound 18a, 0.5 g, 1.20 mmol) in dimethyl sulphoxide (15 ml) was added HATU (1.14 g, 3.00 mmol), DIPEA (0.839 ml, 4.80 mmol). The reaction mixture was warmed to room température and stirred for 0.5 hr. The reaction mixture was cooled to 0 °C and methylamîne (2.4 ml, 4.80 mmol) was added and the reaction was stirred at room température for 16 hrs. The progress of the reaction was monitored by TLC. Ice cold water (20 ml) was added and reaction mass was filtered. The residue obtained was washed with water; dried under vacuum to afford 300 mg 5 (58 %) of the titled compound as yellow solid.
‘H NMR (400 MHz, DMSO-ci,) 6 11.48 (brs-exchangeable with D2O, 1H), 8.91 (dd, J= 4.5, 2.0 Hz, 1H), 8.48 (d, J= 8.0 Hz, 1H), 8.19-8.11 (m, 1H), 7.75-7.69 (m, 2H), 7.51-7.44 (m, 1H), 7.0-6.92 (m, 2H), 6.60 (s, 1H), 3.98-3.88 (m, 1H), 3.27 (d, J - 5.2 Hz, 3H), 2.92-2.86 (m , 1H), 2.83 - 2.57 (m, 7H), 2.55 (s, 2H), 2.15-2.04 10 (m, 1H), 1.98-1.85 (m, 1H).
MS: m/z 430.1 (M+l).
Step 3: (R)-N-methyl-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzamide (Compound 18-hydrochloride sait)
CONHCH3
To the stirred suspension of (R)-N-methyl-4-(4-(3-(5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-1 -yl)piperazin-1 -yl)benzamide (Compound 18, 0.300 g, 0.698 mmol) in methanol (5 ml) and DCM (5 ml) was added dropwise HCl (1.397 ml, 5.59 mmol) 4M in Dioxane at room température. The reaction 20 mixture was stirred for 1 hr. To the reaction mixture, diethyl ether (10 mL) was added. The solid obtained was filtered and dried under vacuum to afford 280 mg (80 %) of the titled compound as white solid.
Ή NMR (400 MHz, DMSO-cfc) 611.67 (brs-exchangeable with D2O, 1H), 10.99 (brs-exchangeable with D2O, 1H), 8.98 (d, J = 4.5 Hz, 1H), 8.57 (d, J= 8.1 Hz,
1H), 8.25 (d, J= 4.5 Hz, 1H), 7.78 (d, 8.5 Hz, 2H), 7.59 (dd, J= 8.1, 4.7 Hz,
1H), 7.06 (d,J= 8.5 Hz, 2H), 6.89 (s, 1H), 6.80 (s, 1H), 4.69 (s, 1H), 4.54 (s, 2H), 4.06 (d, J= 9.6 Hz, 2H), 3.58 (d, J= 11.0 Hz, 2H), 3.19 (s, 2H), 2.91(s, 2H), 2.76 (d, 4.0 Hz, 3H), 2.42-2.38 (m, 2H).
MS: m/z 430.1 (M+l).
The following compounds were prepared using the procedure described above m Example 3 with appropriate changes to the reactants and reaction conditions.
(R)-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-1 -yl)benzamide (Compound 19-hydrochloride sait)
H NMR (400 MHz, DMSO-d(i) δ 11.73 (brs-exchangeable with D2O, 1H), 11.34 (brs-exchangeable with D2O, 1H), 8.99 (dd, J= 5.0,1.7 Hz, 1H), 8.62 (d, J = 8.0 Hz, 1H), 7.81 (d, J= 8.5 Hz, 2H), 7.62 (dd, J = 8.0,5.0 Hz, 1H), 7.05 (d, J= 8.5 Hz, 2H), 6.91 (s, 1H), 6.82 (m, 3H), 4.69 (s, 1H), 4.05(d, 12.3 Hz, 2H), 3.58 (t,
J= 10.6 Hz, 2H), 3.29-3.13 (m, 4H), 2.92-2.88 (m, 2H), 2.41 (d, J= 8.0 Hz, 2H).
MS: m/z 416.3 (M+l).
(R|-N-nIethyl-4-(4.(3.(4-oxo-4,5-dihydrothieno|3,2.clpyridin-6-y1)cyclopent.2-en l-yl)piperazin-l-yl)benzainide (Compound 49-hydrochloride sait)
O
.HCl
H NMR (400 MHz, DMSO-de) ô 11.41 (brs-exchangeable with D2O, 1H), 8.29 (brs-exchangeable with D2O, 1H), 7.78 (d, J= 8.5 Hz, 2H), 7.69 (d, J= 5.0 Hz, 1H), 7.51 (d, J = 5.0 Hz, 1H), 7.10 (s, 1H), 7.05 (d, J= 8.5 Hz, 2H), 6.79 (s, 1H), 4.63 (s, 1H), 4.03 (d, J = 12.0 Hz, 2H), 3.57 (t, J= 13 Hz, 2H), 3.22 - 3.32 (m, 2H), 3.20 - 3.08 (m, 2H), 2.92 - 2.79 (m, 2H), 2.76 (s, 3H), 2.40 - 2.35 (m, 2H).
MS: m/z 435.2 (M+l).
Example 4: Synthesis of ( R)-4-(4-( 3-(l-oxo-l,2-dihydro-2,6-naphthyridin-3yl)cyclopent-2-en-l-yl)piperazin-l-yI)benzonitrile (Compound 36)
Step 1: (R)-methyl 3-((3-(4-(4-cyanophenyl)piperazin-l-yl)cyclopent-l-en-lyl)ethynyl)isonicotinate (Compound 36a)
To a solution of methyl-3-bromoisonicotinate (2.337 g, 10.82 mmol) in anhydrous acetonitrile (100 ml, degassed by nitrogen gas) was added bis(triphenylphosphine) palladium (II) chloride (0.633 g, 0.901 mmol) at 25°C. The reaction mixture was heated and stirred at 80 ’C for 10 min and to this warmed reaction mixture was added diisopropylethyl amine (9,45 ml, 54.10 mmol) followed by the addition of a solution of (R)-4-(4-(3-ethynylcyclopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound Ij-Prepared according to the procedure given in Example 1; step 10, 2.5 g, 9.01 mmol) in acetonitrile (25 ml). The reaction mixture was heated at same température for 18 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température and diluted with ethyl acetate (200 ml), washed with water (100 ml). The aqueous layer was again extracted with ethyl acetate (100 ml) and the combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give crude intermediate, which was purified by flash 5 column chromatography over silica gel (100 - 200 mesh) using 70-100% ethyl acetate in hexane as eluent to obtain title compound (1.5 g, 40.3% yield).
*H NMR (400 MHz, CDCla) ô 8.89 - 8.81 (m, 1H), 8.70 - 8.60 (m, 1H), 7.81 - 7.76 (m, 1H), 7.53 (d, J= 8.6 Hz, 2H), 6.89 (d, J= 8.4 Hz, 2H), 6.31 (s, 1H), 3.99 (s, 3H), 3.54 - 3.38 (m, 4H), 2.85 - 2.63 (m, 6H), 2.24 - 2.02 (m, 3H).
MS: m/z 413 (M+l).
Step 2: (R)-3-((3-(4-(4-cyanophenyl)piperazin-1 -yl)cyclopent-1 -en-1 -yljethynyl) isonicotinic acid (Compound 36b)
To a stirred solution of (R)-methyl 3-((3-(4-(4-cyanophenyl)piperazin-l15 yl)cyclopent-l-en-l-yl)ethynyl)isonicotinate (Compound 36a, 1.5 g, 3.64 mmol) in methanol (100 ml) was added aqueous sodium hydroxide (0.582 g, 14.55 mmol) in water (10 ml), at 25-30 °C. The reaction mixture was stirred for 2 hrs at the same température. The progress of the reaction was monitored by TLC. The reaction mixture was distilled under reduced pressure completely till dryness. 20 The sticky solid obtained was dissolved in water (50 ml), a clear solution was observed and then washed with ethyl acetate (25 ml) to remove the impurities. The aqueous layer was separated, cooled at 0-5 °C and then the pH was adjusted ~3 using dilute aqueous hydrochloric acid (1:1) at 0-5 °C, the solid compound was precipitated out. The obtained solid compound was stirred for 10-15 min at 25 same température and filtered through Buchner funnel, washed with ice cold water (10 ml), dried till dryness to obtain the title compound (1.2 gm, 83.0 % yield).
Ή NMR (400 MHz, DMSO-c^) Ô 8.79 (s, 1H), 8.68 (d, J= 5.0 Hz, 1H), 7.75 (d, J = 5.1 Hz, 1H), 7.61 (d, J= 8.5 Hz, 2H), 7.05 (d, J= 8.6 Hz, 2H), 6.34 (s, 1H), 4.14 (s, 1H), 3.57-3.42 (m, 6H), 2.92 - 2.73 (m, 4H), 2.66-2.57 (m, 1H), 2.18- 1.95 (m, 2H).
MS: m/z 399 (M+l).
Step 3: (R)-4-(4-(3-(l-oxo- lH-pyrano[4,3-c]pyridin-3-yl)cyclopent-2-en-l-yl) piperazin-l-yl)benzonitrile (Compound 36c)
To a solution of (R)-3-((3-(4-(4-cyanophenyl)piperazin-l-yl)cyclopent-l-enl-yl)ethynyl)isonicotinic acid (Compound 36b, 1.1 g, 2.76 mmol) in anhydrous dichloromethane : tetrahydrofuran (100 ml, Ratio: 1:1), was added trifluoromethane sulphonic acid (0.621 g, 4.14 mmol) at 0-5 eC and the reaction mixture was stirred for 48 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was cooled at 0-5 °C and then diluted with diethyl ether (25 ml), a solid compound was precipitated out. The reaction mixture was stirred for 30 min at same température and filtered through Buchner funnel, washed with diethyl ether (10 ml), and dried completely to obtain the title compound (490 mg, 44.5 % yield).
‘H NMR (400 MHz, DMSO-d&) 6 9.84 (s, 1H), 9.10 (s, 1H), 8.83 (d, J= 5.7 Hz, 1H), 7.68 (d, J= 8.5 Hz, 2H), 7.13 (d, J= 8.7 Hz, 2H), 6.61 (s, 1H), 4.72 (s, 1H), 4.24 - 4.07 (m, 2H), 3.75 - 3.50 (m, 2H), 3.35 - 3.20 (m, 1H), 3.18 - 2.99 (m, 3H), 2.96 - 2.68 (m, 3H), 2.46-2.28 (m, 2H).
MS: m/z 399 (M+l).
Step 4: (R)-4-(4-(3-(l -oxo- l,2-dihydro-2,6-naphthyridin-3-yl)cyclopent-2-en-1yl)piperazin-l-yl)benzonitrile (Compound 36)
O
To a solution of (R)-4-(4-(3-(l-oxo-lH-pyrano[4,3-c]pyridin-3-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 36c, 300 mg, 0.753 mmol) in anhydrous tetrahydrofuran (5 ml), was added ammonia in methanol (10.76 ml, 75 mmol) at 25°C. The reaction mixture in Steel bomb reactor was stirred for 12 hrs at 80-85 °C. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température and then concentrated under reduced pressure to obtain crude product which was purified by flash column chromatography over silica gel (100 - 200 mesh) using 2-5% methanol in dichloromethane as eluent to obtain title compound (0.050 g, 16.71% yield).
]H NMR (400 MHz, DMSO-ck) 5 11.53 (brs-exchangeable with D2O, 1H), 9.08 (dd, J= 8.8, 2.0 Hz, 1H), 8.61 (dd, J= 8.0, 2.0 Hz, 1H), 7.97 (d, J =8.8 Hz, 2H), 7.58 (dd, J = 8.0, 2.0 Hz, 1H), 7.03 (d, J= 8.8 Hz, 2H), 6.91 (d, J = 2.0 Hz, 1H), 6.71 (s, 1H), 3.97 - 3.86 (m, 1H), 3.43 - 3.35 (m, 4H), 2.82 - 2.70 (m, 1H), 2.68 - 2.55 (m, 4H), 2.15 - 2.01 (m, 1H), 1.98 - 1.80 (m, 1H), 1.90 - 1.75 (m, 1H).
MS: m/z 398.3 (M+l)
Step 5: (R)-4-(4-(3-( 1 -oxo-1,2-dihydro-2,6-naphthyridin-3-yl)cyclopent-2-en-1 yl}piperazin-l-yl)benzonÎtrile (Compound 36-hydrochloride sait)
.2HCI
A solution of (R)-4-(4-(3-(l-oxo-l,2-dihydro-2,6-naphthyridin-3yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrüe (Compound 36, 40 mg, 0.101 mmol) in dichloromethane (2 ml) and methanol (2 ml) was heated at 65°C and was added hydrochloric acid in methanol (0.587 ml, 0.352 mmol, 3M solution) 5 at same température in small portions over a period of 5 min. The reaction mixture was then stirred for 30 min at 25°C. The reaction mixture was cooled to room température, diluted with diethyl ether (10 ml), and the product was collected upon filtration. The solid compound was washed with diethyl ether (10 ml) and dried under reduced pressure for 3 hr at 40°C to obtain the title 10 compound (0.035 g, 88 % yield).
Ή NMR (400 MHz, DMSO-d&) δ 11.74 (brs-exchangeable with D2O, s, 1H), 11.46 (brs-exchangeable with D2O, s, 1H), 9.19 (s, 1H), 8.70 (d, 5.4 Hz, 1H), 8.10 (d,
J= 5.4 Hz, 1H), 7.68 (d, J= 8.7 Hz, 2H), 7.14 (d, J = 8.7 Hz, 2H), 6.93 (s, 1H), 6.83 (s, 1H), 4.67 (s, 1H), 4.14 (d, J= 13.4 Hz, 2H), 3.64 - 3.52 (m, 2H), 3.34 (t, J 15 = 13.1 Hz, 2H), 3.23 - 3.07 (m, 2H), 2.95 - 2.80 (m, 2H), 2.45 - 2.35 (m, 2H).
MS: m/z 398.3 (M+l).
The following compounds were prepared using the procedure described above in Example 4 with appropriate changes to the reactants and reaction conditions. If required, compound 23b” is used as starting material and 20 procedure described m step 3 to step 6 of example 2 is followed to préparé required intermediate.
(R)-4-(4-(3-(3-fluoro-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cycIopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 2-hydrochloride sait)
.2HCI
H NMR (400 MHz, DMSO-de) Ô 11.70 (brs-exchangeable with D2O, 1H), 11.32 (brs-exchangeable with D2O, 1H), 9.01 (d, J = 3.0 Hz, 1H), 8.29 (dd,J= 8.5, 3.0 Hz, 1H), 7.68 (d, 8.4 Hz, 2H), 7.15 (d, J = 8.6 Hz, 2H), 6.83 (d/j= 13.2 Hz,
2H), 4.67 (d, J= 6.9 Hz, 1H), 4.15 (d, J= 13.3 Hz, 2H), 3.55-3,60 (m, 2H), 3.40 5 3.25 (m, 2H), 3.25 - 3.05 (m, 2H), 2.97 - 2.83 (m, 2H), 2.38 (s, 2H).
MS: m/z 416.1 (M+l).
(S)-4-(4-(3-(3-fluoro-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 5-hydrochloride sait)
H NMR (400 MHz, DMSO-cfc) Ô 11.69 (brs-exchangeable with D2O, 1H), 11 30 (brs-exchangeable with D2O, 1H), 9.00 (d, J= 3.0 Hz, 1H), 8.29 (dd, J = 8.5, 3 0
Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.6 Hz, 2H), 6.83 (d/j= 13.2 Hz,
2H), 4.67 (d, J= 6.9 Hz, 1H), 4.15 (d, 13.3 Hz, 2H), 3.55-3.60 (m, 2H), 3.40 ’
3.25 (m, 2H), 3.25 - 3.05 (m, 2H), 2.96 - 2.83 (m, 2H), 2.39 (s, 2H).
MS: m/z416 (M+l).
(R)-4-(4-(3-(8-oxo-7,8-dihydro-l,7-naphthyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 37-hydrochloride sait)
H NMR (400 MHz, DMSO-^): ô 11.83 (brs-exchangeable with D2O, 1H), 11.60 (brs-exchangeable with D2O, 1H), 8.87 - 8.84 (m, 1H), 8.38 (d, J= 8.2 Hz, 1H),
7.89 7.85 (m, 1H), 7.69-7.66 (m, 2H), 7.14-7.11 (m, 2H), 6.83-6.85 (m, 2HJ.4.62 (s, 1H), 4.14 (d, J= 13.3 Hz, 2H), 3.59 - 3.52 (m, 2H), 3.35 - 3.25 (m, 2H), 3.20 3.07 (m, 2H), 2.88 - 2.78 (m, 2H), 2.41 - 2.34 (m, 2H).
MS: m/z 398.3 (M+l).
(R)-4-(4-(3-( 1 -oxo-1,2-dihydro-2,7-naphthyridin-3-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 38-hydrochloride sait)
H NMR (400 MHz, DMSO cfe) ô 12.08 (brs-exchangeable with D2O, 1H), 11.78 (brs-exchangeable with D2O, 1H), 9.41 (s, 1H), 8.80 (d, J= 6.0 Hz, 1H), 7.97 (d, J = 6.1 Hz, 1H), 7.68 (d, J = 8.6 Hz, 2H), 7.15 (d, 8.6 Hz, 2H), 7.00 {s’ 1H), 6.95 (s, 1H), 4.69 (s, 1H), 4.22 - 4.08 (m, 2H), 3.66 - 3.51 (m, 2H), 3.34-3.32 (m, 2H), 3.24 - 3.06 (m, 2H), 2.99 - 2.80 (m, 2H), 2.44 - 2.37 (m, 2H).
MS: m/z 398.4 (M+l).
(R)-4-(4-(3-(5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-7-yl)cyclopent-2-en-l yl)piperazin-l-yl)benzonitriie (Compound 40-hydrochloride sait)
’H NMR (400 MHz, DMSO-d*) δ 11.93 (brs-exchangeable with D2O, 1H), 11.55 (brs-exchangeable with D2O, 1H), 9.43 (s, 1H), 9.37 (s, 1H), 7.68 (d, J =8.5 Hz, 2H), 7.14 (d, J= 8.7 Hz, 2H), 6.94 (s, 1H), 6.72 (s, 1H), 4.75-4.64 (m, 1H), 4.2018697
4.11 (m, 2H), 3.59 - 3.53 (m, 2H), 3.37-3.28 (m, 2H), 3.26 - 3.07 (m, 2H), 2.96 2.84 (m, 2H), 2.45 - 2.35 (m, 2H).
MS: m/z 399.1 (M+l).
(R)-4-(4-(3-(5-oxo-5,6-dihydropyrido[3,4-b]pyrazin-7-yl)cyclopent-2-en-l yl)piperazin-l-yl)benzonitrile (Compound 41-hydrochloride sait)
H NMR (400 MHz, DMSO-dû) Ô 11.84 (brs-exchangeable with DjO, 1H), 11.59 (brs-exchangeable with D2O, 1H), 8.98 (s, 1H), 8.83 (s, 1H), 7.68 (d, J = 8.5 Hz, 2H), 7.14 (d, J= 8.5 Hz, 2H), 6.89 (s, 1H), 6.78 (s, 1H), 4.68 (s, 1H), 4.14 (d, J = 13.5 Hz, 2H), 3.65-3.53 (m, 2H), 3.34 (d, J= 13.5 Hz, 2H), 3.19 - 3.06 (m, 2H), 2.91 (s, 2H), 2.44-2.34 (m, 2H).
MS: m/z 399.1 (M+l).
(R)-4-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 42-hydrochloride sait)
H NMR (400 MHz, DMSO d&): δ 11.38 (brs-exchangeable with D2O, 1H), 11.08 (brs-exchangeable with D2O, 1H), 7.75 - 7.64 (m, 3H), 7.51 (d, J= 5.3 Hz, 1H),
7.21 - 7.07 (m, 3H), 6.75 (s, 1H), 4.64 (s, 1H), 4.14 (d, 13.3 Hz, 2H), 3.59 -
3.52 (m, 2H), 3.35 - 3.25 (m, 2H), 3.19 - 3.07 (m, 2H), 2.90 - 2.78 (m, 2H), 2.42 2.31 (m,2H).
MS: m/z 403.1 (M+l).
(R)-4-(4-(3-(4-oxo-4,5-dihydrothiazolo(5,4-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 43-hydrochloride sait)
‘H NMR (400 MHz, OMSO-c^): ô 11.81 (brs-exchangeable with D2O, 1H), 10.98 (brs-exchangeable with D2O, 1H), 9.60 (s, 1H), 7.68 (d, J= 8.2 Hz, 1H), 7.19 -
7.11 (m, 3H), 6.79 (s, 1HJ.4.62 (s, 1H), 4.67 (m, 1H), 4.17-4.13 (m, 2H), 3.61 -
3.57 (m, 2H), 3.37 - 3.27 (m, 4 H), 2.92 - 2.88 (m, 2H), 2.41 - 2.37 (m, 2H).
MS: m/z 404.1 (M+l) (R)-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[4,5-c]pyridin-6-yl)cyclopent-2-en-l yl)piperazin-l-yl)benzonitrile (Compound 44-hydrochloride sait)
’H NMR (400 MHz, OMSO-cfe) ô 11.67 (brs-exchangeable with D2O, 1H), 10.96 (brs-exchangeable with D2O, 1H), 9.21 (s, 1H), 7.74 - 7.65 (m, 2H), 7.20 (s, 1H), 7.19 - 7.12 (m, 2H), 6.79 (s, 1H), 4.71 - 4.62 (m, 1H), 4.22 - 4.11 (m, 2H), 3.62 20 3.53 (m, 2H), 3.34 - 3.23 (m, 2H), 3.21 - 3.07 (m, 2H), 2.90 - 2.79 (m’ 2Hh 2.44 2.29 (m, 2H).
MS: m/z 404.2 (M+l).
(S)-4-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound 45-hydrochloride sait)
'H NMR (400 MHz, DMSO-dû): δ 11.39 (brs-exchangeable with D2O, 1H), 11.07 (brs-exchangeable with D2O, 1H), 7.75 - 7.64 (m, 3H), 7.51 (d, J = 5.3 Hz, 1H),
7.21 - 7.07 (m, 3H), 6.75 (s, 1H), 4.64 (s, 1H), 4.14 (d, J= 13.3 Hz, 2H), 3.59 3.52 (m, 2H), 3.35 - 3.25 (m, 2H), 3.19 - 3.07 (m, 2H), 2.91 - 2.77 (m, 2H), 2.44 2.30 (m, 2H).
MS: m/z 425.0 (M+23).
(S)-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[5,4-c]pyridin-6-yl)cyclopent-2-en-lyl)piperazm-l-yl)benzonitrile (Compound 46-hydrochloride sait)
‘H NMR (400 MHz, DMSO-d&): Ô 11.80 (brs-exchangeable with D2O, 1H), 10.99 (brs-exchangeable with D2O, 1H), 9.60 (s, 1H), 7.68 (d, J= 8.2 Hz, 1H), 7.19 -
7.11 (m, 3H), 6.79 (s, 1H), 4.63 (s, 1H), 4.67 (m, 1H), 4.17-4.13 (m, 2H), 3.61 3.57 (m, 2H), 3.37 - 3.27 (m, 4 H), 2.92 - 2.89 (m, 2H), 2.41 - 2.38 (m, 2H).
MS: m/z 404.2 (M+l).
(R)-4-(4-(3-(l -methyl-4-oxo-4,5-dihydro-1 H-pyrazolo[4,3-c]pyridin-6-yl)cyclopent2-en-l-yl)piperazin-I-yl)benzonitrile (Compound 53-hydrochloride sait)
>H NMR (400 MHz, DMSO-cfe) δ 11.25 (brs-exchangeable with D2O, 1H), 10.99 (brs-exchangeable with D2O, 1H), 8.04 (s, 1H), 7.68 (d, J= 8.4 Hz, 2H), 7.15 (d, J = 8.6 Hz, 2H), 6.83 (s, 1H), 6.76 (s, 1H), 4.65 (s, 1H), 4.18-4.11 (m, 2H), 3.99 (s,
3H), 3.77 - 3.48 (m, 4H), 3.38-3.26 (m, 2H), 3.22-3.07 (m, 2H), 2.96 - 2.80 (m,
2H).
MS: m/z 423.1 (M+23).
Example 5: Synthesis of (R)-7-(3-(4-(4-fluorophenyl)piperazin-l-yI)cyclopentl-en-I-yl)-l,6-naphthyridin-5(6H)-one (Compound 22)
Step 1: 3-(4-(4-fluorophenyl)piperazin-l-yl)cyclopent-l-enecarbonitrile (Compound 22a)
To a stirred solution of l-(4-fluorophenyl)piperazine (50.3 g, 279 mmol) in acetonitrile (700 ml), was added potassium carbonate (80 g, 581 mmol) at 0°C and stirred for 30 min at room température and followed by 3-bromocyclopent-lenecarbonitrile (Compound la, 40 g, 233 mmol) at 0°C. The reaction mixture was stirred at room température for 3 hr. The progress of the reaction was monitored 6y TLC. The reaction mixture was diluted with water (3 lit) and extracted with ethyl acetate (4 x 700 ml). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude compound which was purified by column chromatography over silica gel (100 - 200 mesh) using 20-50% ethyl acetate in hexane as eluent to obtain the title compound (50 g, 79 % yield).
Ή NMR (400 MHz, CDCh): Ô 7.08 - 7.01 (m, 2H), 6.99 (q, J= 2.1 Hz, 1H), 6.96 6.90 (m, 2H), 3.97 - 3.86 (m, 1H), 3.05 (t, J= 4.9 Hz, 4H), 2.71 - 2.51 (m, 6H), 2.10- 1.98 (m, 1H), 1.94- 1.79 (m, 1H).
MS: m/z 272.4 (M+l).
Step 2: 3-(4-(4-fluorophenyl)piperazin-l-yl)cyclopent-1-enecarbaldehyde (Compound 22b)
To a stirred solution of 3-(4-(4-fluorophenyl)piperazin-l-yl)cyclopent-lenecarbonitrile (Compound 22a, 50g, 184 mmol) in dichloromethane (100 ml) was added di-isobutyl aluminium hydride (221.0 ml, 221.0 mmol, IM solution in toluene) at -78 C over a period of 30 mm. The reaction mixture was warmed to 25-30 °C and stirred for 18-20 hr. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethylacetate (250 ml) and quenched with saturated aqueous solution of ammonium chloride (100 ml). The reaction mass was filtered through a Celite bed, and the Celite bed was washed with ethyl acetate (100 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product which was purified by column chromatography over silica gel (100 - 200 mesh) using
100
45-50% ethyl acetate in hexane as eluent to obtain the title compound (12 g, 23% yield).
iH NMR (400 MHz, CDCI3) Ô 9.87 (s, 1H), 6.98 (t, J= 8.7 Hz, 2H), 6.94 - 6.86 (m, 3H), 4.10-3.99 (m, 1H), 3.17 (t, J= 4.9 Hz, 4H), 3.03-2.87 (m, 1H), 2.83-2.66 (m, 4H), 2.56-2.44 (m, 1H), 2.26-2.14 (m, 1H), 2.07- 1.97 (m, 1H).
MS: m/z 274.4(M+1).
Step 3: 1 -(3-ethynylcyclopent-2-en-1 -yl)-4-(4-fluorophenyl)piperazine (Compound 22c)
Γ N
N... J
To a stirred solution of trimethylsilyldiazomethane (32.8 ml, 65.6 mmol, 2M solution in hexane) in anhydrous tetrahydrofuran (100 ml) was added n-butyl lithium (41.0 ml, 65.6 mmol) at -78 °C. The reaction mixture was stirred for 30 min at the same température. To this reaction mixture a solution of 3-(4-(4fluorophenyl)piperazin-l-yl)cyclopent-l-enecarbaldehyde (Compound 22b, 12 g, 43.7 mmol) in tetrahydrofuran (20 ml) was added at same température and warmed to room température and stirred for 18-20 hr. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (150 ml) and washed with water (2 x 100 ml). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give crude product, which was purified by flash column chromatography over silica gel (100 - 200 mesh) using 45-50 % of ethyl acetate in hexane as eluent to obtain the title compound (6.0 g, 50 % yield).
>H NMR (400 MHz, CDCI3) ô 7.01 - 6.95 (m, 2H), 6.89 (dd, J = 9.2, 4.6 Hz, 2H),
6.21 (q, J= 2.2 Hz, 1H), 3.97 (s, 1H), 3.17 (s, 4H), 3.08 (s, 1H), 2.74 (s, 4H), 2.64 -2.43 (m, 2H), 2.16- 1.91 (m, 2H).
101
MS: m/z271 (M+l).
A chiral séparation of racemic l-(3-ethynylcyclopent-2-en-l-yl)-4-(4fluorophenyljpiperazine (Compound 22c-racemic, 30 g) was carried out using a chiral column to obtain (R)-1 -(3-ethynylcyclopent-2-en-1 -yl)-4-(4-fluorophenyl)piperazine (Compound
22c’; 12 g)
*H NMR (400 MHz, CDC13) δ 7.01 - 6.95 (m, 2H), 6.89 (dd, J - 9.2, 4.6 Hz, 2H),
6.21 (q, J= 2.2 Hz, 1H), 3.97 (s, 1H), 3.17 (s, 4H), 3.08 (s, 1H), 2.74 (s, 4H), 2.64 10 -2.43 (m, 2H), 2.16-1.91 (m, 2H).
MS: m/z 271 (M+l).
and (S)-1 ~(3-ethynylcyclopent-2-en-1 -yl)-4-(4-fluorophenyl)piperazine 22c”; 11.5 g) (compound
NMR (400 MHz, CDCI3) ô 7.01 - 6.95 (m, 2H), 6.89 (dd, J= 9.2, 4.6 Hz, 2H),
6.21 (q, J= 2.2 Hz, 1H), 3.97 (s, 1H), 3.17 (s, 4H), 3.08 (s, 1H), 2.74 (s, 4H), 2.64 -2.43 (m, 2H), 2.16 - 1.91 (m, 2H).
MS: m/z 271 (M+l).
102
Step 4: (R) -7-(3-(4-(4-fluorophenyl)piperazin-l-yl)cyclopent-1 -en-1 -yl)-1,6naphthyridin-5(6H)-one (Compound 22-hydrochloride sait)
Synthesis of (R)-7-(3-(4-(4-fluorophenyl)piperazin-1 -yljcyclopent- 1-en-1 5 yl)-l,6-naphthyridin-5(6H)-one (Compound 22-hydrochloride sait) was carried out starting from (R)-l-(3-ethynylcyclopent-2-en-l-yl)-4-(4fluorophenyljpiperazine (Compound 22c’) following the procedure described for the synthesis of (RH-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 1-hydrochloride sait) in Example 10 1.
*H NMR (400 MHz, DMSO-cZ6) Ô 11,89 (brs-exchangeable with D2O, 1H), 11,52 (brs-exchangeable with D2O, 1H), 9.04 (s, 1.6 Hz, 1H), 8.73 (d, J = 8.0 Hz, 1H), 7.70(dd, J = 8.0, 5.0 Hz, 1H), 7.14-7.10 (m, 2H), 7.07-7.03 (m, 2H), 6.96 (s, 1H), 6.88 (s, 1H), 4.69 (s, 1H), 3.84-3.75 (m, 2H), 3.62-3.54 (m, 2H), 3.30 - 3.11 (m, 15 4H), 2.94-2.86 (m, 2H), 2.44-2.38 (m, 2H).
MS: m/z 391.2 (M+l).
The following compound was prepared using the procedure described above in Example 5 with appropriate changes to the reactants and reaction conditions.
(R)-6-(3-(4-(4-fluorophenyl)piperazin- l-yl)cyclopent-1 -en-1 -yl)thieno[3,2c]pyridin-4(5H)-one (Compound 47-hydrochloride sait)
103
Ή NMR (400 MHz, DMSO-de) Ô 11.40 (brs-exchangeable with D2O, 1H), 11.15 (brs-exchangeable with D2O, 1H), 7.69 (d, J = 5.0 Hz, 1H), 7.51 (d, J= 5.0 Hz, 1H), 7.14-7.06 (m, 3H), 7.05-7.03 (m, 2H), 4.63 (s, 1H), 3.78 (d, J= 10.8 Hz, 2H), 5 3.56 (t, J= 11.9 Hz, 2H), 3.25 - 3.06 (m, 4H), 2.92 - 2.75 (m, 2H), 2.37 (d, 7.4
Hz, 2H).
MS: m/z 396 (M+l).
Example 6: Synthesis of (R)-4-(4-(3-(2-methyl-5-oxo-5,6-dihydro-l,6naphthy ridin -7-y 1) cyclopent-2-en-l -yl) p ip erazin-1 -y IJbenzonitrile 10 (Compound 6)
Step 1: Synthesis of l-((trimethylsilyl)ethynyl)cyclopent-2-enol (Compound 6a)
15 To a stirred solution of Trimethylsilylacetylene (160 ml, 1,139 mol) in tetrahydrofuran (680 ml) was added n-Butyl Lithium (1.6 M in hexane,712 ml, 1.139 mol) at -78°C over a period of 30 minutes under N2 atmosphère and the resulting mixture was allowed to stir over a period of 60 minute at same température. Cyclopent-2-enone (85 g, 1035 mmol) was added over a period of 30 min at the same température. The reaction mixture was stirred for 2 hrs at same température. The progress of the reaction was monitored by TLC. The reaction mixture was warmed to - -40°C and 20% ammonium chloride solution added slowly (635 ml). The organic layer was separated, aqueous layer extracted with Methyl tert-butyl ether (MTBE) (500 ml). The combined organic layer was washed
104 with water (3 x 500 ml) followed by brine solution (500 ml). The organic layer was separated, dried over sodium sulfate and concentrated under reduced pressure to get oily compound which was purified by high vacuum distillation (Oil bath temp- 115-130°C) to get 101.00 gm (54.1%) of title compound as liquid.
·Η NMR (400 MHz, CDCh) Ô 6.01 (dt, J = 5.0, 2.2 Hz, 1H), 5.82 (dt, J = 4.9, 2.1 Hz, 1H), 2.62 - 2.50 (m, 1H), 2.50 - 2.37 (m, 2H), 2.24 - 2.12 (m, 2H), 0.18 (s, 9H).
Step 2: Synthesis of 3-((trimethylsilyl)ethynyl)cyclopent-2-enol (Compound 6b) r
HO
To a stirred solution of l-((trimethylsilyl)ethynyl)cyclopent-2-enol (Compound 6a, 100 g, 555 mmol) in MTBE ( 800 ml) was added 3% H2SO4 (800 15 ml) at 10 °C and the resulting biphasic reaction mixture was allowed to stir at ambient température for 16 hrs. The progress of reaction was monitored by TLC. The organic layer was separated and aqueous layer was extracted with MTBE (400 ml). The combined organic layer was washed with water (3x 400 ml; pH~ 7) and brme solution (400 ml). The organic layer dried over anhydrous Na2SO4, 20 filtered and concentrated to yield 100.00 gm (99.5%) of title compound as liquid.
>H NMR (400 MHz, CDCI3) δ 6.11 (q, J= 2.1 Hz, 1H), 4.94 - 4.85 (m, 1H), 2.71 2.55 (m, 1H), 2.47 - 2.25 (m, 2H), 1.84 - 1.69 (m, 2H), 0.21 (s, 9H).
Step 3: Synthesis (R)-3-((trimethylsilyl)ethynyl)cyclopent-2-en-l-yl acetate (Compound 6c)
105
To the stirred solution of 3-((trimethylsilyl)ethynyl)cycIopent-2-enol (Compound 6b, 50 g, 277 mmol) in MTBE (650 ml) were added vinyl acetate (51 5 ml) and Lipase PS’Amano”SD (10 g, 20% w/w). The above suspension was stirred at 45°C (internai température) for 18 hrs. The reaction was monitored by TLC, which showed 25-30% conversion. Vinyl acetate (15 ml, 166.2 mmol) was added and stirred at same température for 6 hrs. Additional Vinyl acetate (15 ml, 166.2 mmol) and 3.0 gm of Lipase PS Amano SD enzyme (6% w/w) were added and 10 stirred at same température for 18 hrs and reaction monitored by TLC, which showed approximately 50% conversion. The suspension was filtered through Celite bed and bed was washed with MTBE (300 mL). A crude product was purified by silica (100-200) column chromatography using 5-6% ethyl acetate in n-hexane to yield (23.00 gm, 37.3%) title compound.
Ή NMR (400 MHz, CDC13) δ 6.10 (q, J = 2.2 Hz, 1H), 5.76 - 5.67 (m, 1H), 2.74 2.60 (m, 1H), 2.52 - 2.27 (m, 2H), 2.04 (s, 3H), 1.95 - 1.82 (m, 1H), 0.22 (s, 9H).
Step 4: (R)-tert-butyl 4-(3-((trimethylsilyl)ethynyl)cyclopent-2-en-l-yl)piperazine1-carboxylate (Compound 6d)
To a stirred deoxygenated solution (R)-3-((trimethylsüyl)ethynyl)cyclopent2-en-l-yl acetate (Compound 6c, 23 g, 103 mmol) and tert-butyl piperazine-1carboxylatc (19.27 g, 103 mmol) in 1,4-dioxane: water (370 ml: 95ml) at 0-5°C, 25 Tetrakis(triphenyl phosphine) Pd(O) (0.896 g, 0.776 mmol) was added. The reaction mixture was stirred at 0-5°C for 18 hrs. The progress ofthe reaction was monitored by TLC. The reaction mass was filtered to remove the heterogeneous
106 mass. The filtrate was diluted with n-hexane (120 ml) and quenched with water (120 ml). The organic layer was separated, and the aqueous layer was further extracted with n-hexane (120 ml). The combined organic layer was washed with water (120 ml), brîne (100 ml), dried over anhydrous Na2SO4, and evaporated under reduced pressure to afford the crude product. The obtained crude product was further dissolved in n-heptane (230 ml) and activated carbon (4 gm) was added and stirred at 25-30’C for additional 1 hr. It was filtered through Celite bed and the filtrate was evaporated to dryness under reduced pressure to yield (35.00 gm, 97.00%) title compound.
·Η NMR (400 MHz, 0X713)6 6.11 (q, J-2.2 Hz, 1H), 4.06 - 3.88 (m, 1H),3.6O3.42 (m, 4H), 2.71 - 2.50 (m, 4H), 2.18 - 1.86 (m, 2H), 1.47 (s, 9H), 1.37 - 1.19 (m, 2H), 0.22 (s, 9H).
MS: m/z- 349.11 (M+l).
Step 5: (R)-tert-butyl 4-(3-ethynylcyclopent-2-en-l-yl)piperazine-l-carboxyIate (Compound 23d)
TBAF (7.53 ml, 7.53 mmol) was added slowly to a deoxygenated solution of 20 (R)-tert-butyl 4-(3-((trimethylsüyl)ethynyl)cyclopent-2-en-l-yl)piperazine-1carboxylate (Compound 6d, 5 g, 100 mmol) in tetrahydrofuran (350 ml) at 2530 C over a period of 15 min. The reaction mixture was allowed to stir at the same température for 15-20 min. Water (200 ml) was added to the reaction mixture and the product was extracted with n-hexane (200 ml). The organic layer 25 was separated, and the aqueous layer was further extracted with n-hexane (200 ml). The combined organic layer was washed with water (100 ml) and then with bnne (100 ml). The separated organic layer was dried over anhydrous Na2SO4, and evaporated under reduced pressure to afford the crude product. The obtained crude product was further dissolved in n-heptane (350 ml) and treated with activated carbon (4 g) for 30 min. It was filtered through Celite bed and the fïltrate was evaporated to dryness under reduced pressure to yield crude (23.00 gm with 81%ee).
Process for enhancement of enantiomeric excess (ee) through crystallization
The crude was dissolved in n-heptane (70 ml) at 60-700C and then slowly cooled to 0°C over a period of 30 min. The solution was stirred at 0°C for 3h to observe sélective crystallization of major enantiomer. The solid was separated, filtered and washed with cold (-30 to -40°C) n-heptane (20 ml). The filtered solid was dried at atmospheric pressure to yield title compound (13.50 gm, 48.6%).
Ή NMR (400 MHz, CDC13) δ 6.15 (q, J = 2.2 Hz, 1H), 3.94 - 3.85 (m, 1H), 3.50 3.42 (m, 4H), 3.06 (s, 1H), 2.59 - 2.39 (m, 6H), 2.10 - 1.96 (m, 1H), 1.95-1.81 (m, 1H), 1.47 (s, 9H).
MS: m/z - 277.58 (M+l).
Step 6: (R)-l-(3-ethynylcyclopent-2-en-l-yl)piperazine dihydrochloride (Compound 23e)
N NH.2HCI
To a solution of (R)-tert-butyl 4-(3-ethynylcyclopent-2-en-l-yl)piperazine1-carboxylate (Compound 23d, 57 g, 206 mmol) in dichloromethane (300 ml) was added, hydrochloric acid in 1,4 dioxane ( 516 ml, 2062 mmol, 4M solution in 1,4 dioxane ) at 0-5 °C. The reaction mixture was warmed to room température and stirred for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was evaporated under reduced pressure to obtain solid product which
108 was co-evaporated with diethylether (150 ml), followed by toluene (150 ml) to obtain the title product (51.0 gm, 99.0 %) as a white solid.
JH NMR (400 MHz, DMSO-d6) δ 12.18 (brs-exchangeable with D2O, 1H), 9.70 (brs-exchangeable with D2O, 1H), 6.23 (s, 1H), 4.57 - 4.50 (m, 1H), 4.47 (s, 1H), 3.51-3.21 (m, 7H), 2.73 - 2.59 (m, 1H), 2.50 - 2.40 (m, 2H), 2.36-2.11 (m, 2H).
Step 7: (R) -4-(4-(3-ethynylcyclopent-2-en-1 -yljpîperazin-1 -yl)benzonitrile (Compound lj)
To a solution of (R)-l-(3-ethynylcyclopent-2-en-l-yI)piperazine dihydrochloride (Compound 23e, 47 g, 189 mmol) in dimethylsulfoxide (200 ml) was added potassium carbonate (117 g, 849 mmol) followed by the addition of 4fluoro benzonitrile (29.7 g, 245 mmol) at 25-30 °C. The reaction mixture was warmed and stirred at 120 °C for 18 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into water (1000 ml) and extracted with ethyl acetate (2 x 400 ml), combined organic layer was washed with water (300 ml) and brine solution (300 ml). The organic layer was dried over sodium sulphate and evaporated under reduced pressure to obtain a crude oily product which was purified by column chromatography over silica gel (100-200 mesh) using 35-40% ethyl acetate in hexane as an eluent to obtain the title product (41.0 gm, 78.0 %yield).
‘H NMR (400 MHz, CDCI3) δ 7.51 (d, J = 8.8 Hz, 2H), 6.87 (d, J= 8.8 Hz, 2H), 6.18 (d, J= 2.2 Hz, 1H), 3.98 - 3.89 (m, 1H), 3.40 - 3.27 (m, 4H), 3.08 (s, 1H), 2.73 - 2.61 (m, 4H), 2.59 - 2.46 (m, 2H), 2.14 - 2.00 (m, 1H), 1.99 - 1.85 (m, 1H).’
MS: m/z 277.98 (M+l).
Step 8: (R)-methyl 2-((3-(4-(4-cyanophenyl)piperazin-l-yl)cyclopent-l-en-lyl)ethynyl)-6-methylnicotinate (Compound 6e)
109
Ο
Το a stirred solution of methyl 2-bromo-6-methylnicotinate (US2010144760, 2.79 g, 12.11 mmol) in acetonitrile (50 ml) (degassed by N2 purge separately) was added bis(triphenylphosphine)palladium(II) chloride (1.063 g, 1.514 mmol). The reaction mixture was heated up to 70 °C and diisopropyl ethyl amine (7.83 g, 60.6 mmol) was added slowly, followed by a solution of (R)-4(4-(3-ethynylcyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound Ij, 2.8 g, 10.10 mmol) in acetonitrile (20 ml) was added slowly at the same température. The reaction mixture was heated and stirred at 80-85 °C for 14 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was distilled under vaccum to dryness to obtain a crude product which was purified by column chromatography over silica gel (100-200 mesh) using 60-80% ethyl acetate in hexane as an eluent to obtain the title product (0.9 gm, 20.90 % yield).
‘H NMR (400 MHz, CDC13) δ 8.17 (d, J = 8.1 Hz, 1H), 7.52 (d, J= 8.5 Hz, 2H), 7.20 (d, J =8.2 Hz, 1H), 6.90-6.87 (m, 2H), 6.36 (d, J = 2.3 Hz, 1H), 4.08-4.03 (m, 1H), 3.96 (s, 3H), 3.40 - 3.35 (m, 4H), 2.75 - 2.67 (m, 6H), 2.64 (s, 3H), 2.13 - 2.09 (m, 1H), 2.03 - 1.95 (m, 1H).
MS: m/z 427.24 (M+l).
Step 9: (R)-2-((3-(4-(4-cyanophenyl)piperazin-1 -yljcyclopent-1 -en-1 -yl)ethynyl)-6methylnicotinic acid (Compound 6f)
110
To a stirred solution of (R)-methyl 2-((3-(4-(4-cyanophenyl)piperazin-lyl)cyclopent-l-en-l-yl)ethynyl)-6-methylnicotinate (Compound 6e, 0.9 g, 2.110 mmol) m methanol (10 ml) and tetrahydrofuran (10 ml) was added sodium hydroxide (0.253 g, 6.33 mmol) dissolved in water ( 3 ml) at room température 5 and reaction was stirred at same température for 2 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was distilled under vaccum till dryness to obtain a crude product. To this crude product was added water (5 ml) and pH was adjusted to 5 using 10% aqueous hydrochloric acid. The solid precipitated out was filtered off and dried to obtain the title product (0.87 gm, 10 100%yield).
*H NMR (400 MHz, DMSO-de) Ô 11.87 (brs-exchangeable with D2O, 1H), 8.15 (d, J= 8.2 Hz, 1H), 7.67 (d, J= 8.6 Hz, 2H), 7.41 (d, J= 7.9 Hz, 1H), 7.12 (d, J = 8.7 Hz, 2H), 6.46 (s, 1H), 4.63 - 4.58 (m, 1H), 3.59 - 3.34 (m, 4H), 3.23 - 3.15 (m, 1H), 3.13 - 3.02 (m, 1H), 2.84 - 2.61 (m, 4H), 2.56 (s, 3H), 2.40 - 2.33 (m, 2H).
MS: m/z 413.13 (M+l).
Step 10: (R)-4-(4-(3-(2-methyl-5-oxo-5H-pyrano[4,3-b]pyridin-7-yl)cyclopent-2en-I-yl)piperazin-l-yl)benzonitrile (Compound 6g)
To a stirred solution of (R)-2-((3-(4-(4-cyanophenyl)piperazin-l20 yl)cyclopent-l-en-l-yl)ethynyl)-6-methyInicotinic acid (Compound 6f, 0.87 g, 2.109 mmol) in tetrahydrofuran (10 ml) and dichloromethane (10 ml) was added triflic acid (1.266 g, 8.44 mmol) at room température and reaction was stirred at same température for 48 hr. The progress of the reaction was monitored by TLC. Diethyl ether {20 ml) was added slowly to the reaction mixture and the solid that 25 precipitated out was filtered off and dried under vaccum to obtain the title product (0.8 gm, 92 %yield).
111
Ή NMR (400 MHz, DMSO-*) 6 8.40 (d, J- 8.1 Hz, 1H), 7.67 (d, J-8.6 Hz, 2H) 7.53 (d, J-8.2 Hz, 1H), 7.12 (d, J- 8.7 Hz, 2H|, 6.98 (s, 1H), 6.69 (s, 1H), 4.704.66 (m, 1H), 4.14 - 4.06 (m, 2H), 3.66 - 3.58 (m, 1H), 3.52 - 3.45 (m, IH),’ 3.43 3.32 (m, 2H), 3.31 -3.20 (m, 1H), 3.15-3.07 (m, 1H), 2.98-2.89 (m, 1H), 2.802.72 (m, 1H), 2.65 (s, 3H), 2.44 - 2.37 (m, 2H).
MS: m/z 413.0 (M+l).
Step 11: ^RF4(4‘(3-(2‘inethyl-5-oxo-5,6-dihydro-l,6-naphthyridÎn-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 6)
To a solution of (R)-4-(4-(3.(2-methyl-5-oxo-5H-pyrano(4,3-b]pyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 6g, 0.8 g, 1.939 mmol) in anhydrous tetrahydrofuran (5 ml) was added ammonia in methanol (13.65 ml, 97 mmol, 7M soluüon in methanol) at 25 C. The reaction mixture in Steel bomb reactor was stirred at 80-85 «C for 4 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température and the solid precipitated out was filtered and dried to obtain the title product (0.65 gm, 81 % yield).
H NMR (400 MHz, DMSO-d6) 6 11.38 (brs-exchangeable with D2O, 1H), 8.35 (d,
8.2 Hz, 1H), 7.59 (d, J = 8.6 Hz, 2H), 7.35 (d, 8.4 Hz, 1H), 7.04 (d, J = 8.6
Hz, 2H), 6.95 (s, 1H), 6.54 (s, 1H), 3.93 - 3.88 (m, 1H), 3.21 -3.34 (m, 4H), 2.76 2.56 (m, 9H), 2.11-2.06 (m, 1H), 1.92- 1.87 (m, 1H).
MS: m/z 412.2 (M+l).
112
Step 12: (R)-4-(4-(3-(2-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en- l-yl)piperazin- l-yl)benzonitrile (Compound 6-hydrochloride sait)
To a suspension of (R)-4-(4-(3-(2-methyl-5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 6, 0.05 g, 0.122 mmol) in dichloromethane (5 ml) and éthanol (5 ml), was added hydrochloric acid ( 0.027g, 0.729 mmol, 3M in 1,4-dioxane) at 55-60 “C. The reaction mixture was stirred for 30 min at the same température. The reaction mixture was then cooled to room température, diluted with diethyl ether (10 ml), and product was collected by filtration. The solid compound was washed with diethyl ether (5 ml) and dried under vacuum to obtain the title compound (0.049 g, 90 % yield).
Ή NMR (400 MHz, DMSO-de) δ 11.86 (brs-exchangeable with D2O, 1H), 11.59 (brs-exchangeable with D2O, 1H), 8.64 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.60 (d, J= 8.4 Hz, 1H), 7.15 (d, J= 8.4 Hz, 2H), 6.94 (s, 1H), 6.88 (s, 1H), 4.69 (s, 1H), 4.17-4.13 (m, 2H), 3.64 - 3.54 (m, 2H), 3.42 - 3.30 (m, 2H), 3.23 3.07 (m, 2H), 2.95 - 2.79 (m, 2H), 2.74 (s, 3H), 2.46 - 2.36 (m, 2H).
MS: m/z 412.2 (M+l).
The following compounds were prepared using the procedure described above in Example 6 with appropriate changes to the reactants and reaction conditions.
(R)-7-(3-(4-(4-(methylamino)phenyl)piperazin-1 -yl)cyclopent-1 -en-1 -yl)-1,6 naphthyridin-5(6H)-one (Compound 27-hydrochloride sait)
NH ___ ^\-NHCH
Ή NMR (400 MHz, DMSO-d6) ô 11.65 (brs-exchangeable with D2O, 1H), 10.94 (brs-exchangeable with D2O, 1H), 8.98 (dd, J= 4.7, 1.7 Hz, 1H), 8.56 (d, J= 8.1 Hz, 1HJ.7.58 (dd, J= 8.1, 4.7 Hz, 2H), 7.43 (d, J= 8.5 Hz, 2H), 7.16(d, J= 8.5 Hz, 2H), 6.88 (s, 1H), 6.80 (s, 1H), 4.72-4.70 ( m.lH), 3.97-3.94 (m, 2H), 3.64-3.58 (m,2H), 3.20.3.13 (m,4H), 2.92-2.88 (m, 5H), 1.32 - 1.22 (m, 2H).
MS: m/z 401.5 (M+l).
(R)-7-(3-(4-(4-acetylphenyl)piperazin-1 -yl)cyclopent-1 -en-1 -yl)-1,6-naphthyridin5(6H)-one (Compound 28-hydrochloride sait)
NH
N
N /N ’H NMR (400 MHz, DMSO-d6) 6 11.68 (brs-exchangeable with D2O, 1H), 11.31 (brs-exchangeable with D2O, 1H), 8.98 (dd, J = 4.7, 1.8 Hz, 1H), 8.59 (dd, j= 8.1, 1.8 Ηζ,ΙΗ), 7.87 (d, J= 9.0 Hz, 2H),z 7.60 (dd, J= 8.1, 4.7 Hz, 1H),7.1O (d, J = 9.0 Hz, 2H), 6.89 (s, 1H), 6.81 (s, 1H), 4.69 (s,lH), 4.16-4.13 (m, 2H), 3.66-3.55 (m, 2H), 3.40-3.27 (m,2H), 3.27-3.08 (m, 2H), 2.94-2.89 (m, 2H), 2.49 (s, 3H),2.46 - 2.29 (m, 2H).
MS: m/z 415.2 (M+l).
114 (R)-6-(3-(4-(thiazol-2-yl)piperazm-1 -yl)cyclopent- 1-en-1 -yl)thieno[3,2-c]pyridin4(5H)-one (Compound 51-hydrochloride sait)
‘H NMR (400 MHz, DMSO-cfô) 6 11.74 (brs-exchangeable with D2O, 1H), 11.38 (brs-exchangeable with D2O, 1H), 7.69 (d, J= 5.3 Hz, 1H), 7.51 (d, J= 5.3 Hz, 1H), 7.33 (d, J = 3.8 Hz, 1H), 7.10 (s, 1H), 7.06 (d, J= 3.8 Hz, 1H), 6.74 (s, 1H), 10 4.64 (s, 1H), 4.17-4.13 (m, 2H), 3.77-3.51 (m, 4H), 3.30-3.14 (m, 2H), 2.93-2.76 (m, 2H), 2.40-2.36 (m, 2H).
MS: m/z 385.2 (M+l).
(R)-3-fluoro-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[5,4-c]pyridin-6-yl)cyclopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 52-hydrochloride sait)
Ή NMR (400 MHz, DMSO-de) Ô 11.85 (brs-exchangeable with D2O, 1H), 11.48 (brs-exchangeable with D2O, 1H), 9.61 (s, 1H), 7.81 (dd, J = 13.1, 1.9 Hz, 1H), 7.65 (dd, J= 8.5, 1.9 Hz, 1H), 7.27 (t, J= 8.7 Hz, 1H), 7.11 (s, 1H), 6.81 (d, J = 2.5 Hz, 1H), 4.67 (s, 1H), 3.81 - 3.70 (m, 2H), 3.66 - 3.52 (m, 2H), 3.47 - 3.34 (m, 2H), 3.33 - 3.14 (m, 2H), 2.95 - 2.85 (m, 2H), 2.43 - 2.30 (m, 2H).
MS: m/z 422.1 (M+l).
115
Example 7: Synthesis of 4-((R)-3-methyl-4-((R/S)-3-(5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 14)
Step 1: 3-brornocyclopent-l-enecarbonitrile (Compound 14a)
NC
To a stirred solution of cyclopent-l-enecarbonitrile (50 g, 537 mmol) in tetrachloromethane (400 ml) at 25 ’C was added N-bromosuccinimide (96 g, 537 mmol) under nitrogen atmosphère. The resulting mixture was refluxed for 2 hrs.
The progress of reaction was monitored by TLC. The reaction mixture cooled to 25°C and fîltered through Celite. The nitrate was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography over silica gel (100 - 200 mesh) using 1% ethyl acetate in hexane as an eluent to obtain the title compound (60.0 g, 65 %).
iHNMR (400MHz, CDCb): δ 6.77-6.73 (m, 1H), 5.12-5.09 (m, 1H) 2.95-2.86 (m, 1H) 2.67-2.42 (m, 3H).
Step 2: tert-butyi (3R)-4-(3-cyanocyclopent-2-en-l-yl)-3-methylpiperazine-lcarboxylate (Compound 14b)
116
To a stirred solution of tert-butyl (R)-3-methylpiperazine-l-carboxylate (9.0 g, 44.9 mmol) in acetonitrile (100 ml) was added potassium carbonate (18.63 g, 135 mmol) at 25 °C and stirred the reaction mixture for 10 minutes. To the reaction mixture was added, a solution of 3-bromoçyclopent-1 -enecarbonitrile 5 (Compound 14a, 7.73 g, 44.9 mmol) in acetonitrile (25 ml) and the reaction mixture was stirred for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The residue obtained was diluted with water (100 ml) and extracted with ethyl acetate (2 x 200 ml ). The combined organic layer was dried over anhydrous sodium sulphate 10 and evaporated under reduced pressure to obtain crude product. The crude product purified by flash column chromatography over silica gel (100-200 mesh) using 20 % ethyl acetate in hexane as an eluent to obtain the title compound (8.2 g, 62.6 % yield).
The diastereomers of tert-butyl (3R)-4-(3-cyanocyclopent-2-en-l-yl)-315 methylpiperazine-l-carboxylate was separated by flash column chromatography over silica gel (100-200 mesh) using 10-20% ethyl acetate in hexane as an eluent to obtain two diastereomers separately.
tert-butyl (R)-4-((R/S)-3-cyanocyclopent-2-en-1 -yl)-3-methyIpiperazine-1 carboxylate (Compound 14b*)
NC
Ή NMR |400 MHz, CDCb) δ 6.58 (s, 1H), 4.52 (s, 1H). 4.00 - 3.74 (m, 2H), 3.08 2.90 (m, 1H), 2.64 (s, 3H), 2.57 - 2.40 (m, 1H), 2.36 - 2.18 (m, 1H), 2.02 - 1.81 (m, 2H), 1.63 (s, 1H), 1.48 (s, 9H), 1.19-1.03 (m, 3H).
MS: m/z 292.1 (M+l).
and
117 tert-butyl (R)-4-((S/R)-3-cyanocycIopent-2-en-l-yl)-3-methylpiperazine-lcarboxylate (Compound 14b”)
NC
NBoc ‘H NMR (400 MHz, CDCfr) ô 6.69 (d, J= 2.4 Hz, 1H), 4.32 (s, 1H), 3.71 (s, 2H) 3.18 (s, 1H), 2.68 (s, 3H), 2.57 (dt, J= 16.3, 7.0 Hz, 1H), 2.24 (s, 2H), 1.92 (s 1H), 1.63 (s, 1H), 1.48 (s, 9H), 1.13 (d, J= 6.2 Hz, 3H).
MS: m/z 292.21 (M+l).
Both these diastereomers were processed further individually to obtain the respective title products.
Step 3: tert-butyl (R)-4-((R/S)-3-formylcyclopent-2-en-l-yl)-3-methylpiperazine1-carboxylate (Compound 14c)
A stirred solution of tert-butyl (R)-4-((R/S)-3-cyanocyclopent-2-en-l-yl)-3methylpiperazine-l-carboxylate (Compound 14b’, 4.0 g, 13.73 mmol) in dichloromethane (50 ml) was cooled at -78 °C. Diisobutylaluminium hydride (20.59 ml, 20.59 mmol, IM solution in toluene) was added slowly over 10-15 minutes. The reaction mixture was stirred for 15 min at -78 °C and warmed to room température and stirred for 1 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched by drop wise addition of saturated ammonium chloride solution (20 ml) at 0 °C (carefully: The reaction quenching is exothermic). A gel type reaction mass was observed, Celite (100 g) was added to the reaction mixture and the reaction mixture was diluted with 10 % methanol in
118 dichloromethane (0.3 lit) and stirred for 20 min. The reaction mass was filtered through Celite bed and the bed was washed with 1 Ht. of 10 % methanol in dichloromethane. The combined organic filtrate was dried over sodium sulphate and concentrated under vacuum till diyness to afford the crude product which 5 was purified by column chromatography over süica gel (100-200 mesh) using ethyl acetate in hexane as an eluent to obtain the title product as an yellow solid. (3.05 gm, 75.0 % yield).
’H NMR (400 MHz, CDC13) ô 9.85 (s, 1H), 6.78 (s, 1H), 4.56 (s, 1H), 4.00 - 3.73 (m, 2H), 3.02 (t, J= 11.8 Hz, 1H), 2.79 -2.44 (m, 5H), 2.33 (t, J= 11.2 Hz, 1H), 10 2.03 - 1.84 (m, 2H), 1.47 (s, 9H), 1.16 (d,J= 6.2 Hz, 3H).
MS: m/z 295.1 (M+l).
SUp 4: tert-butyl (R)-4-|(R/S)-3-ethynylcyclopent-2-en-l-yl)-3-methyl piperazine1-carboxylate (Compound 14d)
To a solution of trimethylsilyldiazomethane (8.66 ml, 17.32 mmol) in tetrahydrofuran (100 ml) at -78°C was slowly added, n-butyl Hthium (9.55 ml, 15.29 mmol) solution in hexane (1.6 M). The reaction mixture was stirred for 30 minute at same température. A solution of tert-butyl (R)-4-((R/S)-3formylcyclopent-2-en-1 -yl)-3-methylpiperazine- 1-carboxylate (Compound 14c, 20 3.0 g, 10.19 mmol) in tetrahydrofuran (50 ml) was slowly added to the reaction mixture at -78 °C . The reaction mixture was stirred for 30 minute and then warmed to room température and further stirred for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (100 ml) and then washed with water (50 ml). The organic layer was 25 separated and the aqueous layer was again extracted with ethyl acetate (2 x 100 ml ). The combined organic layer was dried over sodium sulphate and evaporated
119 under reduced pressure to obtain crude oily product which was purified by column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane as an eluent to obtain the title product (1.55 gm, 49.7 % yield).
*H NMR (400 MHz, CDC13) 6 6.07 (s, 1H), 4.47 (s, 1H), 4.02 - 3.64 (m, 2H), 3.10 2.93 (m, 2H), 2.82 - 2.60 (m, 2H), 2.57 - 2.40 (m, 3H), 2.22 (d, J= 13.8 Hz, 1H), 1.96 - 1.76 (m, 2H), 1.48 (s, 9H), 1.20 - 1.06 (m, 3H).
MS: m/z 291.0 (M+l).
Step 5: (R)-H(R/S)-3-ethynylcyclopent-2-en-l-yl)-2-methylpiperazine dihydrochloride (Compound 14e)
NH.2HCI
H3C
To a solution of tert-butyl (R)-4-((R/S)-3-ethynylcyclopent-2-en-l-yl)-3methyl pîperazine-l-carboxylate (Compound 14d, 1.5 g, 5.17 mmol) in dichloromethane (10 ml) was added, hydrochloric acid in 1,4 dioxane (12.91 ml, 51.7 mmol, 4M solution in 1,4 dioxane ) at 0-5 ’C. The reaction mixture was warmed to room température and stirred for 2 h. The progress of reaction was monitored by TLC. The reaction mixture was evaporated under reduced pressure to obtain a solid product which was co-evaporated with diethyl ether (50 ml), followed by toluene (50 ml) to obtain the title product (1.35 gm, 99 %) as a white solid.
‘H NMR (400 MHz, OMSO-cfe) δ 6,05 (s, 1H), 4.91 (s, 1H), 4.37 (d, J= 2.5 Hz 1H), 3.62 - 3.44 (m, 3H), 3.44 -3.11 (m, 4H), 2.95 - 2.54 (m, 2H), 2.36 -2.16 (m, 1H), 2.10 - 1.93 (m, 1H), 1.40 (d, J= 6.4 Hz, 3H).
MS: m/z 191.2 (M+l).
120
Step 6: 4-((R)-4-((R/S)-3-ethynylcyclopent-2-en-l-yl)-3-methylpiperazin-lyljbenzonitrile (Compound 14f)
H3C
To a solution of (R)-l-((R/S)-3-ethynylcyclopent-2-en-l-yl)-2methylpiperazine dihydrochloride (Compound 14e, 1.3 g, 4.94 mmol) in dimethylsulfoxide (10 ml) was added, potassium carbonate (3.07 g, 22.23 mmol) followed by the addition of 4-fluoro benzonitrile (0.778 g, 6.42 mmol) at 25-30 °C The reaction mixture was warmed and stirred at 120 °C for 18 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into water (25 ml) and extracted with ethyl acetate (2 x 50 ml) and the organic layer was washed with water (25 ml) and brine solution (25 ml) simultaneously. The organic layer separated was dried over sodium sulphate and evaporated under vacuum to obtain crude oily product which was purified by column chromatography over silica gel (100-200 mesh) using 35-40% ethyl acetate in hexane as an eluent to obtain the title product (1.15 gm, 80.0 % yield).
Ή NMR (400 MHz, CDC13) δ 7.52 (d, J= 8.5 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 6.07 (s, 1H), 4.51 (s, 1H), 3.76 - 3.46 (m, 2H), 3.25 - 2.88 (m, 2H), 2.91 - 2.12 (m, 6H), 2.15- 1.68 (m, 2H), 1.30 - 1.02 (m, 3H).
MS: m/z 292.2 (M+l).
Step 7: 4-((R)-3-methyl-4-((R/S)-3-(5-oxo-5H-pyrano[4,3-b] pyridin-7-yl) cyclopent -2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 14g)
121
To a stirred solution of 2-bromonicotinic acid (0.763 g, 3.78 mmol) in acetonitrile (50 ml) (degassed by N2 purge) was added bis(triphenylphosphine)palladium(II) chloride (0.265 g, 0.378 mmol). The reaction mixture was heated upto 70 °C and diisopropylethyl amine (2.93 g, 22.65 mmol) 5 was added slowly, followed by a solution of 4-((R)-4-((R/S)-3-ethynylcyclopent-2en-l-yl)-3-methyIpiperazin-l-yl)benzonitrile (Compound 14f, 1.10 g, 3.78 mmol) m acetonitrile (10 ml) was added slowly at same température. The mixture was heated and stirred at 80-85 ‘C for 24 h. The progress of the réaction was monitored by TLC. The reaction mixture was distilled under vacuum to diyness 10 to obtain a crude product which was purified by column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane (100 % ethyl acetate) as an eluent to obtain the title product (0.55 gm, 35.3 % yield).
lH NMR (400 MHz, CDCh) ô 8.97 - 8.90 (m, 1H), 8.58 - 8.51 (m, 1H), δ 7.62 7.54 (m, 2H), 7.46 (dd, J= 11.5, 2.9 Hz, 1H), 6.87 (dd, J= 8.8, 3.5 Hz, 2H), 6.66 15 (d, J= 9.8 Hz, 1H), 4.61 (s, 1H), 3.76 - 3.57 (m, 2H), 3.04 (d, J= 17.1 Hz, 1H),
2.90 - 2.65 (m, 4H), 2.59 - 2.42 (m, 2H), 2.07 (s, 2H), 1.34 - 1.15 (m, 4H).
MS: m/z 413.3 (M+l).
Step 8: 4-({R)-3-methyl-4-((R/S)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 14)
To a solution of 4-((R)-3-methyI-4-((R/S)-3-(5-oxo-5H-pyrano(4,3-b] pyridin-7-yl)cyclopent -2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 14g, 0.5 g, 1.212 mmol) m anhydrous tetrahydrofuran (5 ml) was added ammonia in methanol (8.66 ml, 60.6 mmol, 7M solution in methanol) at 25 °C, reaction 25 mixture in Steel bomb was stirred at 80-85 °C for 24 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was distilled under
122 vacuum. A crude product was purified by chromatography using methanol in dichloromethane. The desîred compound was isolated at 3-4 % of methanol in dichloromethane to obtain the title compound (0.130 mg, 26.1 % yield).
*H NMR (400 MHz, DMSO-dô) ô 11.51 (brs-exchangeable with D2O, 1H), 8.90 (dd, 5 J-4.6, 1.8 Hz, 1H), 8.48 (dd, J= 8.0, 1.8 Hz, 1H), 7.57 (d, J= 8.6 Hz, 2H), 7.47 (dd, J = 8.0, 4.6 Hz, 1H), 7.02 (d, J= 8.7 Hz, 2H), 6.74 (s, 1H), 6.57 (s, 1H), 4.48 (s, 1H), 3.73 (d, J= 11.7 Hz, 2H), 2.94 - 2.89 (m, 1H), 2.80 - 2.54 (m, 5H), 2.40 2.30 (m, 1H), 1.98 - 1.84 (m, 2H), 1.16 (d, J= 5.9 Hz, 3H).
MS: m/z 412.2 (M+l).
Step 9: 4-((R)-3-methyl-4-((R/S)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-1 -yl)piperazin-1 -yljbenzonitrile (Compound 14-hydrochloride sait)
A clear solution of 4-((R)-3-methyl-4-((R/S)-3-(5-oxo-5,6-dihydro-l,6naphthyridin 7-yl) cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 14, 120 mg, 0.292 mmol) in dichloromethane (5 ml) and methanol (5 ml), was warmed and stirred at 55-60 °C, then hydrochloric acid in dioxane (0.583 ml, 1.750 mmol, 3M solution in dioxane) was added at same température in small portions over a period of 5 minute. The reaction mixture was stirred for 30 min at 20 55-60 °C. The reaction mixture was cooled to room température, diluted with diethyl ether (10 ml), and product was collected upon filtration. The solid compound was washed with diethyl ether (10 ml) and dried under reduced pressure for 3 h at 40 °C to obtain the title compound (0.115 g, 81 % yield).
H NMR (400 MHz, DMSO-cfc) ô 11.94 (brs-exchangeable with D2O, 1H), 11.87 25 (brs-exchangeable with D2O, 1H), 9.06 - 8.95 (m, 1H), 8.65 (d, J= 8.0 Hz, 1H),
123
7.74 - 7.56 (m, 3H), 7.14 (d, J = 8.6 Hz, 2H), 6.83 - 6.65 (m, 2H), 5.05 (s, 1H), 4.26 - 4.03 (m, 2H), 3.57 (s, 1H), 3.45 - 3.30 (m, 2H), 3.27 - 3.02 (m, 2H), 2.95 2.78 (m, 2H), 2.40 - 2.20 (m, 2H), 1.54 - 1.35 (m, 3H).
MS: m/z 412.1 (M+l).
The following compound was prepared using the procedure described above in Example 7 by using tert-butyl (R)-4-((S/R)-3-cyanocyclopent-2-en-l-yl)-
3- methylpiperazine-l-carboxylate (Compound I4b”)
4- ((R)-3-methyl-4-((S/R)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 15-hydrochloride sait)
!H NMR (400 MHz, DMSO-<i,) δ 11.88 (brs-exchangeable with D2O, 2H), 9.12 9.00 (m, 1H), 8.77 (t, J= 9.4 Hz, 1H), 7.73 (dd, J= 7.9, 5.3 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.14 (dd, J= 8.6, 5.4 Hz, 2H), 6.91 (s, 1H), 6.85 (s, 1H), 5.06 (s, 1H), 4.20 (d, J= 13.3 Hz, 1H), 4.16 - 3.97 (m, 2H), 3.55 - 3.06 (m, 5H), 3.03 - 2.75 15 (m, 3H), 2.49-2.37 (m, 2H), 1.57 (d, J = 6.3 Hz, 2H).
MS: m/z 412.1 (M+l).
Example 8; Synthesis of 4-(llS,4S)-5-((R/S).3-(S-oxo.S,6-dihydro.l,6-naphthy ndin-7-yl)cyclopent-2-en-l-yl)-2,S-diazabicyclo[2.2.1]heptan-2-yI) benzonitrile (Compound 16)
O
124 SteP 1: tert-butyl (lS,4S)-5-(3-cyanocyclopent-2-en-l-yl)-2,5diazabicycIo[2.2.1]heptane-2-carboxylate (Compound 16a)
NC
O
To a stirred solution of tert-butyl (lS,4S)-2,5-diazabicyclo[2.2.1]heptane-2carboxylate (10.0 g, 50.4 mmol) in acetonitrile (100 ml) was added potassium carbonate (20.91 g, 151 mmol) at 25 °C and stirred the reaction mixture for 10 minutes. To tins was added, a solution of 3-bromocyclopent-l-enecarbonitrile (Compound la, 8.68 g, 50.4 mmol) in acetonitrile (25 ml) and the reaction mixture was stirred for 16 hrs. The progress of reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The residue obtained was diluted with water (100 ml) and extracted with ethyl acetate (2 x 200 ml). The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 20 % ethyl acetate in hexane as an eluent to obtain the title compound (10.0 g, 68.5 % yield).
NMR (400 MHz, DMSO-ck) δ 6.89 (d, J= 8.1 Hz, 1H), 4.19 - 4.11 (m, 1H), 3.88 - 3.78 (m, 1H), 3.57 - 3.51 (m, 1H), 3.32 - 3.24 (m, 1H), 3.13 - 3.02 (m, 1H), 2.89 -2.78 (m, 1H), 2.61 -2.54 (m, 2H), 2.18-2.09 (m, 1H), 1.72 - 1.52 (m, 3H), 1.39 (s, 9H), 1.26 - 1.14 (m, 1H).
MS: m/z 290.0 (M+l).
Step 2: tert-butyl (lS,4S)-5-(3-formylcyclopent-2-en-l-yl)-2,5diazabicyclo[2.2.1]heptane-2-carboxylate (Compound 16b)
125
Ο
A solution of tert-butyl (lS,4S)-5-(3-cyanocyclopent-2-en-l-yl)-2,5diazabicyclo[2.2, l]heptane-2-carboxylate (Compound 16a, 10.0 g, 34.6 mmol) in dichloromethane (50 ml) was cooled at -78 °C. Diisobutylaluminium hydride (51.8 ml, 51.8 mmol, IM solution in toluene) was added slowly within 10-15 minute. The reaction mixture was stirred for 15 min at -78 °C and then warmed at room température and stirred for 1 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched by drop wise addition of saturated ammonium chloride solution (20 ml) at 0 °C (carefully: The reaction quenching is exothermic). A gel type reaction mass was observed, Celite (100 g) was added to the reaction mixture and the reaction mixture was diluted with 10 % methanol in dichloromethane (300 ml) and stirred for 20 min. The reaction mass was fïltered through Celite bed and the bed was washed with 10 % methanol in dichloromethane (300 ml). The combined organic filtrate was dried over sodium sulphate and concentrated under vacuum till dryness to afford the crude product which was purified by column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane as an eluent to obtain the title product as yellow solid. (5.0 g, 49.5 % yield).
Ή NMR (400 MHz, DMSO-cfc) 6 9.77 (s, 1H), 7,01 (d, 9.9 Hz, 1H), 4.21 - 4.13 (m, 1H), 3.96 - 3.83 (m, 1H), 3.58 (s, 1H), 3.33 - 3.29 (m, 1H), 3.16 - 3.05 (m, 1H), 2.89 - 2.81 (m, 1H), 2.65 - 2.56 (m, 1H), 2.47 - 2.38 (m, 1H), 2.36 - 2.22 (m, 1H), 2.21 - 2.09 (m, 1H), 1.74 - 1.61 (m, 3H), 1.40 (s, 9H).
MS: m/z 292.4 (M+l).
126 Step 3: tert-butyl (lS>4S)-5-(3-ethynylcyclopent-2-en-I-yl)-2,5diazabicyclo[2.2.1]heptane-2-carboxylate (Compound 16c)
To a solution of trimethylsilyldiazomethane (12.23 ml, 24.46 mmol) in tetrahydrofuran (50 ml) at -78DC was slowly added, n-butyllithium (15.28 ml, 24.46 mmol) solution in hexane (1.6 M). The reaction mixture was stirred for 30 minutes at same température. A solution of tert-butyl (lS,4S)-5-(3f°rmylcyclopent-2-en-l-yl)-2,5-diazabicyclo[2.2. l]heptane-2-carboxylate (Compound 16b, 5.5 g, 18.81 mmol) in tetrahydrofuran (50 ml) was slowly added to the reaction mixture at -78 °C . The reaction mixture was stirred for 30 minute and then warmed to room température and further stirred for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (100 ml) and then washed with water (50 ml). The organic layer was separated and aqueous layer was again extracted with ethyl acetate (2 x 100 ml). The combmed organic layer was dried over sodium sulphate and evaporated under reduced pressure to obtain crude oily product which was purified by column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane as an eluent to obtain the title product (2.5 g, 46.1 % yield).
H NMR (400 MHz, DMSO-ci,) δ 6.16 - 6.07 (m, 1H), 4.18 - 4.09 (m, 2H), 3.79 3.69 (m, 1H), 3.55 - 3.47 (m, 1H), 3.13 - 3.00 (m, 1H), 2.86 - 2.76 (m, 1H), 2.50 2.37 (m, 3H), 2.35-2.25 (m, 1H), 2.11 -2.01 (m, 1H), 1.72- 1.52 (m, 3H), 1 39 (s, 9H).
MS: m/z 289.2 (M+l).
127
Step 4: (lS,4S)-2-(3-ethynylcyclopent-2-en-l-yl)-2,5-diazabicyclo[2.2.1]heptane dihydrochloride (Compound 16d)
.2HCI
To a solution of tert-butyl (lS,4S)-5-(3-ethynylcyclopent-2-en-l-yl)-2(55 diazabicyclo[2.2.1 ]heptane-2-carboxylate (Compound 16c, 2.5 g, 8.67 mmol) in dichloromethane (10 ml) was added, hydrochloric acid in 1,4 dioxane (21.67 ml, 87 mmol, 4M solution in 1,4 dioxane ) at 0-5 °C. The reaction mixture was warmed to room température and stirred for 2 h. The progress of reaction was momtored by TLC. The reaction mixture was evaporated under reduced pressure 10 to obtain solid product which was co-evaporated with diethyl ether (50 ml), followed by toluene (50 ml) to obtain the title product (2.2 g, 97 % yield) as a white solid.
’H NMR (400 MHz, DMSO-de) δ 6.16 - 6.07 (m, 1H), 4.18 - 4.09 (m, 2H), 3.79 3.69 (m, 1H), 3.55 - 3.47 (m, 1H), 3.13 - 3.00 (m, 1H), 2.86 - 2.76 (m, 1H), 2.50 15 2.37 (m, 3H), 2.35 - 2.25 (m, 1H), 2.11 - 2.01 (m, 1H), 1.72 - 1.52 (m, 3H).
MS: m/z 188.9 (M+l).
Step 5: 4-((lS,4S)-5-(3-ethynylcyclopent-2-en-l-yl)-2,5diazabicyclo[2.2. l]heptan-2-yl)benzonitrile (Compound 16e)
To a solution of (lS,4S)-2-(3-ethynylcyclopent-2-en-l-yl)-2,5-diazabicyclo [2.2.1]heptane dihydrochloride (Compound 16d, 2.2 g, 8.42 mmol) in
128 dimethylsulfoxide (40 ml) was added, potassium carbonate (5.24 g, 37.9 mmol) followed by the addition of 4-fluorobenzonitrile (1.326 g, 10.95 mmol) at 25-30 C. The reaction mixture was warmed and stirred at 120 °C for 18 h. The progress of reaction was monitored by TLC. The reaction mixture was poured 5 into water (25 ml) and extracted with ethyl acetate (2 x 100 ml) and organic layer was washed with water (50 ml) and brine solution (50 ml). The organic layer was dned over sodium sulphate and evaporated under vacuum to obtain crude oüy product which was purified by column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane (35-40 % ethyl acetate) as an eluent to 10 obtain the title product (1.6 gm, 65.6 % yield).
H NMR (400 MHz. CDCh) δ 7.S0 - 7.42 (m, 2H), 6.56 - 6.48 (m, 2H), 6.04 (dd, J - 7.3, 2.2 Hz, 1H), 4.32 (s, 1H), 3.84 - 3.71 (m, 2H|, 3.46 - 3.34 (m, 2H), 3.15 2.99 (m, 2H), 2.77 - 2.52 (m, 2H), 2.51-2.36 (m, 1H), 2.21 - 1.98 (m, 2H), 1.951.88 (m, 1H), 1.78- 1.65 (m, 1H).
MS: m/z 290.1 (M+l).
A chiral seperation of 4-((lS,4S)-5-(3-ethynylcyclopent-2-en-l-yl)-2,5diazabicyclo[2.2. l]heptan-2-yl)benzonitrile by chiral HPLC was carried out using chiral column to obtain
4-((lS,4S)-5-((R/S)-3-ethynylcyclopent-2-en-l-yl)-2,5-diazabicycIo[2.2. IJheptan20 2-yl)benzonitrile (Compound Ibe)
NMR (400 MHz, CDC13) δ 7.46 (d, 8.5 Hz, 2H), 6.52 (d, J= 8.5 Hz, 2H),
6.05 (d, J= 2.5 Hz, 1H), 4.32 (s, 1H), 3.85 - 3.77 (m, 1H), 3.74 (s, 1H), 3.48 3.35 (m, 2H), 3.07 - 3.01 (m, 1H), 2.73 - 2.65 (m, 1H), 2.65 - 2.54 (m, 1H), 2.50
129
2.37 (m, 1H), 2.20 - 2.07 (m, 1H), 2.05 - 1.99 (m, 1H), 1.96 - 1.87 (m, 1H), 1.79 1.68 (m, 2H).
MS: m/z 290.1 (M+l).
and
4-((IS,4S)-5-((S/R)-3-ethynylcyclopent-2-en-l-yl)-2,5-diazabicyclo[2.2.1]heptan2-yl)benzonitrile (Compound 16e”).
‘H NMR (400 MHz, CDC13) Ô 7.46 (d, J = 8.6 Hz, 2H), 6.53 (d, J= 8.6 Hz, 2H),
6.03 (s, 1H), 4.33 (s, 1H), 3.83 - 3.72 (m, 2H), 3.46 - 3.34 (m, 2H), 3.15 - 3.09 (m, 1H), 2.78 - 2.71 (m, 1H), ), 2.65 - 2.54 (m, 1H), 2.51 - 2.39 (m, 1H), 2.21 2.09 (m, 1H), 2.06 - 1.99 (m, 1H), 1.96 - 1.90 (m, 1H), 1.83 - 1.71 (m, 2H).
MS: m/z 290.2 (M+l).
Both these diastereomers were processed further individually to obtain the 15 respective title products.
Step 6: 4-((lS,4S)-5-((R/S)-3-(5-oxo-5H-pyrano[4,3-b]pyridin-7-yl) cyclopent-2en-l-yl)-2,5-diazabicyclo[2.2.l]heptan-2-yl)benzonitrile (Compound 16f)
O
130
To a stirred solution in another round bottom flask of 2-bromonicotinic acid (0.635 g, 3.14 mmol) in acetonitrile (50 ml) (degassed by N2 purge separately) was added bis(triphenylphosphine)palladium(II) chloride (0.085 g, 0.121 mmol). The reaction mixture was heated upto 70 °C and diisopropylethyl amine (2.53 ml, 14.51 mmol) was added slowly, followed by a solution of 4((lS,4S)-5-((R/S)-3-ethynylcyclopent-2-en-l-yl)-2,5-diazabicyc!o[2.2.1]heptan-2yl)benzonitrile (Compound 16e’, 0.700 g, 2.419 mmol) in acetonitrile (10 ml) was added slowly at same température. The mixture was heated and stirred at 80-85 °C for 24 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was distilled under vacuum till dryness to obtain crude product which was purified by column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane (100 % ethyl acetate) as an eluent to obtain the title product (150 mg, 38.0 % yield).
MS: m/z411.3 (M+l).
Step 7: 4-((lS,4S)-5-((R/S)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)-2,5-diazabicyclo[2.2. l]heptan-2-yl)benzonitrüe (Compound 16)
NH
N
N
To a solution of 4-((1 S,4S)-5-((R/S)-3-(5-oxo-5H-pyrano[4,3-b]pyridin-7yl)cyclopent-2-en-l-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzonitrile (Compound 16f, 0.150 g, 0.365 mmol) in anhydrous tetrahydrofuran (5 ml) was added ammonia in methanol (5.22 ml, 36.5 mmol, 7M solution in methanol) at 25 °C, reaction mixture was stirred at 80-85 ’C for 12 h. The progress of the reaction was monitored by TLC. The reaction mixture was distilled under vacuum. A crude product was purified by chromatography using methanol in
131 dichioromethane. The desired compound was isolated at 3-4 % of methanol in dichioromethane. (0.050 g, 33.4 % yield)
MS: m/z 410.1 (M+l).
Step 8. 4(rt$’4S)ri5-((R/S)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-75 yl)cyci°Pent-2-en-l-yl)-2J5-diazabicyclo[2.2. l]heptan-2-yl)benzonitrile (Compound 16-hydrochloride sait)
O
CN
A clear solution of 4-((lS,4S)-5-((R/S)-3-(5-oxo-5,6-dihydro-l,6naphthyridin-7-yl) cyclopent-2-en- l-yI)-2,5-diazabicyclo[2.2. l]heptan-210 yljbenzonitrile (Compound 16, 0.050 g, 0.122 mmol) in dichioromethane (5 ml) and methanol (5 ml), was warmed and stirred at 55-60 °C, and hydrochloric acid in dioxane (0.244 ml, 0.977 mmol, 3M solution in dioxane) was added at the same température in small portions over a period of 5 minutes. The reaction mixture was stirred for 30 min at 55-60 ’C. The reaction mixture was cooled to 15 room température, diluted with diethyl ether (10 ml), and product was collected upon filtration. The solid compound was washed with diethyl ether (10 ml) and dried under reduced pressure for 3 h at 40 °C to obtain the title compound (0.011 g, 18.67 % yield).
*H NMR (400 MHz, DMSO-cZè) δ 11.61 (brs-exchangeable with D2O, 1H), 10.35 (brs-exchangeable with D2O, 1H), 9.01 - 8.91 (m, 1H), 8.60 - 8.51 (m, 1H), 7.72 7.51 (m, 3H), 6.86 - 6.73 (m, 3H), 4.96 - 4.82 (m, 1H), 4.77 - 4.65 (m, 1H), 4.58 (s, 1H), 3.87 - 3.74 (m, 1H), 3.75 - 3.62 (m, 1H), 3.59 - 3.52 (m, 2H), 3.42 - 3.31 (m, 1H), 3.18 - 2.95 (m, 1H), 2.90 - 2.62 (m, 1H), 2.48 - 2.29 (m, 2H), 2.30 - 2.17 (m, 1H), 2.18 - 2.05 (m, 1H).
MS: m/z 410.2 (M+l).
132
The following compound was prepared using the procedure described above in Example 8 by using 4-((lS,4S)-5-((S/R)-3-ethynylcyclopent-2-en-l-yl)2,5-diazabicyclo[2.2.1]heptan-2-yl)benzonitrile (Compound 16e”).
4-(( 1 S,4S)-5-((S/R) -3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)-2,5-diazabicyclo[2.2. l]heptan-2-yl)benzonitrile (Compound 17-hydrochloride sait).
NMR (400 MHz, BMSO-cfe) Ô 11.66 (brs-exchangeable with D2O, 1H), 10.91 (brs-exchangeable with D2O, 1H), 9.08 - 8.97 (m, 1H), 8.71 - 8.56 (m, 1H), 7.75 7.57 (m, 3H), 6.89 - 6.72 (m, 3H), 4.96 - 4.82 (m, 1H), 4.77 - 4.66 (m, 1H), 4.60 (s, 1H), 3.89 - 3.79 (m, 1H), 3.75 - 3.64 (m, 1H), 3.62 - 3.56 (m, 2H), 3.42 - 3.33 (m, 1H), 3.18 - 2.95 (m, 1H), 2.92 - 2.63 (m, 1H), 2.48 - 2.29 (m, 2H), 2.31 - 2.18 (m, 1H), 2.19-2.07 (m, 1H).
MS: m/z 410.2 (M+l).
Example 9: Synthesis of 4-(4-(( lR,3S/3R)-3-(5-oxo-5,6-dîhydro-1,6naphthyridin-7-yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound 11)
O
and
4-(4-(( lR,3R/3S)-3-( 5-oxo-5,6-dihydro-l, 6-naphthyridin-7yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound 12)
133
Ο
Step 1: tert-butyl (Compound lia)
4-((lR)-3-cyanocycIopentyl)piperazine-l-carboxyIate
To a stirred solution of tert-butyl (R)-4-(3-cyanocyclopent-2-en-1yl)piperazine-l-carboxylate (Compound 23b’, 13.5 g, 48.7 mmol) in methanol (150 ml) at 25 C was added 10% Pd/C (5 g). The resulting suspension was stirred under Hydrogen Balloon pressure for 3 hrs. The progress of the reaction was monitored by TLC. The reaction mixture fdtered through a bed of Celite and was washed with methanol (50 ml). The combined filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography over silica gel (100 - 200 mesh) using 50 % ethyl acetate in hexane as an eluent to obtain the title compound (7.4 g, 54%).
HNMR (400 MHz, CDC13): δ 3.47-3.42 (m, 4H), 2.86 - 2.72 (m, 1H), 2.65-2.61 (m , 1H), 2.43 (d, J= 5.3 Hz, 4H), 2.42 - 2.25 (m, 1H), 2.11-2.01 (m, 2H),1.971.88 (m,l H), 1.85 - 1.69 (m, 2H), 1.47 (s, 9H).
MS: m/z 280 (M+l).
Step 2: tert-butyl 4-((1 R)-3-formylcycIopentyl)piperazine-l-carboxylate (Compound 11b)
134
To a stirred solution of tert-butyl 4-((lR)-3-cyanocyclopentyl)piperazine-lcarboxylate (Compound lia, 7.4 g, 26.5 mmol) in dichloromethane (400 ml) at 78 °C. DIBAL-H in toluene (39.7 ml, 39.7 mmol) was added slowly. The reaction mixture was allowed to reach 25-30 °C. The progress of the reaction was monitored by TLC. After completion of reaction, the mixture was cooled to 0°C and then quenched with saturated ammonium chloride solution (30 ml). The reaction mixture was diluted with 10% methanol in dichloromethane (500 ml) and stirred for 30 min. The reaction mass was fïltered through bed of Celite and washed with 10% methanol in dichloromethane (500 ml). The organic layer was concentrated under reduced pressure to obtain crude product, which was purified by flash column chromatography over silica gel (100-200 mesh) using ethyl acetate in hexane as an eluent to obtain title compound (4.1 g, 54.8 % yield).
’HNMR (400 MHz, CDCb): δ 9.64 (dd, J= 8.8, 2.0 Hz, 1H), 3.45-3.40 (m, 4H), 2.84 - 2.70 (m, 1H), 2.65-2.61 (m , 1H), 2.45-2.40 (m, 4H), 2.41 - 2.23 (m, 1H), 2.13-2.04 (m, 2H),1.98-1.85 (m, 1H), 1.82 - 1.67(m, 2H), 1.47 (s, 9H).
MS: m/z 283 (M+l).
Step 3: tert-butyl 4-((lR,3S/3R)-3-ethynylcyclopentyl)piperazine- 1-carboxylate (Compound 11c) / N 0 N. J and tert-butyl 4-(( 1 R,3R/3S)-3-ethynylcyclopentyl)piperazine-1 -carboxylate (Compound 11c’)
135
To a stirred solution of trimethylsilyl diazomethane (11.33 ml, 22.66 mmol, 2.0 M solution in hexane) in diy tetrahydrofuran at -78 eC was added nBuLi (13.28 ml, 21.25 mmol, 1.6 M in toluene) under nitrogen atmosphère. The reaction mixture was stirred for 30 min. A solution of tert-butyl 4-((lR)-3formylcyclopentyl)piperazine-l-carboxylate (Compound 1 Ib, 4.0g ,14.17 mmol) in tetrahydrofuran (50 ml) was added slowly. The reaction mixture was allowed to corne to room temprature and stirred for 2 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (250 ml) and water (150 ml), organic layer was separated dried over sodium sulphate, filtered and filtrate was concentrated under reduced pressure to obtain crude product which was purified by flash column chromatography over silica gel (100 - 200 mesh) using 45-50 % ethyl acetate in hexane as an eluent to obtain the title compound assigned as tert-butyl 4-((lR,3S/3R)-3ethynylcyclopentyl)piperazine-l-carboxylate (Compound 11c, 1.75 gm) and another polar spot was eluted using 45-50 % ethyl acetate in hexane were concentrated as tert-butyl 4-((lR,3R/3S)-3-ethynylcyclopentyl)piperazine-lcarboxylate (Compound 11c’, 0.75 gm).
tert-butyl 4-(( 1 R,3S/3R)-3-ethynylcyclopentyl)piperazine-1 -carboxylate (Compound 11c) lH NMR (400 MHz, CDC13): δ 3.52-3.45 (m, 4H), 2.72 - 2.56 (m, 2H), 2.49 - 2.46 (m, 4H), 2.31 - 2.22 (m, 1H), 2.09 (d, J= 2.2 Hz, 1H), 2.05-1.96 (m, 1H), 1.911.78 (m, 2H), 1.73-1.58 (m, 2H), 1.48 (s, 9H).
MS: m/z279 (M+l).
136 tert-butyl 4-(( 1 R,3R/ 3S)-3-ethynylcyclopentyl)piperazine- 1-carboxylate (Compound 11c1).
H NMR (400 MHz, CDC13): 6 3.53-3.48 (m, 4H), 2.71 - 2.57 (m, 2H), 2.48 - 2.44 (m, 4H), 2.31 - 2.22 (m, 1H), 2.09 (d, J= 2.2 Hz, 1H), 2.05-1.96 (m, 1H),1.915 1.78 (m, 2H), 1.75-1.55 (m, 2H), 1.47 (s, 9H).
MS: m/z 279 (M+l).
Both these diastereomers were processed further individually to obtain the respective title products.
Step 4: 1-((1 R,3S/3R)-3-ethynylcyclopentyl)piperazine dihydrochloride (Compound 11 d) p^NH.2HCI
To a stirred solution of tert-butyl 4-((lR,3S/3R)-3ethynylcyclopentyl)piperazine-1-carboxylate (Compound 11c, 1.7 g, 6.11 mmol) in Dichloromethane ( 40 ml) was added HCl (20.36 ml, 61.1 mmol) in 1,4 15 Dioxane drop wise at 0°C. After complété addition the reaction mixture was stirred at room température for 2 hrs. The progress of reaction was checked by TLC. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was co-evaporated with toluene to remove tracess of moisture and solid was dried under vacuum to obtain compound 1-((1R,3S/3R)20 3-ethynylcyclopentyl)piperazine dihydrochloride (1.25 g, 95%)
MS: m/z 180 (M+l).
Step 5: 4-(4-(( 1 R,3S/3R)-3-ethynylcyclopentyl)piperazin-1 -yljbenzonitrile (compound lie)
137
To a stirred suspension of l-((lR,3S/3R)-3-ethynylcyclopentyl)piperazine hydrochloride (Compound lld, 1.23 g, 5.73 mmol) in dimethyl sulphoxide (20 ml) was added potassium carbonate (3.96 g, 28.6 mmol) and stirred for 30 5 minutes at room température. 4-fluorobenzonitrile (0.902 g, 7.45 mmol) was added and reaction mixture was heated at 120 °C for 15 hrs. The progress of reaction was monitored by TLC. The reaction mixture was cooled to room température and was diluted with ethyl acetate (120 ml) and was washed with water (2 x 100 ml). The separated organic layer was dried over anhydrous sodium 10 sulfate, filtered and concentrated to yield crude compound. A crude compound was purified by flash column chromatography using 50-60% ethyl acetate in hexane to obtain compound (1.35 g, 85%).
>H NMR (400 MHz, CDCh): δ 7.51 (d, J = 8.6 Hz, 2H), 6.88 (d, J= 8.6 Hz, 2H), 3.39-3.36 (m, 4H), 2.77-2.62 (m, 5H), 2.32-2.24 (m, 1H), 2.10 (d, J= 2.2 Hz, 1H), 15 2.06 - 2.01 (m, 1H), 1.97 - 1.65 (m, 5H).
MS: m/z 280 (M+l).
Step 6: methyl 2-(((lS/lR13R)-3-(4-(4-cyanophenyl)piperazin-lyl)cyclopentyl)ethynyl)nicotinate (Compound 1 If)
To a stirred solution of methyl 2-bromonicotinate (1.055 g, 4.89 mmol) and DIPEA (3.94 ml, 22.55 mmol) in acetonitrile (20 ml), nitrogen gas was purged
138 for 20 minutes and bis(triphenylphosphine) palladium (II) chloride (0.264 g, 0.376 mmol) was added. The reaction mixture was heated at 85 °C and solution of 4-(4-((lR,3S/3R)-3-ethynylcyclopentyl)piperazin-l-yl)benzonitrile (Compound lie, 1.05 g, 3.76 mmol) in acetonitrile (20 ml) was added . The reaction mixture was stirred for 18 hrs at 85 °C. The progress of reaction was monitored by TLC. The reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate (2 x 50ml). The combined organic layer was washed with water (70 ml). The organic layer separated was washed with brine (50 ml) and dried over sodium sulphate and concentrated under reduced pressure to obtain crude compound. A crude compound was purified by Flash column chromatography using 30-40 % ethyl acetate in hexane to obtain the title compound (0.51 g, 32.7%).
’H NMR (400 MHz, CDC13): δ 8.77-8.66 (m, 1H), 8.23 (dd, J= 8.0, 1.8 Hz, 1H), 7.52 (8.6 Hz, 2H), 7.32 (d, J= 8.0 Hz, IH), 6.88 (d, 8.6Hz, 2H), 3.97 (s, 3H),
3.51-3.34 (m, 4H), 3.14-3.01 (m, 1H), 2.90-2.63 (m, 5H), 2.42-1.91 (m, 6H).
MS: m/z 415 (M+l) SteP 7: 2-(((lS/lR,3R)-3-(4-(4-cyanophenyl)piperazin-lyl)cyclopentyl)ethynyl)nicotinic acid (Compound 11g)
CN
To a stirred solution of methyl 2-(((lS/ lR,3R)-3-(4-(4cyanophenyl)piperazin-l-yl)cyclopentyl)ethynyl)nicotinate (Compound llf, 0.5 g, 1.206 mmol) in Methanol ( 30 ml) was added solution of NaOH (0.193 g, 4.83 mmol) in water (10 ml) at 0 °C. The reaction mixture was then stirred at 25 °C for 4 hrs. The progress of reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was taken
139 in water (15 ml) and neutralized with 2N HCl, pH was adjusted to 6-7, solid formed was filtered and co evaporated with toluène (3 x 20 ml) to remove moisture. The resulting solid was dried to obtain the title compound (0.460 g, 95 %)
MS: m/z 401 (M+l).
4-(4-((lR,3S/3R)-3-(5-oxo-5H-pyrano[4,3-b]pyridin-7yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound 11 h)
To a stirred solution of 2-(((lS/lR,3R)-3-(4-(4-cyanophenyl)piperazin-lyl)cyclopentyl)ethynyl)nicotinic acid (Compound 11g, 0.45 g, 1.124 mmol) in Dichloromethane ( 20 ml) was added trifluoromethane sulfonic acid (0.422 g, 2.81 mmol) slowly at 0DC. The reaction mixture was then stirred at 25 °C for 42 hrs. The progress of reaction was monitored by TLC. The reaction mixture was cooled in ice bath and diluted with diethyl ether (100 ml) and stirred for 30 minutes, solid obtained was filtered to yield sticky crude compound. A crude compound was purified by flash column chromatography using 4-5% methanol in dichloromethane to obtain the title compound (0.33 g, 73.3%)
Ή NMR (400 MHz, DMSO-dg): Ô 8.99 (dd, J = 4.7,1.8 Hz, 1H), 8.48 (dd, J = 8.2,1.8 Hz, 1H), 7.69 (d, J= 8.4 Hz, 2H), 7.61-7.59 (m, 1H), 7.16(d, J= 8.4 Hz, 2H), 6.82 (s, 1H), 4.14-4.11 (m, 2H), 3.84-3.73 (m, 2H), 3.67-3.65 (m, 2H), 3.353.33 (m,lH), 3.23-3.05 (m, 5H), 2.14-1.98 (m, 4H).
MS: m/z 401 (M+l).
steP 4-(4-((1 R,3S/3R)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopentyl)piperazin-l-yl)benzomtrile (Compound lli)
140
Ο
Το a stirred solution of 4-(4-((1 R,3S/3R)-3-(5-oxo-5H-pyrano[4,3-b]pyridm7-yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound llh, 0.32 g, 0.799 mmol) 5 m methanol (2 ml) was added ammonia (7N in methanol, 10 ml). The reaction mixture in a sealed tube was then stirred at 90°C for 15 hrs. The progress of reaction was monitored by TLC. The reaction mixture was cooled and the solid formed was filtered to yield a dark brown solid. The crude solid was purified by column chromatography over silica gel 100-200 mesh using 5-6 % methanol in 0 dichloromethane to obtain the title compound (0.13 g, 40.7%).
MS: m/z 400.2 (M+l).
Step 10: 4-(4-(( 1 R, 3S/3R)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound 11 -hydrochloride sait)
O
.2HCI
To a solution of 4-(4-((1 R,3S/3R)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin7-yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound 11, 0.12 g, 0.30 mmol) in dichloromethane (5 ml) and éthanol (5 ml), HCl (0.74 ml, 2.403 mmol, 3 M in Dioxane) was added at 25°C. The reaction mixture was further stirred at 25°C for 0.5 h. The reaction mixture was diluted with diethyl ether (30 ml) and stirred for 10 mins. The solid material was separated and dried under vacuum to obtain title compound (0.135 g, 95%).
141 ΣΗ NMR (400 MHz, DMSO-de) δ 12.11 (brs-exchangeable with D2O, 1H), 11.82 (brs-exchangeable with D2O, 1H), 9.04 (d, J = 5.2 Hz, 1H), 8.83 (d, J = 8.0 Hz, 1H), 7.73-7.68 (m, 3H), 7.14 (d, J = 8.0 Hz, 2H), 6.78 (s, 1H), 4.12-4.09 (m, 2H), 3.78 - 3.75 (m, 1H), 3.63 - 3.59 (m, 2H), 3.39 - 2.36 (m, 2H), 3.16 - 3.12 (m, 3H), 5 2.58-2.54 (m, 1H), 2.21 -2.16 (m, 4H), 1.93-1.91 (m,lH)
MS: m/z 400.2 (M+l).
The following compound of the present invention was prepared using a process analogous to Example 9 by changing the reactants to 11c’ in step 4 and following same reaction sequence.
4-(4-(( 1 R,3R/ 3S)-3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7yl)cyclopentyl)piperazin-l-yl)benzonitrile (Compound 12-hydrochloride sait)
O
.2HCI *H NMR (400 MHz, DMSO-d6) δ 12.03 (brs-exchangeable with D2O, 1H), 11.69 (brs-exchangeable with D2O, 1H), 9.01 (d, J = 5.2 Hz, 1H), 8.76 (d, J = 8.0 Hz, 15 1H), 7.69-7.67 (m, 3H), 7.14 (d, J = 8.6 Hz, 2H), 6.71 (s, 1H), 4.11-4.09 (m, 2H),
3.86 - 3.82 (m, 1H), 3.62 - 3.59 (m, 2H), 3.38 - 2.36 (m, 3H), 3.17 - 3.14 (m, 2H), 2.58-2.53 (m, 1H), 2.21 -2.16 (m, 3H), 2.07-2.05 (m,lH), 1.81-1.79 (m,lH).
MS: m/z 400.2 (M+l).
Example 10; Synthesis of (R)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-l,620 naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 9)
142
Ο
and (S)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yI)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 10)
Step 1: methyl 2-(l-cyanoethyl)nicotinate (Compound 9a)
O
CH3
To a solution of methyl 2-(cyanomethyl)nicotinate (prepared according to the procedure reported in WO2015/200677; 15 g, 85 mmol) in dry 10 dimethylformamide (40 ml) was added sodium hydride (3.41 g, 85 mmol) at 0-5 C. The reaction mixture was stirred at room température for 1 hr. To the reaction mixture, methyl iodide (12.09 g, 85 mmol) was added. The reaction mixture was stirred at room température for 1 hr. The progress of reaction was monitored by TLC. The reaction mixture was then concentrated under reduced 15 pressure. The residue obtained was diluted with saturated aqueous ammonium chloride (250 ml) and extracted with ethyl acetate (3 x 250 ml). The combined organic layer was dried over anhydrous sodium sulphate. The organic layer was evaporated under reduced pressure to obtain a crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh)
143 using 30% ethyl acetate in hexane as an eluent to obtain the title compound (8 g, 49.4 % yield).
H NMR (400 MHz, CDCfo δ 8.82 (dd, J= 4.8, 1.8 Hz, 1H), 8.33 (dd, J= 8.0, 1.8 Hz, 1H), 7.40 (dd, J= 7.9, 4.8 Hz, 1H), 5.25 (q, J = 7.1 Hz, 1H), 3.98 (s, 3H), 1.73 5 (d, J= 7.1 Hz, 3H).
MS: m/z 190 (M) (GCMS).
Step 2: 2-(l-cyanoethyl)nicotinic acid (Compound 9b)
O ίι^ψ^ΟΗ kN^YCN ch3
To a solution of methyl 2-(cyanomethyl)nicotinate (Compound 9a, 15 g, 85 10 mmol) in methanol (100 ml) was added sodium hydroxide (5.05 g, 126 mmol) in water (20 ml) at 0-25 °C. The réaction mixture was stirred at room température for 1 hr. The progress of the reaction was monitored by TLC. The reaction mixture was then concentrated under reduced pressure. The residue obtained was diluted with water (100 ml). Aqueous phase was acidified with 2N HCl (15 15 ml) and extracted with ethyl acetate (4 x 100 ml). The combined organic layer was dried over anhydrous sodium sulphate. The organic layer was evaporated under reduced pressure to obtain crude product. The crude product was carried for next step without purification.
Step 3: 5,7-dichloro-8-methyl-l,6-naphthyridine (Compound 9c)
144
PC1S (9.10 g, 43.7 mmol) was dissolved in POC13 (60 ml) and to this solution was added 2-(l-cyanoethyl)nicotinic acid (Compound 9b, 7.0 g, 39.7 mmol) in portions. The reaction mixture was stirred at room température for 90 min. to form a clear solution. The reaction mixture was stirred at 70° C. for 16 5 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The residue obtained was poured cautiously onto 50.0 g of ice and ethyl acetate (300 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (3 x 100 ml). The combined organic layer was dried over anhydrous sodium sulphate. The 10 solvent in the organic layer was evaporated under reduced pressure to obtain crude product. The crude product purified by flash column chromatography over silica gel (100-200 mesh) using 15% ethyl acetate in hexane as an eluent to obtain the title compound (4.0 g, 47.2% yield).
NMR (400 MHz, CDC13) δ 9.17 (d, J = 2.8 Hz, 1H), 8.61 (d, J = 8.5 Hz, 1H), 15 7.63 (dd, J= 8.5, 4.2 Hz, 1H), 2.83 (s, 3H).
MS: m/z 212 (M) (GCMS).
Step 4: 7-chloro-5-methoxy-8-methyl-1,6-naphthyridine (Compound 9d)
OMe
Sodium (2.158 g, 94 mmol) was dissolved in methanol (200ml) at room 20 température to form sodium methoxide. To the sodium methoxide solution was added 5,7-dichloro-8-methyl- 1,6-naphthyridine (Compound 9c, 4.0 g, 18.77 mmol) in small portions. The reaction mixture was stirred at reflux température for 20 hr. The progress of reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The residue obtained was purified by 25 flash column chromatography over silica gel (100-200 mesh) using 20% ethyl acetate in hexane as an eluent to obtain the title compound (3.4g, 87% yield).
145
NMR (400 MHz, CDCh) δ 9.07 (dd, J= 4.3, 1.8 Hz, 1H), 8.52 (dd, J= 8.4, 1.8 Hz, 1H), 7.46 (dd, J= 8.3, 4.3 Hz, 1H), 4.15 (s, 3H), 2.72 (s, 3H).
MS: m/z 208 (M) (GCMS).
Step 5: 3-(5-methoxy-8-methyl-1,6-naphthyridin-7-yl)cyclopent-2-en-1 -one (Compound 9e)
OMe
To a solution of 7-chloro-5-methoxy-8-methyl-l,6-naphthyridine (Compound 9d, 1.5g, 7.188 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)cyclopent-2-enone (1.644 g, 7.92 mmol) (Synthesis reported in US2012/77814) in 1,4 Dioxane (15 ml) was added tripotassium phosphate (4.578 g, 21.57 mmol) and dicyclohexyl-[2-[2,6-di(propan-2yloxy)phenyl]phenyl]phosphane (267 mg, 0.576 mmol) at room température under nitrogen purging in a microwave reaction tube for 15 minutes and Pd(OAc)2 (65 mg, 0.30 mmol) was added to the reaction mixture. The reaction mixture was heated for 1 hr at 110°C in microwave. The progress of reaction was monitored by TLC. The reaction mixture was diluted with water (50 ml) and ethyl acetate (50 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (2 x 20 ml). The combined organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced pressure to obtain a crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 40% ethyl acetate in hexane as an eluent to obtain the title compound (1.5 g, 82% yield).
Ή NMR (400 MHz, CDCh) δ 9.13 (d, 1H), 8.58 (d, J= 8.3 Hz, 1H), 7.54 (dd, J = 8.2, 4.3 Hz, 1H), 6.61 (s, 1H), 4.16 (s, 3H), 3.36 - 3.28 (m, 2H), 2.82 (s, 3H), 2.66 - 2.59 (m, 2H).
146
MS: m/z 255 (M+l)
Step 6: 3-(5-methoxy-8-methyl-1,6-naphthyridin-7-yl)cycIopent-2-en-1 -ol (Compound 9f)
OMe
To a solution of 3-(5-methoxy-8-methyl-l ,6-naphthyridin-7-yl)cyclopent-2enone (Compound 9e, 1.5 g, 5.90mmol) in methanol (Volume: 50 ml) was added Cerium(III) chloride (2.93 g, 7.87 mmol). The reaction mixture was stirred at room température for 1 hr. The reaction mixture was cooled to 0-5 °C and sodium borohydride (0.446 g, 11.80 mmol) was added in portions. The reaction mixture was stirred at room température for 10 min. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 ml) and ethyl acetate (25 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (3 x 25 ml). The combined organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced pressure to obtain a crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 80% ethyl acetate in hexane as an eluent to obtain the title compound (1.5 gm, 99% yield).
Ή NMR (400 MHz, CDCh) δ 9.08 (dd, J= 4.2, 1.6 Hz, 1H), 8.52 (dd, J = 8.2, 1.6 Hz, 1H), 7.44 (dd, J = 8.2, 4.3 Hz, 1H), 6.23 (s, 1H), 5.15 (s, 1H), 4.11 (s, 3H), 3.22 - 3.08 (m, 1H), 2.98 - 2.85 (m, 1H), 2.77 (s, 3H), 2.57 - 2.45 (m, 1H), 1.96 1.85 (m, 1H).
Step 7: 3-(5-methoxy-8-methyl-l,6-naphthyridin-7-yl)cyclopent-2-en-l-yl acetate (Compound 9g)
147
OMe
To a solution of 3-(5-methoxy-8-methyl-l,6-naphthyridin-7-yl)cyclopent-2enol (Compound 9f, 1.5 g, 5.85 mmol) in dichloromethane (25 ml) was added acetic anhydride (1.792 g, 17.56 mmol). The reaction mixture was stirred at room température for 1 hr. The reaction mixture was cooled to 0-5 °C and triethyl amine (1.777 g, 17.56 mmol) and DMAP (0.071 g, 0.585 mmol) were added slowly. The reaction mixture was stirred at room température for 5 min. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with water (50 ml) and ethyl acetate (25 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (3 x 25 ml). The combined organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced pressure to obtain crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 50% ethyl acetate in hexane as an eluent to obtain the title compound (1.1 g, 63% yield).
>H NMR (400 MHz, CDC13) δ 9.08 (d, J= 3.6 Hz, 1H), 8.52 (d, J= 8.2 Hz, 1H), 7.45 (dd, J= 8.2, 4.3 Hz, 1H), 6.21 (s, 1H), 5.97 (d, J = 5.0 Hz, 1H), 4.12 (s, 3H), 3.23-3.11 (m, 1H), 3.02 - 2.92 (m, 1H), 2.77 (s, 3H), 2.58 - 2.46 (m, 1H), 2.142.09 (m, 3H), 2.08 - 1.99 (m, 1H).
MS: m/z 299 (M+l).
Step 8: 4-(4-(3-(5-methoxy-8-methyl-l,6-naphthyridin-7-yl)cyclopent-2-en-1yl)piperazin-l-yl)benzonitrile (Compound 9h)
OMe
148
To a solution of 3-(5-methoxy-8-methyl-l,6-naphthyridin-7-yl)cyclopent2-en-l-yl acetate (Compound 9g, 1.1 g, 3.69 mmol) and 4-(piperazin-lyljbenzomtrile (1.036 g, 5.53 mmol) in dioxane (8 ml) and water (2 ml) was added Pd(PPha)4 (0.032 g, 0.028 mmol). The reaction mixture was stirred at room 5 température for 15 hrs. The progress of reaction was monitored by TLC. The reaction mixture was diluted with water (100 ml) and ethyl acetate (100 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (2 x 100 ml). The combined organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced 10 pressure to obtain crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 40% ethyl acetate in hexane as an eluent to obtain the title compound (1.2 g, 76% yield).
Ή NMR (400 MHz, DMSO-^) 5 9.12 (dd, J = 4.2, 1.6 Hz, 1H), 8.52 (dd, J= 8.2, 1.7 Hz, 1H), 7.69 - 7.53 (m, 3H), 7.05 (d, J= 8.9 Hz, 2H), 6.23 (s, 1H), 4.06 (s, 15 3H, overlap with m, 1H), 3.40-3.35 (m, 4H), 2.95 - 2.83 (m, 2H), 2.73 - 2.64 (m,’
7H), 2.14-2.02 (m, 1H), 1.98- 1.87 (m, 1H).
Step 9: (R)-4-(4-(3-(8-methyl-5-oxo-5,6-dîhydro- l,6-naphthyridin-7-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitiïle (Compound 9)
O
and (S) 4 (4-(3-(8-methyl-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 10)
149
To a solution of 4-(4-(3-(5-rnethoxy-8-methyl-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 9h, 1.0 g, 2.350 mmol) and TMS-C1 (0.511 g, 0.601 mL, 4.70 mmol) in acetonitrile (30 ml) was added sodium iodide (0.705 g, 4.70 mmol). The reaction mixture was stirred at 75°C for 8 hrs. The progress of reaction was monitored by TLC. The reaction mixture was diluted with saturated aqueous sodium bicarbonate (200 ml) and dichloromethane (200 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (3 x 100 ml). The combîned organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced pressure to obtain crude product. The crude product was purifïed by flash column chromâtography over silica gel (100-200 mesh) using 5% methanol in dichloromethane as an eluent to obtain the racemic title compound (0.650g, 67.2%yield).
‘H NMR (400 MHz, DMSO-ck) δ 11.26 (brs-exchangeable with D2O, 1H), 8.99 (dd, J= 4.5, 1.9 Hz, 1H), 8.51 (dd, J= 8.1, 1.9 Hz, 1H), 7.59 (d, J= 8.7 Hz, 2H), 7.51 (dd, J = 8.0, 4.5 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 6.14 (d, J = 2.2 Hz, 1H), 3.96 (s, 1H), 3.40 - 3.35 (m, 4H), 2.76 - 2.62 (m, 6H), 2.33 (s, 3H), 2.11 - 2.01 (m, 1H), 1.99 - 1.87 (m, 1H).
MS: m/z 412.3 (M+l).
Racemic compound was separated by CHIRALCEL OJ-H column using 0.1%DEA in Methanol as mobile phase to obtain:
(R)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 9)
ISO
and (S)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 10)
Step 10: (R)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin- l-yl)benzonitrile (Compound 9-hydrochloride sait)
To a solution of (R)-4-(4-(3-(8-methyl-5-oxo-5,6-dîhydro-l,6-naphthyridin7-yl)cycIopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 9, 100 mg, 0.243 mmol) in dichloromethane (10 ml) and methanol (5 ml) was added methanolic HCl (0.243 ml, 0.972 mmol). The reaction mixture was stirred at room 15 température for 1 hr. After completion of reaction, solvent was distilled out under vaccum till dryness. A product was washed with diethyl ether (2 x 50 ml). A residue was dried under vacuum to obtain the title compound (80 mg, 68.0 % yield).
151 *H NMR (400 MHz, DMSO-cÎg) ô 11.41 (brs-exchangeable with D2O, 1H), 10.97 (brs-exchangeable with D2O, 1H), 9.02 (dd, J= 4.5, 1.6 Hz, 1H), 8.55 (dd, J= 8.0, 1.5 Hz, 1H), 7.69 (d, J= 8.9 Hz, 2H), 7.56 (dd, J= 8.0, 4.6 Hz, 1H), 7.16 (d, J = 8.9 Hz, 2H), 6.27 (s, 1H), 4.68 (s, 1H), 4.16 (d, J = 11.5 Hz, 2H), 3.62 (d, J= 11.9 S Hz, 2H), 3.36 - 3.15 (m, 4H), 2.88 (d, J= 9.0 Hz, 2H), 2.43 - 2.37 (m, 2H), 2.35 (s, 3H).
MS: m/z 412.3 (M+l).
Step 11: (S)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-1 -yl)piperazin-1 -yljbenzonitrile (Compound 10-hydrochloride 10 sait)
To a solution of (S)-4-(4-(3-(8-methyl-5-oxo-5,6-dihydro-l,6-naphthyridin7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 10, 100 mg, 0.243 mmol) in dichloromethane (10 ml) and methanol (5 ml) was added 15 methanolic HCl (0.243 ml, 0.972 mmol). The reaction mixture was stirred at room température for 1 hr. After completion of the reaction, the solvent was distilled out under vaccum till dryness. The product was washed with diethyl ether (2 x 50 ml). The residue was dried under vacuum to obtain the title compound (100 mg, 85 % yield).
>H NMR (400 MHz, DMSO-d&) ô 11.42 (brs-exchangeable with D2O, 1H), 11.14 (brs-exchangeable with D2O, 1H), 9.06 - 8.98 (m, 1H), 8.55 (dd, J = 8.1, 1.5 Hz, 1H), 7.69 (d, J= 8.8 Hz, 2H), 7.57 (dd, J= 8.0, 4.6 Hz, 1H), 7.16 (d, J = 9.0 Hz, 2H), 6.28 (s, 1H), 4.68 (s, 1H), 4.15 (d, J= 13.5 Hz, 2H), 3.62 (d, J= 12.5 Hz, 2H), 3.38 - 3.14 (m, 4H), 2.88 (q, J= 9.7 Hz, 2H), 2.44 - 2.36 (m, 2H), 2.35 (s, 3H).
MS: m/z 412.3 (M+l),
152
Example 11: Synthesis of (R)-6-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridiii-7yl)cyclopent-2-en-l-yl)piperazm-l-yl)nicotinonitriIe (Compound 34)
Step 1: (R)-tert-butyl 4-(3-(5-oxo-5H-pyrano[4,3-b]pyridin-7-yl)cyclopent-2- enl-yl)piperazine-l-carboxylate (Compound 34a)
To a stirred solution of 2-bromonicotinic acid (5 g, 25 mmol) in acetonitrile (50 ml) (degassed by N2 purge seperately), was added bis(triphenylphosphine)palladium(II) chloride (0.7 g, 1 mmol) and the reaction mixture was heated to 70°C. At this température, diisopropyl ethylamine (18.96 ml, 109 mmol) was added followed by the addition of (R)-tert-butyI 4-(3ethynylcyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 23d, 5.3 g, 20 mmol) in acetonitrile (50 ml). The mixture was heated and stirred at 80-85 °C for 16 h. The progress of the reaction was monitored by TLC. Upon completion ofthe reaction, the reaction mixture was diluted with ethyl acetate (200 ml). The reaction mixture was washed with water (50 ml). The aqueous layer was extracted with ethyl acetate (2 x 100 ml) and the combined organic layer was dried over sodium sulphate and concentrated under reduced pressure. The crude product thus obtained was used without purification for the further reaction (yield 3.1 g, 41%).
MS: M/Z = 398 (M+l).
Step 2: (R)-tert-butyl 4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazine-l-carboxylate (Compound 34b)
153
Ο
In a steel bomb, a solution of (R)-tert-butyl 4-(3-(5-oxo-5H-pyrano[4,3b]pyridin-7-yl)cyclopent-2-en-l-yl)piperazine- 1-carboxylate (Compound 34a, 3.0 g, 7.55 mmol) m tetrahydrofuran (5 ml) and ammonia (32 ml, 150 mmol, 7M 5 solution in methanol) was stirred at 25 eC for 5 min and the reaction was continued at 80-85 °C for 24 h. The progress of the reaction was monitored by TLC. Upon completion, the reaction mass was distilled under vacuum till dryness. The crude product thus obtained, was purified by chromatography using methanol in dichloromethane. The desired compound was isolated at 3-4 10 % of methanol in dichloromethane. The combined fractions were concentrated to obtain the title compound as brown solid. (1.5 g, 50% yield).
’HNMR (400 MHz, DMSO-cfc) 6 11.44 (brs-exchangeable with D2O, 1H), 8.90 (dd, 4.5, 1.5 Hz, 1H), 8.47 (d, J= 7.8 Hz, 1H), 7.47 (dd, J= 8.0, 4.6 Hz, 1H), 6.91 (s, 1H), 6.58 (s, 1H), 3.89 (s, 1H), 3.33 - 3.29 (m, 4H), 2.77 - 2.60 (m, 2H), 2.49 15 2.35 (m, 4H), 2.10 - 1.99 (m, 1H), 1.91 - 1.79 (m, 1H), 1.40 (s, 9H).
MS: M/Z = 397 (M+l).
Step 3: (R)-7-(3-(piperazin-l-yl)cyclopent-l-en-l-yl)-l,6-naphthyridin-5(6H)- one (Compound 34c)
To a solution of tert-butyl (R)-4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 34b, 1.3 g, 5 17 mmol) in dichloromethane (10 ml), hydrochloric acid in 1,4 dioxane (12.91 ml, 51.7 mmol, 4M solution in 1,4 dioxane) was added at 0-5 °C. The reaction
154 mixture was warmed to room température and stirred for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was evaporated under reduced pressure to obtain solid product which was co-evaporated with diethyl ether (50 ml), followed by toluene (50 ml) to obtain hydrochloride sait. The resulting sait was neutralized with ammonia solution (30 ml, 7M in methanol) to obtain a crude product. The crude product was purified by chromatography using methanol-dichloromethane. The desired compound was eluted in 5-7% methanol in dichloromethane. The combined fractions were concentrated to yield the title compound as an off white solid (0.65 gm, 67%).
[H NMR (400 MHz, DMSO-dt,) 5 11.49 (brs-exchangeable with D2O, IH), 8.90 (dd, J= 4.5, 1.8 Hz, 1H), 8.47 (dd, J= 8.1, 1.7 Hz, 1H), 7.48 (dd, J= 8.0, 4.6 Hz, 2H), 6.87 (d, J= 2.3 Hz, 1H), 6.60 (s, 1H), 3.93 (s, 1H), 3.05 (d, J= 5.6 Hz, 4H), 2.80 2.59 (m, 6H), 2.14 - 2.00 (m, 1H) , 1.91 - 1.77 (m, 1H).
MS: M/Z = 297 (M+l).
Step 4: (R)-6-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)nicotinonitrile (Compound 34)
To a solution of (R)-7-(3-(piperazin-l-yl)cyclopent-l-en-l-yl)-l,6naphthyridin-5(6H)- one (Compound 34c, 100 mg, 0.337 mmol) in DMSO (5 ml) was added potassium carbonate (280 mg, 2.025 mmol) and 6fluoronicotinonitrile (53.6 mg, 0.439 mmol) at 27°C. The reaction mixture was stirred at 120°C for 18 hrs. The reaction mixture was poured into ice; the solid thus separated was filtered, washed with water (50 ml) and ether (20 ml). The solid was dissolved in methanol (2 ml) and precipitated with Diethyl ether (20
155 ml). It was filtered and dried to obtain the title compound (40 mg, 0.100 mmol, 29.8 % yield) as light brown solid.
‘H NMR (400 MHz, DMSO-cfc) Ô 11.45 (brs, exchangeable with D2O, 1H), 8.90 (d, J= 4.3 Hz, 1H), 8.47 (d, J = 10.4 Hz, 2H), 7.85 (d, J= 9.1 Hz, 1H), 7.48 (t, J= 6.5
Hz, 1H), 6.95 (d, J= 9.9 Hz, 2H), 6.59 (s, 1H), 3.97 - 3.88 (m, 1H), 3.78 - 3.58 (m, 4H), 2.79 - 2.65 (m, 2H), 2.65 - 2.55 (m, 4H), 2.17 - 2.01 (m, 1H), 1.97 - 1.82 (m, 1H).
MS: M/Z = 399 (M+l).
Step 5: (R)-6-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 10 yl)piperazin-l-yl)nicotinonitrile (Compound 34-hydrochloride sait)
. 2HCI
To a solution of (R)-6-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridm-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)nicotinonitrile (Compound 34, 40 mg,0.1 mmol) m dichloromethane (5 ml) and methanol (5 ml), hydrochloric acid in 15 dioxane (0.5 ml, 1 mmol, 3M solution in dioxane) was added at same température in small portions over a period of 2 minutes. The reaction mixture was stirred for 30 min at 55-60 °C. The reaction mixture was cooled to room température, diluted with diethyl ether (10 ml), and product was collected upon filtration. The solid compound was washed with diethyl ether (10 ml) and dried 20 under reduced pressure at 40 °C to obtain the title compound as brown solid (40 mg, 78 % yield).
Ή NMR (400 MHz, DMSO-d&) 6 11.73 (brs-exchangeable with D2O, 1H), 11.59 (brs-exchangeable with D2O, 1H), 9.00 (d, J= 4.8 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.58 (d, J= 2.2 Hz, 1H), 7.99 (dd, J =9.1, 2.3 Hz, 1H), 7.63 (dd, J = 8.0, 4.9
156
Hz, 1H), 7.10 (d, J - 9.2 Hz, 1H), 6.85 (d, J= 18.1 Hz, 2H), 4.72 - 4.58 (m, 3H), 3.58 (t, J = 12.1 Hz, 2H), 3.48 (t, J = 13.2 Hz, 2H), 3.19 - 3.02 (m, 2H), 2.96 2.85 (m, 2H), 2.45 - 2.33 (m, 2H).
MS: M/Z = 399.1 (M+l).
The following compound was prepared using the procedure described above m Example 11 with appropriate changes to the reactants and reaction conditions.
(R)-2-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2-en-lyl)piperazin-l-yl)thiazole-5’carbonitrile (Compound 35-hydrochloride sait)
Ή NMR (400 MHz, DMSO-d&) Ô 11.69 (brs-exchangeable with D2O, 1H), 11.65 15 (brs-exchangeable with D2O, 1H), 8.99 (d, J= 4.2 Hz, 1H), 8.59 (d, J= 8.1 Hz, 1H), 8.13 (s, 1H), 7.60 (dd, J= 7.9, 4.6 Hz, 1H), 6.84 (s, 1H), 6.81 (s, 1H), 4.69 (s, 1H), 4.26 - 4.12 (m, 2H), 3.71 (t, 12.6 Hz, 2H), 3.59 (t, J= 12.6 Hz, 2H), 3.32
-3.13 (m, 2H), 2.96 - 2.82 (m, 2H), 2.43 - 2.31 (m, 2H).
MS: M/Z = 405.3 (M+l).
Example 12: Synthesis of (R)-4-(4-(3-(l-oxo-l,2-dihydropyrrolo[l,2c]pyrimidin-3-yl)cyclopent-2-en-l-yl)piperazin-l-yI)benzonitrile (Compound 54)
1S7
Step 1: N-(pivaIoyloxy)-lH-pyrrole-l-carboxamide (Compound 54a)
To a stirred solution of oxalyl chloride (0.945 ml, 10.80 mmol) in tetrahydrofuran (25 ml) was added dimethyl formamide (0.070 ml, 0.90 mmol) at 0°C. The reaction mixture was stirred for 10 min and IH-pyrrole-l-carboxylic acid (1.0 g, 9.00 mmol) was added at 0°C in two portions. The reaction mixture was stirred for 15 min at 0°C, cooling bath was removed and the reaction mixture was stirred at room température for 15 min. The solvent was evaporated under reduced pressure to obtain a crude acid chloride. In another round bottom flaskcontaining a stirred solution of sodium carbonate{1.90 g, 18.00 mmol) in ethyl acetate (40 ml) and water (20 ml) was added O-pivaloylhydroxylammonium trifluoromethanesulfonate (2.396 g, 9.00 mmol) at 0’C, followed by the addition of the acid chloride in ethyl acetate (5 ml). The reaction mixture was stirred at 0°C for 2 hr, the progress of the reaction was monitored by TLC, and ethyl acetate (60 ml) was added to it. The two layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 50 ml). The combined organic layer was dried over sodium sulphate, filtered and concentrated to obtain crude product. The crude product was purified by flash column chromatography (20-25 % ethyl acetate in hexane) to obtain the title compound as a white solid (0.30 e 16%).
’H NMR (400 MHz, CDC13) ô 7.20-7.26 (m, 2H), 6.29-6.33 (m, 2H), 4.82 (bs exchanges with D2O, 1H), 1.37 (s, 9H).
MS: m/z 233 (M+23).
158
Step 2: (R) - 4-(4-(3 - ( 1 -oxo-1,2-dihydropyrrolo[ 1,2-c]pyrimidin-3-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 54)
To the stirred solution of N-(pivaloyloxy)-lH-pyrrole-l-carboxamide 5 (Compound 54a, 0.1 g, 0.476 mmol) in methanol (10 ml) were added césium acetate (0.091 g, 0.476 mmol), Bis[(pentamethylcyclopentadienyl)dichlororhodium] (0.029 g, 0.048 mmol) and (R)-4-(4-(3-ethynylcyclopent-2-en-lyl)piperazin-l-yl)benzonitrile (Compound Ij, 0.1 g, 0.476 mmol). The réaction mixture was stirred at room température for 18 hrs. The progress of the reaction 10 was monitored by TLC. The reaction mixture was concentrated to obtain the crude product; which was purified by flash column chromatography using 5% methanol in dichloromethane as an eluent to obtain the title compound (0.08 g, 44.0%).
NMR (400 MHz, DMSO-dû) 610.78 (bs-exchanges with D2O, 1H), 7.56 - 7.50 15 (m, 1H), 7.05 (t, J= 8.7 Hz, 2H), 6.95 (dd, J= 9.1, 4.7 Hz, 2H), 6.69 (s, 1H), 6.65 (t, J= 3.3 Hz, 1H), 6.50 (s, 1H), 6.40 (d, J = 3.5 Hz, 1H), 3.84 (s, 1H), 3.10 (m, 4H), 2.63-2.61 (m, 6H), 2.04-2.01 (m, 1H), 1.88 (m, 1H).
MS: m/z 386 (M+l).
Step 3: (R)-4-(4-(3-( 1 -oxo-1,2-dihydropyrrolo[ 1,2-c]pyrimidin-3-yl)cyclopent-220 en-l-yl)piperazin-l-yl)benzonitrile (Compound 54-hydrochloride sait)
HCI
159
To the solution of (R)-4-(4-(3-(l-oxo-l,2-dihydropyrrolo[l,2-c]pyrimidin-3yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 54, 0.06 g, 0.159 mmol) in dichloromethane (10 ml) was added hydrochloric acid (0.159 ml of 4M solution in dioxane, 0.634 mmol,) at O°C. The reaction mixture was stirred for Ih at 25°C. The reaction mixture was diluted with diethyl ether (10 ml), and filtered through a Buchner funnel. The resulting solid was washed with diethyl ether (10 ml) and dried under reduced pressure to obtain the title compound (0.052 g, 87 % yield).
'H NMR (400 MHz, DMSO-dy 5 11.16 (brs-exchanges with D2O, 1H), 10.89 (s D2O exchangeable, 1H), 7.68 (d, J = 8.5 Hz, 2H), 7.61 - 7.55 (m, 1H), 7.14 (d, J = 8.6 Hz, 2H), 6.71 (s, 1H), 6.69 (t, J= 3.3 Hz, 1H), 6.60 (s, 1H), 6.49 (d, J = 3.5 Hz, 1H), 4.62-4.60 (m, 1H), 4.18-4.09 (m, 2H), 3.61-3.50 (m, 2H), 3.34-3.26 (m, 2H), 3.18-3.05 (m, 2H), 2.92-2.69 (m, 2H), 2.41-2.31 (m, 2H).
MS: m/z 386.2 (M+l).
The following compound was prepared using a process analogous to Example 12 by appropriately changing the reactants/intermediates and reaction conditions as required.
(R)-3-(3-(4-(4-fluorophenyl)piperazin-1 -yljcyclopent-1 -en-1 -yl)pyrrolo[ 1,2c]pyrimidin-l(2H)-one (Compound 55-hydrochloride sait) >N ’H NMR (400 MHz, DMSO-dô) δ 11.23 (brs-exchanges with D2O, 1H), 10.92 (bsexchanges with D2O, 1H), 7.58 (d, J= 2.9 Hz, 1H), 7.20 - 7.00 (m, 4H), 6.73-6.67 (m, 2H), 6.63-6.61 (s, 1H), 6.49 (d, J= 3.5 Hz, 1H), 4.61 (s, 1H), 3.83-3,73 (m, 2H), 3.57- 3.47 (m, 2H), 3.19-3.10 (m, 4H), 2.89-2.71 (m, 2H), 2.39-2.32 (m, 2H).
160
MS: m/z 379.1 (M+l).
Example 13: Synthesis of (R)-4-(4-(3-(l-oxo-l,2-dihydropyrrolo[l,2-a]pyrazin-
3-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzomtrile (Compound 56)
Step 1: tert-butyl (R)-4-(3-acetylcyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 56a)
O
A solution of methyl lithium (40 ml of 5% solution in tetrahydrofuran, 90.0 mmol) was added to a cooled methyl tert-butyl ether (200 ml) at 0 °C. A solution of tert-butyl (R)-4-(3-cyanocyclopent-2-en- l-yl)piperazine-l-carboxylate (Compound 23b’, 10 g, 36.1 mmol) in methyl tert-butyl ether (70 ml) was added drop wise to the reaction mixture at 0 °C. After complété addition, the reaction mixture was stirred at 0 °C for 30 min. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with saturated aqueous ammonium chloride (10 ml), diluted with methyl tert-butyl ether (200 ml) and washed with water (50 ml). The separated organic layer was dried over anhydrous sodium sulphate and concentrated to obtain a crude product. The crude product was purified by flash column chromatography using 50% ethyl acetate in hexane to obtain the titie compound (5.0 g, 47.1%).
!H NMR (400 MHz, CDC13) δ 6.71-6.69 (m, 1H), 3.98-3.89 (m, 1H), 3.51-3.41(m, 4H), 2.68 -2.42(m, 6H), 2.36(s, 3H), 2.12-2.02 (m, 1H), 1.92-1.84(m, 1H), 1.48 (s, 9H).
161
MS: m/z 295 (M+l).
Step 2: tert-butyl (R)-4-(3-(2-chloroacetyl)cyclopent-2-en-l-yl)piperazine-lcarboxylate (Compound 56b)
N—Boc
To a stirred solution of lithium di-isopropyl amide in tetrahydrofuran (25 ml); which was prepared from diisopropylamine (1.81 ml, 12.74 mmol) and nbutyl lithium (6.90 ml of 1.6 M in hexane, 11.04 mmol) was added a solution of tert-butyl (R)-4-(3-acetylcyclopent-2-en-1-yljpiperazine-1 -carboxylate (Compound 56a, 2.5 g, 8.49 mmol) in tetrahydrofuran (25 ml) under a nitrogen atmosphère at -78 °C. The reaction mixture was stirred at -78 ’C for Ihr. A solution of Nchloro succinimide (1.58 g, 11.89 mmol) in tetrahydrofuran (12 ml) was added in 1 min at -78 °C. The reaction mixture was stirred for 1 hr at -78°C. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with saturated aqueous solution of ammonium chloride (10 ml) and stirred at room température for 15 min. The reaction mixture was diluted with ethyl acetate (100 ml). The organic layer was separated, washed with water (50 ml), brine (50 ml), dried over sodium sulphate and concentrated to obtain a crude compound. The crude compound was purified by flash column chromatography using 50% ethyl acetate in hexane to obtain the title compound (1.0 g, 35.8%).
‘H NMR (400 MHz, CDC13) Ô 6.81-6.80(m, 1H), 4.46-4.38 (m, 2H), 3.88-4.01 (m, 1H), 3.49-3.41(m, 4H), 2.55-2.44 (m, 6H), 2.09-2.06 (m, 1H), 1.93-1.90 (m, 1H), 1.48 (s, 9H).
MS: m/z 329 (M+l).
Step 3: tert-butyl (R)-4-(3-(2-(2-(ethoxycarbonyl)-lH-pyrrol-l-yl)acetyl)cyclopent2-en-1-yljpiperazine-1 -carboxylate (Compound 56c)
162
COOEt
Ο
N—Boc
To a stirred solution of ethyl lH-pyrrole-2-carboxylate (0.931 g, 6.69 mmol) in dimethyl formamide (10 ml) was added césium carbonate (3.27 g, 10.04 mmol) and stirred at 50 °C for 15 minutes. To this suspension, tert-butyl (R)-4-(3-(2-chloroacetyl)cyclopent-2-en-1 -yl)pipcrazine- 1-carboxylate (Compound 56b, 1.1 g, 3.35 mmol) in dimethyl formamide (5 ml) was added at 50 °C. The reaction mixture was stirred for I hr. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température and diluted with water (100 ml) and extracted with ethyl acetate (2 x 100 ml). The combined organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to obtain the crude product. The crude compound was purified by column chromatography over silica gel (100-200 mesh) using 75% ethyl acetate in hexane as an eluent to obtain the title compound (0.80 gm, 55.4%).
Ή NMR (400 MHz, CDC13) δ 7.02 (dd, J= 4.0, 1.8 Hz, 1H), 6.81-6.76 (m, 2H), 6.23 (dd, J= 4.0, 1.8 Hz, 1H), 5.54 (d, J= 17.4 Hz, 1H), 5.36 (d, J= 17.4 Hz, 1H), 4.22 (q, J= 7.1 Hz, 2H), 4.05 - 3.94 (m, 1H), 3.50-3.45 (m, 4H), 2.57 - 2.43 (m, 6H), 2.06-2.04 (m, 1H), 1.97 - 1.69 (m, 1H), 1.48 (s, 9H), 1.32 (t, J= 7.1 Hz, 3H).
MS: m/z 432 (M+l).
Step 4: tert-butyl (R)-4-(3-(l-oxo-l,2-dihydropyrrolo[l,2-a]pyrazin-3yl)cyclopent-2-en-l-yl)piperazine- 1-carboxylate (Compound 56d) 'N N
N-Boc
163
A stirred solution of tert-butyl (R)-4-(3-(2-(2-(ethoxycarbonyl)-lH-pyiTol-lyl)acetyl)cyc!opent-2-en-l-yl)piperazine-l-carboxylate (Compound 56c, 0.8 g, 1.854 mmol) in methanolic ammonia (5 ml) was heated at 90°C for 14 hr in a sealed tube. The reaction mixture was cooled to room température and the 5 progress of the reaction was monitored by TLC, the solvent was evaporated under reduced pressure to obtain a crude product, which was purified by flash column chromatography using 6% methanol in dichloromethane to obtain the title compound (0.55 g, 77.0%)
Ή NMR (400 MHz, DMSO-de) Ô 10.44 (brs-exchanges with D2O, 1H), 7.47-7.44 10 (m, 1H), 7.43 (s, 1H), 6.89 (dd, J = 3.9, 1.5 Hz, 1H), 6.59 (s, 1H), 6.55-6.53 (m, 1H), 3.82-3.80 (m, 1H), 3.33-3.30 (m, 4H), 2.43-2.39 (m, 6H), 2.01-1.99 (m, 1H), 1.88-1.87 (m, 1H), 1.40 (s, 9 H).
MS: m/z 385 (M+l).
Step 5: (R)-3-(3-(piperazin-1 -yl)cyclopent-1 -en-1 -yl)pyrrolo[ 1,2-a]pyrazin-1 (2H)15 one dihydrochloride (Compound 56e)
To a stirred solution tert-butyl (R)-4-(3-(l-oxo-l,2-dihydropyirolo[l,2a]pyrazin-3-yl)cyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 56d, 0.43 20 g, 1.19 mmol) in dichloromethane (10 ml) at 0 OC was added hydrochloric acid (2.24 ml of 4M solution in dioxane, 8.95 mmol). The reaction mixture was allowed to corne to room température and stirred for 2 hr. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under
164 reduced pressure to yield a crude compound which was washed with hexane to obtain title compound (0.38 g, 95.0%)
MS: m/z 285 (M+l).
Step 6; (R)-4-(4-(3-( 1-oxo-1,2-dihydropyrrolo[ 1,2-a]pyrazin-3-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 56)
NH 'N N
To a stirred solution of (R)-3-(3-(piperazin-l-yl)cyclopent-l-en-lyl)pyrrolo[l,2-a]pyrazin-l(2H)-one dihydrochloride (Compound 56e, 0.20 g, 0.56 mmol) in dimethyl sulphoxide (10 ml) was added potassium carbonate (0.31 g, 2.24 mmol), and the reaction mixture was stirred at room température for 10 min. To this suspension, 4-fluorobenzonitrile (0.088 g, 0.730 mmol) was added and the reaction mixture was heated at 115°C for 18 hrs. The reaction mixture was cooled to room température and the progress of the reaction was monitored by TLC. The reaction mixture was diluted with ethyl acetate (30 ml), filtered through Celite®, and the filtrate was washed with water (2 x 20 ml). The separated organic layer was washed with brine (20 ml), dried over sodium sulphate, filtered and concentrated under reduced pressure to yield a crude compound; which was purified by flash column chromatography using 70-80% ethyl acetate in hexane to obtain the title compound (0.07 g, 32.0%).
Ή NMR (400 MHz, DMSO-cfe) 6 10.46 (brs-exchanges with D2O, 1H), 7.58 (d, J = 8.6 Hz, 2H), 7.46-7.45 (m, 2 H), 7.03 (d, J= 8.6 Hz, 2H), 6.90 (d, J= 3.9 Hz, 1H), 6.65 (s, 1H), 6.57-6.56 (m,lH), 3.85-3.83 (m, 1H), 3.36 - 3.32 (m, 4H), 2.66 3.52 (m, 6H), 2.06-2.02 (m, 1H), 1.89-1.86 (m, 1H).
165
MS: m/z386 (M+l).
Step 7: (R)-4-(4-(3-( 1-oxo-1,2-dihydropyrrolo[ 1,2-a]pyrazin-3-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzonitrile (Compound 56-hydrochloride sait)
CN
To a stirred solution of (R)-4-(4-(3-(l-oxo-l,2-dihydropyrrolo[l,2-a]pyrazin3-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrüe (Compound 56, 0.06 g, 0.156 mmol) in dichloromethane (10ml) was added hydrochloric acid (0.311 ml of 4.0M in dioxane, 1.245 mmol) at 0eC. The reaction mixture was warmed to room température and stirred for 1 hr. The reaction mixture was diluted with ether (10 ml), stirred for 10 minutes, solid was filtered and well dried under vacuum to obtain the title compound (0.052 g, 79.0%).
Ή NMR (400 MHz, DMSO-ck) δ 11.21 (bs-exchanges with D2O, 1H), 10.55 (bsexchanges with D2O, 1H), 7.69 - 7.64 (m, 3H), 7.51-7.47 (m, 1H), 7.14 (d, J= 8.7 Hz, 2H), 6.94 (d, J= 3.9 Hz, 1H), 6.62-6.56 (m, 2H), 4.59 (s, 1H), 4.18-4.12 (m, 2H), 3.62 - 3.46 (m, 2H), 3.42 - 3.24 (m, 2H), 3.18-3.02 (m, 2H), 2.88 - 2.76 (m, 1H), 2.74-2.64 (m, 1H), 2.46-2.33 (m, 2H).
MS: m/z 386 (M+l).
Example 14: Synthesis of (R) 4-(4-(3-(8-nitro-5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 8}
166
Ο
Step 1: tert-butyl (R)-4-(3-(8-nitro-5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazine-l-carboxylate (Compound 8a)
To a solution of (R)-tert-butyl 4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazine-l-carboxyIate (Compound 34b, 250 mg, 0.631 mmol) in trifluoroacetic acid (I ml) was added nitric acid (0.028 ml, 0.631 mmol). The reaction mixture was stirred at 25 °C for 15 hrs. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ice cold water (10 ml) and basifïed with 2N sodium hydroxide (10 ml). To the resulting solution, BOC anhydride (1 ml) was added and stirred for another 2 hrs. The reaction mixture was diluted with dichloromethane (50 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (3 x 100 ml). The combined organic layer was dried over anhydrous sodium sulphate. The solvent in the organic layer was evaporated under reduced pressure to obtain a crude product. The crude product was carried forward without purification (0.250 g, 90% yield).
Step 2: (R)-4-(4-(3-(8-nitro-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 8)
167
To a solution of (R)-tert-butyl 4-{3-(8-nitro-5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en- l-yl)piperazine-1 -carboxylate (Compound 8a, 250 mg, 0.566 mmol) in dichloromethane (5 ml) was added trifluoroacetic acid (1 ml). The reaction mixture was stirred at 25°C for 2 hrs. The progress of the 5 reaction was monitored by TLC. After completion of the reaction, the solvent was removed by distillation and the product dried under vacuum. To this crude material, dimethyl sulphoxide (5 ml) was added, followed by the addition of 4fluorobenzonitrile (274 mg, 2.265 mmol) and potassium carbonate (391 mg, 2.83 mmol). The reaction mixture was stirred at 120°C for 15 hrs. The progress ofthe 10 reaction was monitored by TLC. After completion of the reaction, water (50 ml) was added and the precipitated solid material was filtered, washed with diethyl ether (25 ml) and dried to obtain a crude product. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 5% methanol in dichloromethane as an eluent to obtain the title compound (50 15 mg, 0.113 mmol, 20 % yield).
MS: m/z 443 (M+l).
Step 3: (R)-4-(4-(3-(8-nitro-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 8 - hydrochloride sait)
O
.2HCI
To a solution of (R)-4-(4-(3-(8-nitro-5-oxo-5Î6-dihydro-l,6-naphthyridin7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 8, 20 mg, 0.045 mmol) in dichloromethane (5 ml) and methanol (10 ml) was added methanolic HCl (4 M, 0.045 ml, 0.181 mmol). The reaction mixture was stirred at room température for 1 hr. After completion of the reaction, the solvent was distilled out under vaccum till diyness. The product was washed with diethyl ether (2 x
168 ml). The residue was dried under vaccum to obtain the title compound (15 mg, 0.034 mmol, 75 %yield).
NMR (400 MHz, DMSO-de) Ô 12.24 (brs-exchangeable with D2O, 1H), 11.38 (brs-exchangeable with D2O, 1H), 9.01 (s, 1H), 8.60 (d, J= 8.1 Hz, 1H), 7.77 7.61 (m, 3H), 7.16 (d, J = 8.3 Hz, 2H), 6.59 (s, 1H), 4.72 (s, 1H), 4.16 (d, J= 12.9 Hz, 2H), 3.43 - 3.09 (m, 6H), 2.94 - 2.64 (m, 2H), 2.43 - 2.30 (m, 2H).
MS: m/z 443 (M+l).
Example 15: Synthesis of (R)-4-(4-(3-(3-amino-5-oxo-5ï6-dihydro-l,6naphthyridin-7-yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 7)
Step 1: (R)-4-(4-(3-(3-nitro-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 7a)
A solution of (R)-4-(4-(3-ethynylcyclopent-2-en-l-yl)piperazin-lyl)benzonitrile (Compound Ij-prepared according to the procedure given in Example 6, 0.70 g, 2.52 mmol) and 2-bromo-5-nitronicotinic acid (0.81 g, 3.28 mmol) in anhydrous acetonitrile was added to a m î xti i re of bis(triphenylphosphine)palladiuin (II) chloride (0.177 g, 0.252 mmol) and diisopropylethyl amine (1.95 g, 15.14 mmol) in acetonitrile (70 ml) at 60-65eC under nitrogen and the reaction mixture was heated at same température for 3 h. The progress of the réaction was monitored by TLC. The réaction mixture was
169 cooled to room température and diluted with water (5 ml). The aqueous layer was extracted with dichloromethane (2 x 25 ml), combîned organic layer was dried over anhydrous sodium sulphate, fïltered and concentrated under reduced pressure to obtain crude product (0.750 g), which was dissolved in tetrahydrofuran (15 ml). To this crude product in tetrahydrofuran was added ammonia (11.28 ml, 79 mmol, 7N solution in methanol) and the réaction mixture was heated at 85°C for 3 h in a sealed tube. The progress of réaction was monitored by TLC. The reaction mixture was cooled to room température and solvent was evaporated under reduced pressure to obtain crude product which was purified by flash column chromatography over silica gel (100 -200 mesh) using 3% methanol in dichloromethane as an eluent to obtain the title compound (0.150 g, 21%).
Ή NMR (400 MHz, DMSO-dd) δ 11.96 (brs-exchangeable with D2O, 1H), 9.60 (d, J = 2.4 Hz, 1H), 9.10 - 8.97 (m, 1H), 7.59 (d, J= 8.8 Hz, 2H), 7.12 (s, 1H), 7.04 (d, 8.8 Hz, 2H), 6.77 (s, 1H), 3.92 - 3.83 (s, 1H), 3.25 - 3.16 (m, 4H), 2.76 2.54 (m, 6H), 2.12 - 1.79 (m, 2H).
MS: m/z 443.2 (M+l).
Step 2: (R)-4-(4-(3-(3-amino-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 7)
To a solution of (R)-4-(4-(3-(3-nitro-5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 7a, 60 mg, 0.1355 mmol) in acetic acid (5 ml) and éthanol (5 ml) was added iron powder (30.0 mg, 0.542 mmol) at 25°C. The reaction mixture was heated at 80-85°C for 1 hr under nitrogen atmosphère. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room température, solvents were removed under
170 reduced pressure, and residue was dissolved in ammonium hydroxide (30%), The aqueous layer was extracted with ethyl acetate (3 x 30 ml). The combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain crude product which was purifïed by flash 5 column chromatography over silica gel (100 - 200 mesh) using 4% methanol in dichioromethane as an eluent to obtain the title compound (0.025 g, 44%).
*H NMR (400 MHz, OMSO-cfe) δ 11.06 (brs-exchangeable with D2O, 1H), 8.35 (d, J= 2.8 Hz, 1H), 7.58 (d, J= 8.4 Hz, 2H), 7.51 (d, J = 2.8 Hz, 1H), 7.03 (d, J= 8.4 Hz, 2H), 6.78 (s, 1H), 6.44 (s, 1H), 5.86 (brs-exchangeable with D2O, 1H), 3.92 10 3.83 (s, 1H), 3.25 -3.16 (m, 4H), 2.76 - 2.54 (m, 6H), 2.12 - 1.79 (m, 2H).
MS: m/z 413.3 (M+l).
Step 3: (R)-4-(4-(3-(3-amino-5-oxo-5,6-dihydro- l,6-naphthyridin-7-yl)cyclopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 7-hydrochloride sait).
.2HCI
A clear solution of (R)-4-(4-(3-(3-amino-5-oxo-5,6-dihydro-l,6naphthyridin-7-yl)cydopent-2-en-1 -yl)piperazin-1 -yl)benzonitrile (Compound 7, 25 mg, 0.061 mmol) in dichioromethane (5 ml) and methanol (5 ml) was warmed and stirred at 55-60 °C, and a solution of hydrochloric acid in dioxane (0.13 ml, 0.364 mmol, 3M solution in dioxane) was added at the same température in 20 small portions over a period of 5 minute. The reaction mixture was stirred for 30 min at 55-60 C. The reaction mixture was cooled to room température, diluted with diethyl ether (10 ml), and the product obtained was collected upon filtration. The solid compound was washed with diethyl ether (10 ml) and dried under reduced pressure for 3 hrs at 40 °C to obtain the title compound (0.015 g, 55 % 25 yield).
171 JH NMR (400 MHz, DMSO-de) 6 11.59 (brs-exchangeable with D2O, 1H), 8.45 (s, 1H), 7.94 (s, 1H), 7.68 (d, J= 8.2 Hz, 2H), 7.14 (d, J= 8.2 Hz, 2H), 6.81 (s, 1H), 6.74 (s, 1H), 4.69 - 4.63 (m, 1H), 4.41 (s, 2H), 4.18 - 4.09 (m, 2H), 3.62 - 3.52 (m, 2H), 3.22 - 3.04 (m, 3H), 2.94 - 2.72 (m, 2H), 2.44 - 2.31 (m, 3H).
MS: m/z 413.3 (M+l).
Example 16: PARP1 biochemical assay
The assay was performed using BPS Bioscience kit. The 96-well strip plate was coated with 50 μΐ of histone mixture and incubated at 4°C ovemight. The next day, the wells were blocked by adding 100 μΐ of blocking buffer. The plate was 10 washed and 25 μΐ of appropriate concentration of PARP1 (25-75 ng/well) was added in ail of the Test and Positive control wells. In the Négative control wells, the enzyme was replaced with 25 μΐ of water. 5 μΐ each of 10X PARP assay buffer and activated DNA was added in ail the wells (Test, Positive and Négative control wells). 10X concentration of the test compounds were prepared and 5 μΐ test 15 compounds were added to the respective wells. The reaction volume was made up to 45 μΐ by adding water to ail of the wells. 5 μΐ of 10X PARP assay mixture containing biotinilated NAD* was added in each well and the plate was incubated at ambient température (250C) for 60 min. After washing the plate 50 μΐ of Streptavidin-HRP was added in each well, the plate was incubated at RT for 30 20 min. The plate was washed and the luminescence was read in PHERAStar plate reader after adding 100 μΐ of chemiluminescent substrate.
PARP inhibition was calculated using the following formula:
% PARP inhibition » 100 - [(RLU test compound treated sample - RLU négative control)/(RLU Positive control - RLU négative control) x 100]
IC50 values were calculated by plotting % inhibition against the respective concentrations of test compounds using GraphPad Prism 5.
172
PARP 1 inhibition ICSq of the compounds of invention is provided in Table 1 below: Compounds with IC50 between 0.5 nM and 5 nM are grouped under group A, and compounds with IC50 between 5.1 nM and 50 nM are grouped under group B.
Table 1:
Group | Compound Nos. |
A | 1, 2, 3, 6, 7, 8, 9, 10, 11, 14, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 47, 48, 49, 50, 52, 53, 54, 55, and 56. |
B L__J | 4, 12, 13, 15, 16, 27, 33, 41, 45, and 51. |
Claims (32)
1. A compound of the general formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait,
wherein,
------is either a single or a double bond;
X and Y independenüy represent carbon or nitrogen;
10 ring Ar is selected from
a) 6 membered heteroaromaÜc ring containing 1 to 2 nitrogen atoms, with X and Y being carbon; and
b) 5 membered heteroaromaÜc ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein both X and Y L5 æ76 not selected as nitrogen at the same time;
R> is independenüy selected at each occurrence from halogen, nitro, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, substituted- or unsubstituted- cyclopropyl, -NH2, -N(H)CH3, -OH, and -OCH3;
174
R2 is selected from hydrogen, haiogen, nitro, cyano, -NH2, -NfHJCHa, -OH, OCH3, substituted- or unsubstituted- cyclopropyl, and substituted- or unsubstituted- alkyl;
R3 is independently selected at each occurrence from haiogen, and substituted- or unsubstituted- alkyl, or two R3 on the same carbon form an oxo (=O), or two R3 groups together with the carbon atom(s) to which they are attached form a substituted- or unsubstituted- carbocycle;
R4 is independently selected at each occurrence as substituted- or unsubstituted- alkyl, or two R4 on the same carbon form an oxo (=O), or two R4 groups together with the carbon atom(s) to which they are attached form a substituted- or unsubstituted- carbocycle or substituted- or unsubstituted- heterocycle;
ring Bis selected from cycloalkyl, heterocyclyl, aryl, and heteroaiyl;
R5 is independently selected at each occurrence from haiogen, nitro, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, C(=O)Rla, -C(=O)ORlb, C(=O)NRlbRlc, -NRldRIc, and -ORlf;
Rla is selected from substituted- or unsubstituted- alkyl, and substitutedor unsubstituted- cycloalkyl;
Rlb and Rlc are each independently selected from hydrogen, substituted- or unsubstituted- alkyl, and substituted- or unsubstituted- cycloalkyl;
Rld and Rlc are each independently selected from hydrogen, -C(=O)alkyl, substituted- or unsubstituted- alkyl, and substituted- or unsubstitutedcycloalkyl;
Rlf is selected from hydrogen, -C(=O)alkyl, substituted- or unsubstitutedalkyl, perhaloalkyl, and substituted- or unsubstituted- cycloalkyl;
p is selected from 0, 1, and 2;
175 q is selected from O, 1, 2, and 3;
r is selected from O, 1, 2, and 3;
s is selected from O, 1, 2, and 3;
when 'alkyl’ is substituted, it is substituted with 1 to 3 substituents independently selected from oxo (=O), halogen, nitro, cyano, perhaloalkyl, cycioalkyl, cycloalkenyl, heterocyclyl, -OR6b, -SO2R6a, -C(=O)OR6a, OC(=O)R6a, -C(=O)N(H)R6, -C(=O)N(alkyl)R6, -N(H)C(=O)Rba, -N(H)Re, and N(aIkyl)R6;
when ‘cycioalkyl’ and ‘carbocycle’ are substituted, each is substituted with 1 to 3 substituents independently selected from oxo (=0), halogen, nitro, cyano, alkyl, alkenyl, perhaloalkyl, heterocyclyl, -OR6b, -SO2R6a, -C(=O)OR6a, -OC(=O)R6a, -C(=O)N(H)R6, -C(=O)N(alkyl)R6, -N(H)C(=O)R6a, -N(H)R6, and N(aIkyl)R6;
when the ΊιεΐβΓοογοΙε’ is substituted, it is substituted either on one or more ring carbon atoms or on one or more ring hetero atoms, and when it is substituted on ring carbon atom(s), it is substituted with 1 to 3 substituents independently selected from oxo (=0), halogen, cyano, alkyl, alkenyl, perhaloalkyl, -ORb, -SO2(alkyl), -C(=O)O(alkyl), -C(=O)N(H)R&, C(=O)N(alkyl)R6, -N(H)C(=O)(alkyl), -N(H)R6, and -N(alkyl)2; and when the heterocyclic group is substituted on ring nitrogen atom(s), it is substituted with a substituent or substituents independently selected from alkyl, alkenyl, cycioalkyl, cycloalkenyl, -SO2(alkyl), -C(=O)(alkyl), C(=O)O(alkyl). C(=O)N(H)R6, and -C(=O)N(alkyl)R*;
each R6 is independently selected from hydrogen, alkyl, alkenyl, cycioalkyl, cycloalkenyl, and heterocyclyl;
each R6a is independently selected from alkyl, alkenyl, perhaloalkyl, cycioalkyl, cycloalkenyl, and heterocyclyl; and
176
R6b is selected from hydrogen, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, and heterocyclyl.
2. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in claim 1, wherein ring Aris
wherein a and b represent the points of attachment of the C=O and CR2 moieties of the adjoining dihydropyridinone ring.
3. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in claim 1 or 2, wherein R> is independently selected at each occurrence from halogen, substituted- or unsubstituted- alkyl, and -NH2.
4. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 3, wherein Ri is independently selected at each occurrence from fluorine, methyl, and amino.
5. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 4, wherein p is 0 or 1.
6. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 5, wherein R2 is selected from hydrogen, nitro, and substituted- or unsubstituted- alkyl.
7. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 6, wherein R2 is selected from hydrogen, nitro, and methyl.
177
8. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 7, wherein q is 0.
9. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 8, wherein R4 is independently selected at each occurrence as substituted- or unsubstituted- alkyl, or two R4 on the same carbon form an oxo (=0), or two R4 groups together with the carbon atoms to which they are attached form a substituted- or unsubstituted- heterocycle.
10. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 9, wherein R4 is independently selected at each occurrence as methyl, or two R4 on the same carbon form an oxo (=O), or two R4 groups together with the carbon atoms to which they are attached form a 2,5diazabicyclo[2.2. ljheptane.
11. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 10, wherein r is selected from 0, 1, and 2.
12. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 11, wherein ring B is selected from aryl and heteroaryl.
13. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 12, wherein ring B is selected from phenyl, pyridinyl, thiazolyl, 2,3-dihydroindene-5-yl, 2,3-dihydro-l-indenone-5-yl, l-isoindolinone-5-yl, and 2,3dihydro-1 -isobenzofuranone-5-yl.
14. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 13, wherein R= is independently selected at each occurrence from halogen, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, C(=O)Ri*, -C(=O)ORib, C(=O)NRIbRlc, -NRidRie, and -ORif, wherein R'a is substituted- or unsubstituted- alkyl; Rib and Ric are each independently selected from
178 hydrogen, and substituted- or unsubstituted- alkyl; Rid and Ri<= are each independently selected from hydrogen and substituted- or unsubstitutedalkyl; and Rlfis substituted- or unsubstituted- alkyl.
15. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 14, wherein R5 is independently selected at each occurrence from fluorine, chlorine, cyano, trifluoromethyl, methyl, -C(=O)CH3, -C(=O)OCH2CH3 C(=O)NHCH3, -C(=O)NH2j -NHCH3i and -OCH3.
16. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 15, wherein s is selected from 0, 1, and 2.
17. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 16, ring Ar is
wherein a and b represent the points of attachment of the C=O and CR2 moieties of the adjoining dihydropyridinone ring;
R1 is independently selected at each occurrence from halogen, substitutedor unsubstituted- alkyl, and -NH2;
R2 is selected from hydrogen, nitro, and substituted- or unsubstitutedalkyl;
R4 is independently selected at each occurrence as substituted- or unsubstituted- alkyl, or two R4 on the same carbon form an oxo (=O), or two R4 groups together with the carbon atoms to which they are attached form a substituted- or unsubstituted- heterocyde;
179 ring B is selected from aryl and heteroaryl;
R5 is independently selected at each occurrence from halogen, cyano, perhaloalkyl, substituted- or unsubstituted- alkyl, C(=O)Ri% -C(=O)ORu>, C{=O)NRlbRlc, -NRWRie, and -ORlf, wherein R1® is substituted- or unsubstituted- alkyl; Rlb and Rlc are each independently selected from hydrogen and substituted- or unsubstituted- alkyl; Rid and Rle are each independently selected from hydrogen and substituted- or unsubstitutedalkyl; and Rlfis substituted- or unsubstituted- alkyl;
p is 0 or 1 ;
q is 0;
r is selected from 0, 1, and 2; and s is selected from 0, 1, and 2.
18. The compound of formula (I), its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, as claimed in any one of claims 1 to 17, wherein ring Ar is
wherein a and b represent the points of attachaient of the C=O and CR2 moieties of the adjoining dihydropyridinone ring;
R1 is independently selected at each occurrence from fluorine, methyl, and amino;
R2 is selected from hydrogen, nitro, and methyl;
180
R4 is independently selected at each occurrence as methyl, or two R4 on the same carbon form an oxo (=O), or two R4 groups together with the carbon atoms to which they are attached form a 2,5-diazabicyclo[2.2. l]heptane;
ring B is selected from phenyl, pyridinyl, thiazolyl, 2,3-dihydro-indene-5-yl, 5 2,3-dihydro-l-indenone-5-yl, 2,3-dihydro-l-isobenzofuranone-5-yI, and 1i soindolin one-5 -yl ;
R5 is independently selected at each occurrence from fluorine, chlorine, cyano, trifluoromethyl, methyl, -C(=O)CH3, -C(=O)OCH2CH3, -C(=O)NHCH3j C(=O)NHa, -NH(CH3), and -OCH3;
10 p is 0 or 1 ;
q is 0;
r is selected from 0, 1, and 2; and s is selected from 0, 1, and 2.
19. The compound of formula (I), its tautomeric form, its stereoisomer, 15 racemates or its pharmaceutically acceptable sait, as claimed in any one of daims 1 to 18, wherein the compound is selected from:
(R)-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1yl)piperazin-l-yl)benzonitrile (Compound 1);
(R)-4-(4-(3-(3-fluoro-5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent20 2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 2);
(R) -7-(3-(4-(o-tolyl)piperazin-1 -yl)cyclopent-1 -en-1 -yl) -1,6-naphthyridin5(6/i)-one (Compound 3);
(S) -4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1yl)piperazin-l-yl)benzonitrile (Compound 4);
25 (S)-4-(4-(3-(3-fluoro-5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cycIopent2-en-l-yl)piperazin-l-yl)benzonitrile (Compound 5);
181
182 4‘((lS,4S)-5-((S/R)-3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7yl)cyclopent-2-en-l-yI)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzonitrile (Compound 17);
(R)-N-methyl-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7yl)cyclopent-2-en-l-yl)piperazin-l-yl)benzamide (Compound 18);
(R)-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1 yl)piperazin-l-yl)benzamide (Compound 19);
Ethyl(R)-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cycIopent-2en-l-yl)piperazin-l-yl)benzoate (Compound 20);
(R)-7-(3-(4-phenyipiperazin-1 -yljcyclopent-1 -en-1 -yl)-1,6-naphthyridin5(6F?)-one (Compound 21);
(R)-7-(3-(4-(4-fluorophenyl)piperazin-1 -yljcyclopent-1 -en-1 -yl)-1,6naphthyndin-5(6H)-one (Compound 22);
(R)-3-fluoro-4-(4-(3-(5-oxo-5,6-dihydro-l,6-naphthyridin-7-yl)cyclopent2-en-l-yl)pîperazin-l-yl)benzonitrile (Compound 23);
(R)-7-(3-(4-(4-chlorophenyl)piperazm-1 -yl)cyclopent-1 -en-1 -yl) -1,6naphthyridin-5(6H)-one (Compound 24);
(R)-7-(3-(4-(4-methoxyphenyl)pîperazin-1 -yljcyclopent-1 -en-1 -yl)-1,6naphthyridin-5(6H}-one (Compound 25);
(R)-7-(3-(4-(p-tolyl)piperazin- l-yl)cy dopent-1 -en-1 -yl)-1,6-naphthyridin5(6H)-one (Compound 26);
(R)-7-(3-(4-(4-(methylamino)phenyl)PiPerazin-1 -yljcyclopent-1 -en-1 -yl) l,6-naphthyridin-5(6H)-one (Compound 27);
(R) -7-(3-(4-(4-acetylphenyl)piperazin-1 -yljcyclopent-1 -en-1 -yl)-1,6naphthyridin-5(6H)-one (Compound 28);
183
184 (R)-4-(4-(3-(5-oxo-5,6-dihydropyrido[3,4-b]pyrazin-7-yl)cydopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 41);
(R)-4-(4-(3-(4-oxo-415-dihydrothieno[3J2-c]pyridin-6-yl)cydopent-2-en-l yl)piperazin-l-yl)benzonitrile (Compound 42);
(R)-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[5,4-c]pyridin-6-yl)cycIopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 43);
(R) -4-(4-(3-(4-oxo-4,5-dihydrothiazolo[4,5-c]pyridin-6-yI)cydopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 44);
(S) -4-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cydopent-2-en-lyl)piperajzm-l-yl)benzonitrile (Compound 45);
(S)-4-(4-(3-(4-oxo-4,5-dihydrothiazolo[5,4-c]pyridin-6-yl)cydopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 46);
(R)-6-(3-(4-(4-fluorophenyl)piperazin-1 -yl)cy dopent-1 -en-1 -yl)thieno[3,2c]pyridin-4(5H)-one (Compound 47);
(R)-6-(3-(4-phenylpiperazin-1 -yl)cydopent-1 -en-1 -yl)thieno[3,2c]pyndïn-4(5i/)-one (Compound 48);
(R)-N-methyl-4-(4-(3-(4-oxo-4J5-dihydrothieno[3,2-c]pyridin-6yl)cydopent-2-en-l-yl)pîperazin-l-yl)benzamide (Compound 49);
(R)-6-(4-(3-(4-oxo-4,5-dihydrothieno[3,2-c]pyridin-6-yl)cydopent-2-en-lyl)piperazin-l-yl)nicotinonitrile (Compound 50);
(R)-6-(3-(4-(thiazol-2-yl)piperazin-1 -yljcydopent-1 -en-1 -yl)thieno[3,2c]pyridin-4(5H)-one (Compound 51);
(R)-3-fluoro-4-(4-(3-(4-oxo-4>5-dihydrothiazolo[5I4-c]pyridin-6yl)cydopent-2-en-l-yl)piperazin-l-yl)benzonitrüe (Compound 52);
185 (R)-4-(4-(3-(l -methyl-4-oxo-4,5-dihydro-1 H-pyrazolo[4,3-c]pyridin-6yl)cyclopent-2-en-l-yl)piperazm-l-yl)benzonitxile (Compound 53);
(R)-4-(4-(3-( 1 -oxo-1,2-dihydropyrrolo[ 1,2-c]pyrimidin-3-yl)cyclopent-2en-l-yl)piperazin-l-yl)benzonitrile (Compound 54);
5 (R)3-(3'(4-(4-fluorophenyl)piperazin-l-yl)cyclopent-l-en-lyl)pyrrolo[l,2-c]pyrimidin-l(2H)-one (Compound 55); and (R)-4-(4-(3-(l-oxo-l,2-dihydropyrrolo[l,2-a]pyrazin-3-yl)cyclopent-2-enl-yl)piperazin-l-yl)benzonitrile (Compound 56).
20. A pharmaceutical composition comprising the compound of any one of claims
10 1 to 19, its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, and a pharmaceutically acceptable carrier.
21. The pharmaceutical composition of claim 20, further comprising at least one anticancer agent, or a pharmaceutically acceptable sait of said anticancer agent,
15
22. The pharmaceutical composition of claim 21, wherein the anticancer agent is selected from busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium, etoposide, 5-azacytidine, gemcitabine, 20 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, Vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, campath, imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolimus, ?5 everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, thahdomide and lenalidomide.
23. A method of treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom, comprising administering to 0 the mammal in need of such treatment a therapeutically effective amount of a
186 compound, its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, of any one of claims 1 to 19 or the pharmaceutical composition of claim 20.
24. The method of claim 23, wherein said disorder is cancer.
5
25. The method according to claim 24, wherein said cancer is liver cancer, melanoma, Hodgkin's disease, non-Hodgkin’s lymphomas, acute or chronic lymphoçytic leukaemia, multiple myeloma, neuroblastoma, breast carcinoma, ovanan carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, 10 bladder carcinoma, chronic granulocytic leukaemia, primaiy brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, chorio carcinoma, mycosis fungoide, head or neck carcinoma, ostéogénie sarcoma, pancreatic carcinoma, acute granulocytic 15 leukaemia, haiiy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinaiy carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, rénal cell carcinoma, endométrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, or prostatic carcinoma.
20
26. A method of potentiating the efficacy of chemotherapeutic regimen for a patient undergoing chemotherapeutic treatment comprising co-administering to the patient an effective amount of a compound, tautomer, stereoisomer, or sait of any one of claims 1 to 19.
27. The method of claim 26, wherein the compound, tautomer, stereoisomer, or 25 sait is co-administered simultaneously, sequentially, or cyclically with the anticancer agent.
28. The method of claim 27, wherein the anticancer agent is selected from busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin,
JO carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2--deoxy-uridine, fludarabine,
187 nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguamne, colchicine, Vinblastine, vincristine, vinorelbine, paclitaxel, ixabepüone, cabazitaxel, docetaxel, campath, panitumumab, ofatumumab, bevacizumab, trastuzumab, adalimumab, imatinib, gefitinib, erlotinib, lapatimb, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolimus, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid’ bortezomib, thalidomide and lenalidomide.
29. A method for sensitizing a patient who has developed or who is likely to develop résistance to chemotherapie agents comprising administering an effective amount of a compound, its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, of any one of claims 1 to 19.
30. A compound, its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, according to any one of claims 1 to 19 for use in treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom.
31. A compound, its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, according to any one of claims 1 to 19 for use in potentiating the efficacy of chemo therapeutîc regimen for a patient undergoing chemotherapeutic treatment.
32. A compound, its tautomeric form, its stereoisomer, or its pharmaceutically acceptable sait, according to any one of claims 1 to 19 for use in sensitizing a patient who has developed or who is likely to develop résistance to chemotherapie agents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN311/MUM/2015 | 2015-08-17 | ||
IN3588/MUM/2015 | 2015-09-21 | ||
IN201621000832 | 2016-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18697A true OA18697A (en) | 2019-05-17 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017029601A1 (en) | Heteroaryl derivatives as parp inhibitors | |
AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
AU2018255300B2 (en) | Bicyclic compounds and their use in the treatment of cancer | |
AU2017200493B2 (en) | Heterocyclyl compounds as MEK inhibitors | |
AU2013288265B2 (en) | Tetrahydroquinazolinone derivatives as PARP inhibitors | |
US9000186B2 (en) | Ring-fused heterocyclic derivative | |
AU2020232026A1 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
EP3675847A1 (en) | Spirocycle compounds and methods of making and using same | |
US11066405B2 (en) | Bicyclic compounds and their use in the treatment of cancer | |
TWI835840B (en) | INHIBITORS OF αVβ6 INTEGRIN | |
EA033827B1 (en) | Benzimidazole derivatives as antihistamine agents | |
WO2022266258A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
OA18697A (en) | Heteroaryl derivatives as PARP inhibitors | |
WO2016012956A1 (en) | Isoquinolinone derivatives as parp inhibitors | |
WO2017013593A1 (en) | Isoquinolinone derivatives as parp inhibitors | |
WO2017103825A1 (en) | Quinolizinone derivatives as pi3k inhibitors | |
TW202330519A (en) | Pyrazolopyridine compounds as tam inhibitors | |
TW202334096A (en) | Quinazoline derivative compounds, and uses thereof | |
TW202423925A (en) | Inhibitors of αvβ6 integrin |